��ࡱ�>��  ��������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~�Root Entry�������� �F�ֶdћ��@Workbook�������������� ETExtData����*SummaryInformation(�������� ��������������������������������������������������������������������������������������������������������������������������������      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~��������������������������������������������������������������������������������������������������������������������������������      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~����������������������������������������������������������������������������������������������������������������������������������� � �������\pyjh B�a�=��=W]n(8X@�"��1����[SO10����[SO10����[SO10����[SO1�����[SO1����[SO1�����[SO1�����[SO1���Arial1,>���[SO1>���[SO1����[SO1����[SO1����[SO1�>���[SO1� ���[SO1�>���[SO1� ���[SO1����[SO1� ���[SO1h>���[SO1����[SO1�?���[SO1�5���[SO1� ���[SO1�5���[SO1����[SO1����[SO1���Calibri+"��"#,##0;"��"\-#,##05"��"#,##0;[Red]"��"\-#,##07"��"#,##0.00;"��"\-#,##0.00A"��"#,##0.00;[Red]"��"\-#,##0.00i*2_ "��"* #,##0_ ;_ "��"* \-#,##0_ ;_ "��"* "-"_ ;_ @_ W))_ * #,##0_ ;_ * \-#,##0_ ;_ * "-"_ ;_ @_ y,:_ "��"* #,##0.00_ ;_ "��"* \-#,##0.00_ ;_ "��"* "-"??_ ;_ @_ g+1_ * #,##0.00_ ;_ * \-#,##0.00_ ;_ * "-"??_ ;_ @_ /\$#,##0_);\(\$#,##0\)9\$#,##0_);[Red]\(\$#,##0\);\$#,##0.00_);\(\$#,##0.00\)E \$#,##0.00_);[Red]\(\$#,##0.00\)u�8_-"�"* #,##0.00_-;\-"�"* #,##0.00_-;_-"�"* "-"??_-;_-@_- �0_ � "$"#,##0.00��� @ @ � ����� ����� ����� ����� ����� ����� ����� ����� ����� ����� ����� ����� ����� ����� � @ @ � �*���@ @ � � ���@ @  ����� � / ���� �@ @ � �)���@ @ � � ���@ @ * � ���@ @ - �+���@ @ � ����@ @  ����@ @ � � �� �@ @ � ����@ @ � ����   ����@ @  ����@ @ � ����@ @ � ����@ @ � ����@ @ � � ��� @ @� � ��� @ @� ����@ @  ���� @ @� ����@ @  ������ ����� �  ����ff��7 � ���@ @  ����@ @  ����`@ @� ����a@ 6� ����@ @ * ����@ @ + � ���@ @  ����@ @ 6 � ���@ @  � ���@ @  � ���@ @  � ���@ @ / ����@ @  ����@ @ 6 � ���@ @  � ���@ @  ����@ @ 1 � ���@ @  ����@ @ , ����@ @  � ���@ @ / ����@ @ / � H@ @ � �!X@ @ � � X@ @ � ��"\@ @ � � H@ @ � �X@ @ � �X@ @ � ��\@ @ � �X@ @ � �X@ @ � �!X@ @ � � X@ @ � ��"T@ @ � �!P@ @ � � P@ @ � ��"\@ @ � �  X@ @ � � �"\@ @ � � !X@ @ � �  H@ @ � ��1"\@ @ � � � X@ @ � �  \@ @ � � @@ @ � � !|@ @ � � �!\@ @ � � (X@ @ � � X@ @ � � � \@ @ � �  x@ @ � � !x@ @ � �  h@ @ � � "x@ @ � ||ab���}-} }}}A}df }�} � ����̙� ??v�}}}}}A}�L }A}���� ��}}}A}13 }-} ��}}}-} ���}}} ���� ����������������}A}13 }-} }-} ��}-}  }-}! �}A}" }A}# }A}$13 }A}%�? }A}&13 }�}' ???� ???�???�???����� ???�}�}( � ������� �}�}�}) ???� ???�???�???����� ����}A}*df }A}+ }A},��� �}�}U}- }A}.���� a�}A}/��� �e�}A}0df }A}1 }A}2df }A}3�L }A}4df }A}5�L }A}6 }A}7 }A}8df }A}9�L }A}: }A};�L }A}<13 }A}= }A}>�L }A}?13 }-} }}@}-}A }-}B }-}C }-}D }-}E }-}F }-}G }}H}}I}}J}}K}-}L }-}M }-}N }-}T }-}W ������8^ĉ����!20% - :_��eW[��r� 3�2�&�20% - :_��eW[��r� 3� ��eQ�����eQ�������!40% - :_��eW[��r� 3�2�'�40% - :_��eW[��r� 3��]����]����!60% - :_��eW[��r� 3�2�(�60% - :_��eW[��r� 3�������� �� �lʑ�� ��lʑ�!60% - :_��eW[��r� 2�2�$�60% - :_��eW[��r� 2� h�� 4���h�� 4� f�JT�e,g�� �f�JT�e,g� h�����h���!�ʑ'`�e,g� �5��ʑ'`�e,g� "h�� 1���h�� 1� #h�� 2���h�� 2�!$60% - :_��eW[��r� 1�2� �60% - :_��eW[��r� 1� %h�� 3���h�� 3�!&60% - :_��eW[��r� 4�2�,�60% - :_��eW[��r� 4� '���Q������Q� (���{������{�)�h�gUSCQ40% - :_��eW[��r� 6�2�3�40% - :_��eW[��r� 6�!?60% - :_��eW[��r� 6�2�4�60% - :_��eW[��r� 6�� �PK �N�@theme/PK �N�@ theme/theme/PK�N�@ky�}�theme/theme/themeManager.xml �M � @�}�w��7c�(Eb�ˮ��C�AǠҟ����7��՛K Y,� �e�.���|,���H�,l����xɴ��I�sQ}#Ր���� ֵ+�!�,�^�$j=�GW���)�E�+& 8�PK�N�@�b�m��theme/theme/theme1.xml�YOo�6��w tom'�u�ر��M�n�i��XS�@�I}��úa���0l+��t�&[����HJ��K��ՇD"|���#u�ڃ��C"$�q۫]�z��>�8h{w��K� �c�xL�ޜH�����]ś*$A�>����J%����a��ACM��ʈ���J����&M�;��4B�e� t�Y�>c~4$��� &�^������ �L1�bma]���u��t���(gZ��[Wvr���2���u{���`�M�,E���F���,���2�n�Q�����%�[�N��Je�D �>֗��f}{����7����v��t�d��%|�J�Yw�2O��ڡ�~J=�L8�-�o|���(��<�4� �ժX��}.��@����'d�}��.�F�b�o\��C�\Ҽ��MT��0�� z�����S�����ώ�t�����--g�.���—�~����?�~����xY����'���y92h!ы/����ɋ�>����%�m�GE��FD�[��t3�q%'#q��Sg�v � �9fe�q�wW@�(^��wd�b�h �a��8g.J pC�*Xx8��r�bV�`|Xƻ�cǵ�YU3 J��ݐ8b�3+��(�������Q��u���K>Q�ELKM2�#'��vi~��� �vl�wu8+�z��HH�J���:�)��� ~��L��\�E\O*�t@G�1��l�m��~C�*u��G.R(:-�ys^D��i7�QR��8,b?�SQ���*��q7C�;��+�}��ݧ�;4pDZ����_^'܉���M01UJ�S�#�]�f���l��m��ʒg�D�^����<�� d����B����[_�W�����E)�*��k��;Z�xO(c5g�4��� h܇A��:I~KBxԙ \ �Y�WQB�@�^�4�@���.�h�Kik<��ʞ6�b+��j����Ύ9#U`δ�uM��֯�DA��aV�B��[͈f���-WY�؜���j0�[:�X� �~��;������Q�ㅋt� �>�z/��f���ʒ"Z ��x�� �Z��p;�����+�e�{/e��P;��,.&'��Q�k5��q��&pT��(�K�Lb�}��� �S��d�›�L17 jp�a��S!��� 3���5'+�Z�zQ �T��I����Ivt]K&⫢� #�v�5-�|����#4b3q���:TA�1�p�a*�~��9mm3��4銗bg�1KB��[��Y&[�)H� � �V*�Q������ U�a�?SE�'p�>���vX`�3��q�BU( ���8���W�0 Aw�� ����9Kä5�$� ����P�e�D�)�j��eI�������2�b��!aC]�zo�P�n�IZ �d���i����ͩd��ks���|l2�Rn6 Mf�\ļ=X�v�Y��EE�ĢͪgY� [A+M���[��XK�52�����`�%p���������7�!?�ڊ���&aQ}�6HH;8����`Ҥ�i��I[-۬/�����0���,�>�����e���E;��ck;����ٓ) C�� cc��?f��}p�|6�1%M0��*����<���ҭ�PK �N�@_rels/PK�N�@�֧�6 _rels/.rels���j�0 ���}Q��%v/��C/�}�(h"���O� ������=������ ����C?�h�v=��Ʌ��%[xp��{۵_�Pѣ<�1�H�0���O�R�Bd���JE�4b$��q_����6L��R�7`�������0̞O��,�En7�Li�b��/�S���e��е����PK �N�@theme/theme/_rels/PK�N�@ ѐ��'theme/theme/_rels/themeManager.xml.rels��M �0���wooӺ�&݈Э���5 6?$Q�� �,.�a��i����c2�1h�:�q��m��@RN��;d�`��o7�g�K(M&$R(.1�r'J��ЊT���8��V�"��AȻ�H�u}��|�$�b{��P����8�g/]�QAsم(����#��L�[����PK�N�@ �$��[Content_Types].xml���N�0E�H���-J��@%�ǎǢ|�ș$�ز�U��L�TB� l,���x\���v��T�U^h�d}㨫���)��*1P�'���^ח��0)�T�9��l�#��$��>����� `?�Cs]7�zb$�x��u��-lV�{9>�D�V�Nj����,���5�(�Bȥs��zҕhhs�0U~,}�2��To�F�0,�į�*�=댬o[g��v;� �9���'�3��3�y ; ��o�OPK�N�@ �$�� � [Content_Types].xmlPK �N�@�_rels/PK�N�@�֧�6  �_rels/.relsPK �N�@theme/PK �N�@ $theme/theme/PK �N�@�theme/theme/_rels/PK�N�@ ѐ��' �theme/theme/_rels/themeManager.xml.relsPK�N�@�b�m�� theme/theme/theme1.xmlPK�N�@ky�}� Ntheme/theme/themeManager.xmlPK ? ���X��TableStyleMedium2PivotStyleLight16`�"� CGS Catalogue���VV���4"� 3> '��S�T Tĉ300,000 Da) having more binding sites per molecule. This product s molecular weight ranges from 70,000 to 150,000 Da yielding a solution viscosity for easy handling while providing sufficient binding sites for cell attachment.AP18 Poly-L-Lysine�Poly-L-Lysine is a synthetic amino acid chain that is positively charged having one hydrobromide per unit of Lysine. The molecular weight of Poly-L-Lysine can vary significantly with lower molecular weight (30,000 Da) being less viscous and higher molecular weight (>300,000 Da) having more binding sites per molecule. This product s molecular weight ranges from 70,000 to 150,000 Da yielding a solution viscosity for easy handling while providing sufficient binding sites for cell attachment.AP19Poly-L-Ornithine�Poly-L-Ornithine is a synthetic amino acid chain that is positively charged having one hydrobromide per unit of ornithine. The molecular weight of Poly-L-Ornithine can vary significantly with lower molecular weight (30,000 Da) being less viscous and higher molecular weight (>300,000 Da) having more binding sites per molecule. This product s molecular weight ranges from 70,000 to 150,000 Da yielding a solution viscosity for easy handling while providing sufficient binding sites for cell attachment.AP21Tropoelastin, Lyophilized1 mg(Human Tropoelastin is the precursor to the elastin molecule. It is not normally available in its native state since it becomes cross-linked immediately after its synthesis by the cell, during its export into the extracellular matrix. Tropoelastin is produced using recombinant production methods.AP22Fibronectin, 0.5 mg/mldry ice�Human Fibronectin has been purified from human plasma where it is found as a dimer and has a size of 440-500 kDa with two similar subunits (220-250 kDa) linked by two disulfide bonds.AP23Fibronectin, 0.5 mg/m2.5 mgSM07-50 5-Azacytidine50 mg�5-Azacytidine is an epigenetic modifier,�a potent growth inhibitor and a cytotoxic agent. 5-Azacytidine acts as a demethylating agent by inhibiting DNA methyltransferase (DNMT), forming covalent adducts with cellular DNMT1 depleting enzyme activity. This small molecule enhances differentiation to cardiomyocytes from human embryonic stem cells. 5-Azacytidine also increases reprogramming efficiency of mouse fibroblasts to pluripotent stem cells.SM07-200200 mgSM08-2A7696622 mgjA769662 is a potent, reversible activator of AMP-activated protein kinase (AMPK). It activates beta1-containing AMPK complexes, but induces glucose uptake via a PI3 kinase-dependent pathway. A769662 inhibits 3T3-L1 adipocyte differentiation and may be used to treat obesity. It also inhibited the function of the 26S proteasome via an AMPK-independent mechanism.SM08-10SM08-50SM08-200SM09-1ALK5 Inhibitor II�ALK5 Inhibitor II is a cell permeable, potent, selective and ATP-competitive inhibitor of TGF-� RI kinase (IC50 = 23 nM, 4 nM and 18 nM for binding, auto-phosphorylation and cellular assay in HepG2 cells of TGF-� RI kinase, respectively). TGF � RI (ALK5) Inhibitor II affects a panel of 9 closely related kinases including p38 MAPK. ALK5 can replace Sox2 for generation of induced pluripotent stem cells (iPSC).SM09-5SM09-10SM09-2525 mgSM09-50SM10-1BI-D18705BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 < kinase) isoforms, which inhibits RSK1, RSK2, RSK3 and RSK4�in vitro. BI-D1870 does not significantly inhibit ten other AGC kinase members and over 40 other protein kinases tested at 100-fold higher concentrations. BI-D1870 does not affect the agonist-triggered phosphorylation of substrates for six other AGC kinases. Additionally, BI-D1870 does not suppress the phorbol ester- or EGF-induced phosphorylation of CREB (cAMP-response-element-binding protein). BI-D1870 induces apoptosis, although preferentially, in a p21-deficient background. BI-D1870 also induces a strong transcription- and p53-independent accumulation of p21 protein and protects cells from gamma irradiation (�IR)-induced apoptosis, driving them into senescence even in the absence of �IR.SM10-5SM10-10SM11-2BIRB796�BIRB796 (Doramapimod) is a protein kinase inhibitor of p38 MAPK. BIRB796 (Doramapimod) has high picomolar affinity for p38 MAP kinase and low nanomolar inhibitory activity against TNF� in THP-1 cell culture. The p38 inhibitor BIRB796 (Doramapimod) binds tightly to ABL(T315I) and inhibits the BMS-354825- and imatinib-resistant ABL(T315I) kinase. BIRB796 has been used as part of the NHSM media to create naive state human cells.SM11-10SM11-25SM11-50SM11-100SM12-2"BIX01294 Trihydrochloride Hydrate�OBIX01294 is a G9a-like protein and G9a histone lysine methyltransferase inhibitor (IC values are 0.7 and 1.7 �M, respectively) that displays no activity at other histone methyltransferases up to 37 �M. BIX01294 modulates H3K9me2 levels in mammalian cells and potentiates induction of pluripotent stem cells from somatic cells in vitro.SM12-10SM12-50SM13-1 CHIR99021 at -80�C �CHIR99021 is an aminopyrimidine derivative. CHIR99021 inhibits GSK3� (IC50 = 6.7 nM) and GSK3� (IC50 = 10 nM) and functions as a WNT pathway activator. CHIR99021 is widely used in definitive endoderm differentiation protocols.SM13-5SM13-10 CHIR99021�SM13-50SM43-50Cyclosporin A (CsA)�Cyclosporin A is a non-polar cyclic oligopeptide metabolite. It possesses potent immunosuppressive properties, affecting primarly T-lymphocytes. Cyclosporin A is the primary tool used to prevent rejection following solid organ and/or bone marrow transplantation. Cyclosporin A inhibits phosphatase activity of calcineurin. This small molecule also inhibits formation and opening of the mitochondrial permeability transition pore (MPTP). SM43-10001 g SM43-50005 gSM44-2CYT387 CYT387 is an ATP competitive inhibitor of JAK1 and JAK2 (Janus kinases). CYT387 inhibits the proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated by IL-3. Furthermore, CYT387 also causes the inhibition of cell proliferation in cell lines constitutively activated by JAK2 or MPL signaling. CYT387 has been shown to inhibit erythroid colony growth in vitro. CYT387 inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less inhibitory effect on the self-renewal of CD34+ hematopoietic progenitors.SM44-10SM44-50SM15-2DAPTDAPT is a potent and specific inhibitor of gamma-secretase. This reduces Ab levels in vivo in plasma and cerebrospinal fluid. It blocks the proteolytic processing of neurotrophin receptor alike death domain protein (NRADD). DAPT causes neural cells to commit to neuronal differentiation.SM15-10SM15-50SM45-20 Dasatinib20 mg�Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit. Dasatinib treatment inhibits SRC signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer stem cells.SM45-100SM45-500500 mg SM45-1000 SM45-5000SM46-5 DecitabineDecitabine is a potent inhibitor of�DNA methylation�in different kinds of cells. Decitabine has been reported to cause phosphorylation inhibition of 2'-deoxycytidine in certain cells and the incorporation of 2'-deoxycytidine into DNA. Experiments have shown that this compound induces changes in the differentiated state of cultured mouse embryo cells and additionally inhibits Dnmt (DNA methyltransferase). DNA methylation has been noted to be important in det< ermining apoptotic susceptibility to histone deacetylase inhibitors, and its prevention can cause gene silencing and transcriptional repression. Other studies suggest that cell exposure to Decitabine causes a change in replication timing, reactivation of repressed genes, and decondensation of heterochromatin.SM46-25SM46-50SM46-250250 mg SM46-1000SM47-25Dexamethasone (Dex)gDexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant properties. Dexamethasone is used to treat many inflammatory and autoimmune conditions, such as rheumatoid arthritis and bronchospasm. Dexamethasone inhibits induction of nitric oxide synthase. Dexamethasone reduces levels of activated NF-�B in immature dendritic cells (DCs) and inhibits differentiation into mature DCs. This biomolecule induces differentiation of human mesenchymal stem cells (MSCs). It also induces autophagy in acute lymphoblastic leukemia (ALL) cell lines.SM47-250SM47-500 SM47-1000SM03-2Dorsomorphin Dihydrochloride�Dorsomorphin is a BMP pathway inhibitor, which inhibits bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK 6). Dorsomorphin, also named as AMPK Inhibitor, has also been shown to play role as a potent and selective inhibitor of AMPK, induced by AICAR and metformin. Dorsomorphin promotes cardiomyogenesis in mouse embryonic stem cells (ESC) and induces autophagy in cancer cell lines via a mechanism independent of AMPK inhibition.SM03-10SM03-50SM03-200SM49-10Fasudil Hydrochloride�Fasudil hydrochloride is a cyclic nucleotide-dependent Rho-associated kinase inhibitor. The Rho-kinase (ROCK) mediates vasoconstriction and vascular remodeling. Fasudil effectively inhibited ISO-induced heart failure, as evaluated by biometric, hemodynamic, and histological examinations. It has been demonstrated that fasudil decrease human embryonic stem cells (hESC) dissociation-induced apoptosis, increase hESC cloning efficiency and facilitate hESC subcloning after gene transfer.SM49-50SM49-250SM49-500 SM49-1000SM18-2 Forskolin�Forskolin is a cAMP pathway activator, by activating adenylyl cyclase. Forskolin allows maintenance of human embryonic stem cells in a naive or ground state similar to mouse embryonic stem cells. Forskolin also enables chemical reprogramming of mouse embryonic fibroblasts to induced pluripotent stem cells, when combined with other small molecules. Forskolin is a vasodilator, which can help in controlling the cause of glaucoma and reduce urinary tract infections.SM18-10SM18-50SM18-100 SM18-1000SM52-1GarcinolVGarcinol is a polyisoprenylated benzophenone derivative from the rind of�Garcinia indica�fruit and is a potent inhibitor of histone acetyltransferases p300 and PCAF�in vitro. p300, also known as E1A binding protein p300, regulates cell growth and division through interacting with numerous transcription factors, and the p53 associated trancriptional coactivator PCAF (P300/CBP-associated factor) plays a direct role in transcriptional regulation. Garcinol predominantly down-regulates global gene expression in HeLa cells. Additional research shows that Garcinol exhibits anti-carcinogenic and anti-inflammatory properties through selectively suppressing Prostaglandin E2 synthesis and 5-lipoxygenase product formation. It promotes neurogenesis in corticol progenitor cells and contributes for ex vivo expansion of human hematopoietic stem cells (hHSC).SM52-5SM52-25SM54-5GDC-0449�GDC-0449 is a potent and specific hedgehog signaling pathway inhibitor. GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. GDC-0449 prevents multiple ATP-binding cassette (ABC) transporters. GDC-0449 prevents the growth of primary pancreatic xenografts without non-specifically inhibiting pancreatic cell proliferation.SM54-25SM54-50SM54-200SM19-2GDC-0941#GDC-0941 is a cell-permeable, selective small molecule that inhibits Class I<  phosphatidylinositide 3-kinase (PI3K). GDC-041 plays a vital role in diverse cellular functions such as cell growth and proliferation. This small molecule is deregulated in a number of conditions, including cancer.SM19-10SM19-25SM19-50SM19-200SM55-2 Geldanamycin�Geldanamycin is a natural existing HSP90 (Heat Schock Protein 90) inhibitor, specifically disrupts glucocorticoid receptor (GR)/HSP association. The Hsp90 chaperone is required for the activation of several families of eukaryotic protein kinases and nuclear hormone receptors, many of which are proto-oncogenic and play a prominent role in cancer. Geldanamycin has antiproliferative and antitumor effects, as it binds to Hsp90, inhibits the Hsp90-mediated conformational maturation/refolding reaction. It interferes with cellular stress response. Geldanamycin decrease the expression of hypoxia inducible factor (HIF-1alpha) in neural stem/progenitor cells.SM55-10SM55-25SM55-50SM55-250SM20-1Go 6983 Go 6983 is a protein kinase C (PKC) inhibitor for PKC�, PKC�, PKC�, PKC� and PKC�. This compound does not effectively inhibit PKC� and therefore can be used to differentiate PKC� from other isoforms. Go 6983 inhibits intracellular Ca2+ accumulation, suggesting a mechanism for its vasodilator properties. The inhibition of PKC signaling is an efficient strategy to establish and maintain pluripotent rat embryonic stem cells and to facilitate reprogramming of rat embryonic fibroblasts to rat induced pluripotent stem cells.SM20-5SM20-10SM21-2 GSK429286A�GSK429286A is a cell-permeable, selective Rho-associated kinase (ROCK) inhibitor, active for ROCK1 and ROCK2. GSK429286A is a more selective ROCK2 inhibitor than the widely utilized ROCK inhibitor Y-27632 as assessed on kinase-specificity panel, and does not significantly inhibit LRRK2. GSK429286A significantly inhibits rat aortic ring dilation and reduces mean arterial pressure in the spontaneously hypertensive rats (SHRs).SM21-10SM21-50SM56-2GX15-070�GX15-070 is a novel Bcl-2 homology domain-3 (BH3) mimetic.� It occupies a hydrophobic cleft within the BH3 binding groove of Bcl-2, antagonizing Bcl-2 and thus inducing apoptosis. GX15-070 enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. GX15-070 potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells.SM56-10SM56-50SM56-200SM01-1ID-8�ID-8 is a DYRK inhibitor. ID-8 enables the long term expansion of embryonic stem cells (ESC). ESC treated with ID-8 in a serum-free medium were subsequently consistently differentiated into many cell types, including neurons, muscle cells and hepatocytes.SM01-5SM01-50SM01-100SM04-2IM-12�IM-12 is a cell-permeable indolylmaleimide that acts as a Glycogen synthase kinase 3� (GSK-3�) inhibitor, activating downstream components of canonical Wnt signaling. IM-12 significantly increases �-catenin levels. IM-12 leads to TCF-induction and promotes neuronal differentiation in human neural progenitor cells by activating Wnt pathway. IM-12 when combined with other small molecules supports the self-renewal of naive human embryonic stem cells and maintenance of ground state pluripotency.SM04-10SM04-25SM04-100SM04-500SM61-5#Irinotecan Hydrochloride Trihydrate�Irinotecan hydrochloride trihydrate (CPT 11), a compound within the camptothecin family, is an inhibitor of Topo I (topoisomerase I) involved in cellular DNA replication and transcription. This compound is a prodrug which needs to be transformed by carboxylesterases to its active metabolite SN-38. As a Topo I inhibitor, Irinotecan inhibits the religation step of the enzyme's normal action, inducing single stranded DNA breaks. These single stranded breaks are then converted to double-stranded breaks within the course of DNA replication which is reported to induce apoptosis or repair mechanisms as a result. Irinotecan has a therapeutic effect in malignant brain tumors, with increased efficacy when combined in ne< ural stem cells therapies.SM61-25SM61-100SM61-250 SM61-1000SM39-2IWP-2�IWP-2 is an inhibitor of Wnt processing and secretion. It appears that IWP inactivates Porcn function either by directly inhibiting the Porcn active site or by modulating the function of a Porcn regulator. IWP-2 promotes cardiomyocyte differentiation from human pluripotent stem cells. This small molecule also suppresses self-renewal in mouse embryonic stem cells and supports their conversion to epiblast-like stem cells.SM39-10SM39-50SM39-100SM62-1 JNJ-10198409�JNJ-10198409 is a potent ATP-competitive inhibitor of Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK). JNJ-10198409 displays potent antiproliferative properties in human tumor cell lines and antiangiogenic activity.SM62-5SM62-5050 mg SM64-2KY02111KY02111 is a Wnt signaling pathway inhibitor. KY02111 promotes differentiation of human pluripotent stem cells (hPSCs) to cardiomyocytes by inhibiting Wnt signaling in hPSCs in a manner that is distinct from that of previously studied Wnt inhibitors. The substantial (98%) differentiation of hPSCs to cardiomyocytes with KY02111 is achieved in xeno-free and cytokine-free conditions.SM64-10SM64-50SM23-1 LDN193189�#LDN193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3. BMPs induce Smad1/5/8 plus non-Smad pathways, such as MAPK and Akt. BMP signaling pathway is the key regulator of cell fate decisions during embryogenesis and tissue homeostasis. It inhibits the activation of p38, ERK1/2 and Akt in C2C12 cells. LDN193189 only weakly inhibits ALK4, ALK5, and ALK7. LDN193189 affects not only the Smad but also the non-Smad signalling pathways induced by either BMP2, BMP6 or GDF5. LDN193189 inhibits ectopic ossification and it is a potential agent in the treatment of NSCLC lung tumors, showing significant in vivo clinical utility. LDN193189 has been used to reduce ectopic ossification in a mouse model of fibrodysplasia ossificans progressiva.SM23-5SM23-10SM23-50SM24-10 LY294002�qLY294002 shows a highly selective inhibitor of PI3K in vivo. LY294002 can transfer cells to specific inhibition of PI3K, inhibition of PI3K/Akt signaling pathways, including inhibition of common Akt phosphorylation. LY294002 inhibits cell proliferation of choroidal melanoma OCM-1 cells. In mouse embryonic stem cells, LY294002 prevents self-renewal by inhibiting LIF2.SM24-50SM24-100 SM24-1000SM25-1LY411575�LY411575 is a potent gamma secretase inhibitor. It is able to block Notch activation and reduces A beta/42 post treatment (acute or chronic). Notch signaling is a pathway known to regulate both differentiation and proliferation of cells in diverse adult tissues. LY411575 has been shown to promote goblet cell differentiation in mice intestine. It has also been observed to promote neural differentiation of mouse embryonic stem cells (ESC).SM25-5SM25-10SM25-50SM25-100SM69-25 NVP-BEZ235SNVP-BEZ235 is a PI 3-kinase (PI3K) tyrosine kinase inhibitor and shows dual PI3K/mTOR inhibition. NVP-BEZ235 also inhibits ATR. However, NVP-BEZ235 has been shown to be poor inhibitory to Akt and PDK1. NVP-BEZ235 shows high target specificity and demonstrates antiproliferative activity against tumor cell lines in animal models of cancer.SM69-100 SM69-1000SM26-2 PD0325901�PD0325901, a MEK inhibitor, is a synthetic organic molecule targeting mitogen-activated protein kinase (MAPK/ERK kinase or MEK). PD0325901 has potential antineoplastic activity. This molecule inhibits the growth of melanoma cell lines in vitro and in vivo.SM26-10SM26-25SM26-100SM27-2 PD173074�)The fibroblast growth factor receptors (FGFRs) are cell surface receptors with intrinsic tyrosine kinase activity, which is necessary for receptor activation and signal propagation. PD173074 is a potent and selective inhibitor of FGFR tyrosine kinase activity, blocking autophosphorylation of FGFR1 and FGFR3. However, poorly inhibits PDGFR and c-Src and has no effect on EGFR, InsR, MEK, or PKC. PD173074 inhibits prolife< ration and differentiation of oligodendrocyte progenitors. PD173074 also blocks tumor growth in H510 and H69 SCLC xenograft models.SM27-10SM27-25SM27-100SM73-2PD1843523PD184352 is a highly selective non-competitive inhibitor of MEK, a kinase upstream in the mitogen-activated protein kinase pathway (MAPK). PD184352 has anti-cancer properties, suppresses the ERK pathway, and has been used along with other classes of inhibitors to establish embryonic stem cell (ESC) lines. SM73-10SM73-25SM73-100SM28-2PD98059�.PD98059 is a potent and selective cell permeable inhibitor of MAP kinase kinase (MEK). It selectively blocks the activation of MEK, thereby inhibiting the phosphorylation and the activation of MAP kinase. PD98059 inhibits cell growth and reverses the phenotype of ras-transformed BALB3T3 mouse fibroblasts and rat kidney cells. PD98059 inhibits cell growth and proliferation in acute myelogenous leukemia (AML) cell lines and causes G1 arrest by blocking p53-dependent p21 induction. This small molecule also enhances embryonic stem cell (ESC) self-renewal. SM28-10SM28-25SM28-50SM74-2PI-103 hydrochloride�PI-103 is a cell-permeable pyridinylfuranopyrimidine compound that acts as an ATP-competitive inhibitor of DNA-PK, PI 3-kinase (Class IA), and FRAP (mTOR) complex 1 and 2. When PI-103 is combined with rapamycin, a prototypic mTORC1 inhibitor, synergistic suppression of AKT and ribosomal S6 protein phosphorylation are observed. In addition, PI-103 has been seen to have nominal effects inhibiting basal Na+ transport, but is very effective in abolishing insulin-induced Na+ absorption in the nephron. In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells.SM74-10SM74-25SM74-100SM29-2.5 Pifithrin-�\Pifithrin � selectively interacts with HSP70 and disrupts its association with co-chaperones and substrate proteins. It induces apoptosis and it is cell permeable. Also, inhibits p53 binding to mitochondria by reducing its affinity for antiapoptotic proteins Bcl-2 and Bcl-XL. Pifithrin � rescues cells from lethal �-irradiation-induced cell death.SM29-10SM29-50SM76-2PIK-75 hydrochlorideRPIK-75 is a cell-permeable selective inhibitor of PI 3-kinase p110�. This molecule inhibits production of PIP2 and PIP3 in adipocytes, phosphorylation of Akt and also activation of mTORC1. It has been studied that PIK-75 significantly reduces leukemia burden and increases the survival of mice engrafted with human acute myeloid leukemia.SM76-10SM76-50SM76-100SM78-2 Plerixafor9Plerixafor is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4. The CXCR4 alpha-chemokine receptor and one of its ligands, SDF-1, are important in hematopoietic stem cell homing to the bone marrow and in hematopoietic stem cell quiescence. Plerixafor is one of the most efficient bone marrow stem cell mobilizers. Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells (HSC) into the peripheral circulation and is synergistic when combined with G-CSF.SM78-10SM78-25SM78-50SM78-200SM79-1PP1;PP1 is a selective and potent Src-family tyrosine kinase inhibitor. PP1 studies have proved its ability to potently inhibit Lck and Fyn (FynT), IL-2 gene activation in T lymphocytes, and anti-CD3-induced protein tyrosine phosphorylation. Research indicates that PP1 effectively blocks LPA and EGF-enhanced tyrosine phosphorylation, MAPK activation downstream of EGFR, Rsk-1 (p90RSK) activation by H2O2, Kit and Bcr-Abl tyrosine kinases, and degrades RETMEN2A and RETMEN2B oncoproteins via proteosomal targeting. PP1 and its analog, PP2, are powerful inhibitors of TGF-�-induced cell migration and invasion in vitro. It inhibits anti-CD3-induced T cell tyrosine phosphorylation, TcR-induced T cell proliferation, and IL-2 gene induction. PP1 has been demonstrated to reduce the expression of vascular endothelial growth fact< or (VEGF), protect the blood-brain barrier, reduce brain edema immediately after subarachnoid hemorrhage, and offer cerebral protection against stroke. It prevents metastatic spread in late-stage pancreatic ductal adenocarcinoma and non-small cell lung cancer.SM79-5SM79-25SM80-5PTK787pPTK787 is an inhibitor of VEGFR2/KDR, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. PTK787 also inhibits Flk, c-Kit and PDGFR-�. PTK787 inhibits VEGFR-dependent tumor angiogenesis and EGFR- and RET-dependent tumor cell proliferation and survival. It shows the anti-proliferation effect by inhibiting thymidine incorporation induced by VEGF in HUVECs.SM80-25SM80-100 SM80-1000SM30-1Purmorphamine��Purmorphamine is an agonist of the protein Smoothened (Hh), a key part of the hedgehog signaling pathway, which is involved in bone growth and brain development as well as having a number of other functions in the body. Purmorphamine has been shown to induce osteogenesis in bone tissue as well as influencing growth and differentiation of neurons in the brain. The EC50 value for differentiation of C3H10T1/2 cells based on alkaline phosphatase expression is 1 �M.SM30-5SM30-10SM83-5 RapamycinsThis small molecule is a specific inhibitor of mTOR (mammalian target of Rapamycin). It forms a complex with FKBP12 that binds to and inhibits the molecular target of rapamycin (mTOR). It also exhibits selective signal blocking leading to the activation of p70/85 S6 kinase, which is potentially due to the inhibition of FRAP autophosphorylation or protein kinase activity. Rapamycin is a potent immunosuppressant and it has anticancer activity. It induces autophagy in yeast and mammalian cell lines. It is unique in its ability to inhibit lymphokine induced cell proliferation at the G1 and S phase as well as an irreversible cellular arrest at the G1 phase in S. cerevisiae cells. Angiogenesis inhibition is also exhibited, possibly through the inhibition of the Akt pathway. Rapamycin has been used in some endoderm differentiation studies from human embryonic stem cells (hESC).SM83-25SM83-50SM83-100 SM83-1000SM84-2Reboxetine mesylate�Reboxetine is a potent and selective norepinephrine reuptake inhibitor. It displays >1000-fold selectivity over �-adrenoceptors, 5-HT, dopamine and muscarinic ACh receptors. This small molecule stimulates neural stem cell (NSC) expansion.SM84-10SM84-25SM84-100SM85-1 Reversine�Reversine is a novel class of ATP-competitive Aurora kinase inhibitors. Reversine inhibits the phosphorylation of histone H3, a direct downstream target of Aurora kinases.�It acts as a selective A3 adenosine receptor antagonist.�Reversine functions as a dual inhibitor of MEK1 and nonmuscle myosin II heavy chain. It also acts as an ATP-competitive, reversible and selective inhibitor of ARK-1, ARK-2, and ARK-3. Reversine is the first organic molecule that has been demonstrated to reverse the cellular differentiation process. It is shown to induce mouse C2C12 myoblast cells to become multipotent mesenchymal progenitor cells, that could then be induced by osteogenic or adipogenic medium to re-differentiate into bone or adipose precursors, respectively. Moreover, reversine has been shown to promote cell reprogramming and induce dedifferentiation of multiple terminally differentiated mesodermal origin cells, and then differentiate into other cell types within mesodermal lineages as well as neuroectodermal.SM85-5SM85-10SM31-2RG108�DRG108 is a non-nucleoside DNA methyltransferase (DMNT) inhibitor. RG108 effectively blocked DNA methyltransferases in vitro and does not cause covalent enzyme trapping in human cell lines. RG108 significantly reduces the methylation of genomic DNA in cells at 10 �M without detectable toxicity, distinguishing it from nucleoside-based inhibitors like 5-azacytidine. Through these actions, RG108 demethylates and reactivates epigenetically silenced tumor suppressor genes. RG108 inhibits human tumor cell line (HCT116, NALM-6) proliferation and increased doubling time in culture.SM31-10SM31-50SM86-10 Rosiglita< zone�Rosiglitazone is a potent and selective agonist for PPAR� (Peroxisome proliferator-activated receptor). PPAR� plays a functional role in adipogenesis, it belongs to a group of nuclear receptor proteins that are essential to the regulation of cellular differentiation, development and metabolism. It activates luciferase-based expression constructs PPAR�1 and PPAR�2. It is antidiabetic, working as an insulin sensitizer by binding to the PPAR� receptors in fat cells and making the cells more responsive to insulin. Rosiglitazone induced adipocyte differentiation in pluripotent C3H10T1/2 stem cells. It also significantly increased the differentiation of multinucleated osteoclasts.SM86-50SM86-200 SM86-1000SM87-2 Ruxolitinib�Ruxolitinib is a JAK inhibitor of JAK1, JAK2, and JAK3. JAKs, or Janus-associated kinases, are tyrosine kinases found in the cytoplasm that are known to active the signaling of certain growth factor receptors and cytokines. AK inhibition with ruxolitinib could work as pretreatment for allogeneic stem cell transplantation in myelofibrosis. Ruxolitinib inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less inhibitory effect on the self-renewal of CD34+ hematopoietic progenitors.SM87-10SM87-25SM87-100SM88-10SAHA�SAHA (suberoylanilide hydroxamic acid) is a potent, reversible pan-histone deacetylase (HDAC) inhibitor. It inhibits both class I and class II HDACs. Experiments suggest that SAHA causes morphological changes, such as enlargement and flattening of the cytoplasm, resulting in growth inhibition. SAHA alters gene transcription and induces cell cycle arrest and/or apoptosis in a wide variety of transformed cells. It suppresses cell growth in a range of cancer cell lines; induces apoptosis in cutaneous T-cell lymphoma cells in vitro. This small molecule improves reprogramming efficiency after transduction of iPSC transcription factors in mouse embryonic fibroblasts.SM88-50SM88-250SM88-500 SM88-1000SM32-2 SB203580��SB203580 is a specific inhibitor of p38-MAPK pathway. SB203580 also inhibits protein kinase B (PKB, also known as Akt) and TLR signaling pathway. SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3-5 �M. SB203580 suppresses the development of endometriosis by down-regulating proinflammatory cytokines and proteolytic factors in a mouse model. It is a new reversal agent of P-glycoprotein-mediated multidrug resistance.SM32-10SM32-50SM32-100SM90-2SB216763�SB216763 is a potent, selective, and cell permeable glycogen synthase kinase-3 (GSK-3) inhibitor. It competes with ATP and potently inhibits the activity � and � isozymes of GSK-3. GSK-3 is a serine/threonine protein kinase that is inhibited by an assortment of extracellular stimuli including insulin, growth factors, cell specification factors, and cell adhesion. SB216763 protects both central and peripheral nervous system neurones in culture from death induced by reduced PI 3-kinase pathway activity. Treatment of primary neural progenitor cells with SB216763 resulted in an increase in the percentage of TuJ1-positive immature neurons, suggesting an inhibitory role of GSK3 in embryonic neurogenesis. It stimulates glycogen synthesis in Chang human liver cells. SB216763 treatment reduces cell viability in a dose-dependent manner, and leads to significant increase in apoptosis due to the specific down regulation of GSK-3�.SM90-10SM90-25SM90-50SM90-200SM33-2 SB431542�JSB431542 is a potent and selective inhibitor of the transforming growth factor-� superfamily type 1 (TGF-�1) activin receptor-like kinase (ALK5) receptors, and its relatives ALK4 and ALK7. It does not affect the BMP receptors ALK2, ALK3, ALK6. SB431542 inhibits the TGF-�-mediated activation of SMAD proteins, expression of collagen and fibronectin, cell proliferation and cell motility. It does not inhibit kinases that are activated in response to serum or stress such as ERK, p38 or JNK. It suppresses TGF-�-induced proliferation of human osteosarcoma cells. SB4315< 42 treatment of glioma cultures inhibited proliferation, TGF-beta-mediated morphologic changes, and cellular motility. Small molecule inhibitors of TGF-beta receptors may offer a novel therapy for malignant gliomas by reducing cell proliferation, angiogenesis, and motility.SM33-10SM33-50SM33-200SM48-1SB590885YSB590885 is another selective small-molecule inhibitor of the B-Raf kinase. It has been used to overcome the dependence of MAPK signaling and tumor cell growth on BRaf kinase activity. The inhibition of MAP kinase is one of the vital ways to get rid of un-wanted tumor growth. SB590885 also act as an angiogenesis inhibitor and it helps in the research studies of different important kinase pathways. In melanoma and colorectal cancer cell lines with B-Raf V600E mutation, an effective inhibition of cell proliferation was achieved by using SB590885 at concentrations that blocked ERK phosphorylation.SM48-5SM48-50SM95-10 Sorafenib;Sorafenib is a multikinase inhibitor with activity against Raf kinase and several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), FLT3, Ret, and c-Kit. It suppresses ERK phosphorylation. It also induces the phosphorylation of PKA. Sorafenib has anti-tumor activity in HCC models may be attributed to inhibition of tumor angiogenesis (VEGFR and PDGFR) and direct effects on tumor cell proliferation/survival (Raf kinase signaling-dependent and signaling-independent mechanisms).SM95-50SM95-500 SM95-1000SM41-2SP600125eSP600125 is a potent, selective and reversible inhibitor of the three JNK enzymes (c-Jun N-terminal kinases). Inhibition is competitive with respect to ATP, and over 300-fold more selective for JNK as compared to ERK1 and p38-2 MAP kinases. SP600125 was shown to cause a dose-dependent inhibition of the phosphorylation of c-Jun, and thereby the expression of inflammatory genes COX-2, IFN-�, IL-2 and TNF-�. SP600125 blocks the activation and differentiation of primary human CD4 cell cultures. SP600125 has also been shown to prevent apoptosis in an array of cell types, and it inhibits autophagy in HeLa cells.SM41-10SM41-50SM41-100SM41-300300 mgSM96-1 Stauprimide�Stauprimide is an indolocarbazole semi-synthetic small molecule. Stauprimide inhibits the nuclear localization of NME2, blocking and downregulating c-Myc expression. The expression of c-Myc is crucial for embryonic stem cell (ESC) self-renewal, and intervention by Stauprimide allows for more efficient lineage-specific differentiation. NME2 is also indicated to be upregulated in certain cancers, indicating further application for the blocking action of this small molecule. Stauprimide may be used to study the signaling involved in differentiation of ESC. It increased definitive endodermal markers but not markers for visceral/parietal endoderm or mesoderm. Stauprimide-differentiated cells could be further differentiated into hepatocytes. It also enabled differentiation into other cell lineages under varying differentiation conditions, including neurons, hematopoietic mesoderm, beating cardiac myocytes, and skeletal muscle.SM96-5SM96-100SM97-1 Staurosporine#Staurosporine is a potent inhibitor of phospholipid/calcium-dependent protein kinase. It also inhibits the upregulation of VEGF expression in tumor cells. It partially reverses MDR, sensitizing cells with MDR phenotype to cytotoxic agents. It inhibits Pgp phosphorylation. It is also a broad spectrum inhibitor of serine/threonine kinases. Staurosporine has several effects on cell function, including interruption of cell-cell contacts, decreasing focal contact size, inducing epithelial to mesenchyme transition, and promoting cell differentiation. Staurosporine has the ability to influence lineage choice during pluripotent cells differentiation. The addition of staurosporine to differentiating mouse EPL resulted in preferential formation of mesendoderm and mesoderm populations, and inhibited the formation of neurectoderm. Addition of staurosporine to human ESC similarly indu< ced primitive streak marker gene expression. Staurosporine induced the expression of mesendoderm markers in the absence of known inducers of formation, such as serum and BMP4.SM97-5SM97-10SM97-50SM98-5 StemRegenin 1tStemRegenin 1 is an AhR inhibitor. StemRegenin 1 induces CD34+ cell expansion by binding and antagonizing AhR. StemRegenin 1 treatment accelerates the proliferation of CD34+ cells. Sequential coculture with BMP-4, PGE2, and StemRegenin 1 leads to robust Macaca nemestrina iPSC hematopoietic progenitor cell formation. Culture of mPB CD34+ cells with cytokines plus StemRegenin 1 increases the number of CD34+, CD133+ and CD90+ hematopoietic stem and progenitor cell populations compared to control cells. StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells.SM98-25SM98-50SM98-100SM99-1SU5402�SU5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor. Multiple myeloma studies suggest that SU5402 inhibits FGFR3 phosphorylation in vitro. Additionally, SU5402 has been observed to inhibit IL-1�-induced MAPK activity. SU5402 is used in an embryonic stem cells (ESC) culture method with three inhibitors (3i: SU5402 for FGFR, PD184352 for ERK, and CHIR99021 for GSK3). It has been showed that this 3i method is extremely instrumental in establishing and culturing germline-competent ESC. It inhibits embryonic left-right determination and exhibits potent anticancer activity in vitro and in vivo.SM99-5SM99-10SM99-50SM100-2SU6668�SU6668 is an ATP-competitive PDGFR, Flk-1/KDR and FGFR inhibitor. It presents little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2. It does not inhibit EGFR. SU6668 inhibits proliferation of HUVEC and NIH3T3 cells in vitro and induces >75% growth inhibition against a broad range of tumor types. SU6668 shows antiangiogenic, anti-inflammatory, antimetastatic and proapototic activity and is orally active.SM100-10SM100-50 SM100-200SM101-10 Sunitinib^Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFR�. It also inhibits c-Kit. Sunitinib inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Sunitinib has been shown to impinge on the osteoblast differentiation process in vitro. It exhibits antiangiogenic and antitumor activity in multiple xenograft models.SM101-50 SM101-300 SM101-500 SM101-1000SM102-10 Tandutinib�Tandutinib is a piperazinyl quinazoline receptor tyrosine kinase inhibitor. Tandutinib inhibits the autophosphorylation of Flt-3/Flk-2 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases. Tandutinib is an inhibitor of PDGFR-beta. Tandutinib inhibits cellular proliferation and induces apoptosis. Tandutinib works as a stem-like cells targeted agent to increase efficiency of anticancer drugs. It has antineoplastic activity.SM102-50 SM102-100 SM102-1000SM103-1TG101348ETG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor.TG101348 also inhibits FLT3 and RET. TG101348 exhibits promising pharmacokinetic profiles. TG101348 inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less inhibitory effect on the self-renewal of CD34+ hematopoietic progenitors.SM103-5SM103-10SM103-50SM35-2 Thiazovivin�7Thiazovivin is a selective, cell permeable small molecule that directly inhibits Rho-associated kinase. Thiazovivin protects human embryonic stem cells (hESC) in the absence of ECM by regulating E-cadherin mediated cell-cell interaction. Thiazovivin also promotes single cell passage of human pluripotent cells.SM35-10SM35-50SM36-1Trichostatin A��Trichostatin A is a potent and specific inhibitor of histone deacetylase (HDAC). HDAC is overexpressed in a variety of cancers and is closely correlated with oncogenic factors.SM36-5SM36-25SM105-2TWS119�TWS119 is a cell-permeable pyrrolopyrimidine compound that acts as a glycogen synthase kinase-3� (GSK-3�) inhibitor. TWS119 is thought to bind < GSK-3� with high-affinity and increases the level of �-catenin, a downstream substrate of GSK-3� in the Wnt signaling pathway. TWS119 induces neuronal differentiation in pluripotent murine embryonal carcinoma cells and embryonic stem cells (ESC). Because neuronal differentiation can be achieved without embryoid bodies (EB) formation and RA treatment, TWS119 may act by a novel mechanism on early processes involved in determining cell fate. TWS119 treatment towards hepatic stellate cells leads to reduced �-catenin phosphorylation, induces nuclear translocation of �-catenin, elevates glutamine synthetase production, impedes synthesis of smooth muscle actin and Wnt5a, but promotes the expression of glial fibrillary acidic protein, Wnt10b, and paired-like homeodomain transcription factor 2c.SM105-10SM105-25SM105-50SM106-5U01261U0126 is a selective MAP Kinase inhibitor, displaying a preference for MEK-1 and MEK-2. It is known that U0126 binds to MEK in a noncompetitive manner compared to ATP. Studies suggest that U0126 antagonizes the transcription of AP-1, via the inhibition of MEK. In addition, U0126 has been observed to inhibit promoters containing an AP-1 response element, while in contrast having no effect on promoters that lack an AP-1 response group. U0126 is an activator of PGC-1, mtTFA and Nuclear Respiratory Factor. Inhibition of MEK/ERK activity by specific MEK inhibitors PD98059 and U0126 rapidly causes the loss of human embryonic stem cells (hESC) pluripotency, acting as a promoter of hESC differentiation. U0126 is also useful in neuronal studies in mice since it displays inhibitory effects against oxidative stress. SM106-25 SM106-100 SM106-300SM107-2 VandetanibAVandetanib is an antagonist of VEGFR and EGFR families. Specifically inhibits kinase activity of Flk-1. It is also an inhibitor of Flt-4. Vandetanib is not sensitive to PDGFR�, Flt1, Tie-2 and FGFR1, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R. Vandetanib is an antagonist of VEGFR and EGFR families. Specifically inhibits kinase activity of Flk-1. It is also an inhibitor of Flt-4. Vandetanib is not sensitive to PDGFR�, Flt1, Tie-2 and FGFR1, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R.SM107-25 SM107-100 SM107-500SM16-1WH-4-023WH-4-023 is a potent and selective inhibitor for Lck and Src kinase respectively. It poorly inhibits p38� and KDR. WH-4-023 in combination with other small molecules supports the self-renewal of naive human embryonic stem cells and maintenance of ground state pluripotency.SM16-5SM16-25SM16-50SM16-100SM16-500SM38-2XAV939XAV939 is a beta-catenin-mediated transcription inhibitor of selective Wnt pathway. Alternatively, it acts as axin stabilizing agent for the inhibition of TNKS1 and TNKS2. XAV939 inhibits growth of DLD-1 cells, an APC-deficient colorectal cancer cell line.SM38-10SM38-50SM38-200SM02-1Y-27632�Y-27632 dihydrochlorIde is a water-soluble Rho-associated protein Kinase (ROCK) inhibitor. Y-27632 increases the cloning efficiency of human embryonic stem cells (hESC). Enables the long term expansion of embryonic stem cells (ESC) with single cell passage. ESC treated with Y-27632 in a serum-free medium were consistently differentiated into many cell types, including neurons, muscle cells and hepatocytes.SM02-5SM02-10SM02-100GFH6-2 Activin A�Human Activin A is a disulfide-linked homodimer of two beta A chains. Activin A is a TGF-beta family member with a wide range of biological activities including regulation of cellular proliferation and differentiation, and promotion of neuronal survival. The biological activities of Activin A can be counteracted by inhibins and also by the diffusible TGF-beta antagonist, Follistatin.GFH6-1010 ugGFH6-100GFH6-500500 ug GFH6-1000GFH6AF-2Activin A (AF) GFH6AF-10 GFH6AF-100 GFH6AF-500 GFH6AF-1000GFM29-2xActivin A is a member of the TGF-beta family of proteins produced by many cell types throughout development. Activins interact with Type I and Type II serine/threonine < kinases to signal to SMAD proteins to regulate a variety of functions, including cell proliferation, differentiation, wound healing, apoptosis and metabolism. Activin A is a homodimer of two beta A chains and is not biologically active until the N terminal propeptide is cleaved from each. Mouse Activin A has 100% amino acid sequence identity to human, rat, porcine, bovine and feline proteins. Recombinant mouse Activin A is a non-glycosylated homodimer peptide.GFM29-10 GFM29-100 GFM29-500 GFM29-1000 GFM29AF-2 GFM29AF-10 GFM29AF-100 GFM29AF-500 GFM29AF-1000GFR6-2nActivin A is a member of the TGF-beta family of proteins produced by many cell types throughout development. Activins interact with Type I and Type II serine/threonine kinases to signal to SMAD proteins to regulate a variety of functions, including cell proliferation, differentiation, wound healing, apoptosis and metabolism. Activin A is a homodimer of two beta A chains and is not biologically active until the N terminal propeptide is cleaved from each. Rat Activin A has 100% amino acid sequence identity to human, mouse, porcine, bovine and feline proteins. Recombinant rat Activin A is a non-glycosylated homodimer.GFR6-10GFR6-100GFR6-500 GFR6-1000GFR6AF-2 GFR6AF-10 GFR6AF-100 GFR6AF-500 GFR6AF-1000GFH23-5Artemin5 ugQArtemin is a novel member of the glial cell line-derived neurotrophic factor (GNDF) ligand family. Current evidence suggests that Artmenin signals through the receptor complex, GFRalpha3-RET, to influence neuron survival�in vitro�and�in vivo. Recombinant human Artemin is a disulfide-linked homodimer, non-glycosylated polypeptide chain.GFH23-20 GFH23-100 GFH23-500 GFH23-1000GFH24-5BAFF�Recombinant Human B cell activating factor (BAFF), is a Type II member of the TNF superfamily. Although it is typically a transmembrane protein expressed on T cells, macrophages and dendritic cells, it can also be cleaved in the extracellular region to produce a soluble form detectable in the serum. BAFF is thought to be important for the survival and maturation of peripheral B cells. This recombinant human BAFF contains the TNF-like domain.GFH24-20 GFH24-100 GFH24-500 GFH24-1000GFH27-5BCA-1 / CXCL13vB-cell Attracting Chemokine-1 (BCA-1) is also known as CXCL13 and has been shown to be expressed at high levels in lymphoid tissues such as the spleen, lymph nodes and Peyer s patches. It has been shown to activate signaling through the receptor BLR1 (Burkitt s lymphoma receptor 1) to chemoattract B cells. Recombinant Human BCA-1 is a non-glycosylated, polypeptide chain. GFH27-20 GFH27-100 GFH27-500 GFH27-1000GFH1-2BDNF$BDNF is a member of the nerve growth factor family of trophic factors. In the brain BDNF has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons. Some protein domains of BDNF are identical with those of NGF and another neurotrophic factor, designated NT-3 (neurotrophin-3). Polyclonal antibodies raised against murine NGF have been shown to cross-react with both NT-3 and BDNF. Recombinant Human BDNF is a homodimer, non-glycosylated, polypeptide chain.GFH1-10GFH1-100GFH1-500 GFH1-1000GFH192-5Beta-Defensin 3sBeta-Defensin 3 (BD-3), also known as DEFB-3, is a member of the defensin class of antimicrobial peptides. Beta-Defensins exert host defense responses against viruses, bacteria, and fungi through the binding and permeabilizing of microbial membranes. BD-3 expression is stimulated by interferon-gamma and is an important molecule during adaptive immunity. BD-3 functions to activate monocytes and mast cells and has antibacterial functions towards Gram-negative and Gram-positive bacteria. Further, BD-3 blocks human immunodeficiency virus type 1 (HIV-1) replication through the downregulation of the HIV-1 co-receptor, CXCR4. GFH192-20 GFH192-100 GFH192-500 GFH192-1000GFH53-2BMP-2�BMP-2 belongs to the bone-growth regulatory factors that are members of the transforming growth factor-beta (TGF-beta) superfamily of proteins. They are syn< thesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins. Recombinant Human Bone Morphogenetic protein-2 produced in E. coli is a homodimeric non-glycosylated protein.GFH53-10 GFH53-100 GFH53-500 GFH53-1000GFH25-10 CD40 Ligand#CD40 Ligand or CD154 is a membrane glycoprotein and differentiation antigen expressed on the surface of T-cells. The CD40 ligand stimulates B-cell proliferation and secretion of all immunoglobulin isotypes in the presence of cytokines. CD40 ligand has been shown to induce cytokine production and tumoricidal activity in peripheral blood monocytes. It also co-stimulates proliferation of activated T-cells and this is accompanied by the production of IFN-gamma, TNF-alpha, and IL-2. Recombinant Human CD40L is a non-glycosylated polypeptide chain.GFH25-5050 ug GFH25-100 GFH25-500 GFH25-1000 GFH25AF-10CD40 Ligand (AF) GFH25AF-50 GFH25AF-100 GFH25AF-500 GFH25AF-1000GFM10-5'CD40 Ligand or CD154 is a membrane glycoprotein and differentiation antigen expressed on the surface of T-cells. The CD40 ligand stimulates B-cell proliferation and secretion of all immunoglobulin isotypes in the presence of cytokines. CD40 ligand has been shown to induce cytokine production and tumoricidal activity in peripheral blood monocytes. It also costimulates proliferation of activated T-cells and this is accompanied by the production of IFN-gamma, TNF-alpha, and IL2. Recombinant Mouse CD40 ligand is a non-glycosylated polypeptide chain.GFM10-2525 ug GFM10-100 GFM10-500 GFM10-1000GFH36-5ChemerinCChemerin is a chemoattractant expressed in white adipose, liver and lung tissues. Chemerin is a ligand for the G-protein coupled receptor known as ChemR23 (or chemokine-like receptor-1), which is expressed mainly on dendritic cells, macrophages and some adipocytes. Recombinant human Chemerin is a non-glycosylated protein.GFH36-25 GFH36-100 GFH36-500 GFH36-1000GFH59-5CNTFCNTF is a neurotrophic factor that promotes the survival of various neuronal cell types and may play an important role in the injury response in the nervous system. CNTF, like FGF-1, FGF-2 and PD-ECGF (platelet-derived endothelial cell growth factor), does not possess a signal sequence that would allow secretion of the factor by classical secretion pathways (endoplasmatic reticulum/Golgi system). The mechanism underlying the release of CNTF is unknown. Recombinant Human CNTF is a single, non-glycosylated polypeptide chain.GFH59-20 GFH59-100 GFH59-500 GFH59-1000 GFH59AF-5 CNTF (AF) GFH59AF-20 GFH59AF-100 GFH59AF-500 GFH59AF-1000GFH60-5CTGFPCTGF belongs to the CCN family of secreted proteins. CTGF is a member of cysteine rich regulatory proteins that are both mitogenic and chemotactic. Each protein has an Insulin-like Growth Factor (IGF)-binding domain, a thrombospoindin type 1 domain and cysteine knot region. CTGF has multiple effects on development and differentiation.GFH60-20 GFH60-100 GFH60-500 GFH60-1000 GFH26-100EGFEpidermal growth factor (EGF) is a neurotrophic factor that promotes the survival of various neuronal cell types and may play an important role in the injury response in the nervous system. Recombinant Human EGF is a single, non-glycosylated, polypeptide chain. GFH26-500 GFH26-1000 GFH26-5000 GFH26AF-100EGF (AF) GFH26AF-500 GFH26AF-1000 GFH26AF-5000 GFM53-100�Recombinant Mouse Epidermal Growth Factor has an effect on the differentiation of specific cells in vivo and is a potent mitogenic factor for a variety of cultured cells of both ectodermal and mesodermal origin. EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Epidermal Growth Factor Mouse Recombinant is a single, non-glycosylated, polypeptide chain containing 3 intramolecular disulfide-bonds. GFM53-500 GFM53-1000 GFM53-5000 GFM53AF-100Epidermal Growth Factor (EGF) is a growth factor that stimulates the proliferation of epithelial and < epidermal cells. EGF family members are characterized by three intramolecular disulfide bonds and can bind to four different receptor tyrosine kinases known as EGFR/ErbB1, ErbB2, ErbB3, and ErbB4. Recombinant mouse EGF is a non-glycosylated protein with 3 intra-molecular disulfide-bonds. Animal Free: This product is produced with no animal derived raw products, animal free equipment and animal free protocols. GFM53AF-500 GFM53AF-1000 GFM53AF-5000GFR5-20\Epidermal Growth Factor (EGF) is a growth factor that stimulates the proliferation of epithelial and epidermal cells. EGF family members are characterized by three intramolecular disulfide bonds and can bind to four different receptor tyrosine kinases known as EGFR/ErbB1, ErbB2, ErbB3, and ErbB4. Recombinant rat EGF is a non-glycosylated protein.GFR5-100100 ug GFR5-250250 ugGFR5-500 GFR5-10001 mg GFH7-5EG-VEGF / PROK1�Endocrine Gland-derived Vascular Endothelial Growth Factor (EG-VEGF) is an angiogenic growth factor specifically expressed in the ovaries, testis, adrenal and placental tissues. The identification of tissue-selective angiogenic factors raises the possibility that other secreted molecules in this class exist. EG-VEGF expression correlates with vascularity in polycystic ovary syndrome, a leading cause of infertility. Recombinant human EG-VEGF is a non-glycosylated protein.GFH7-20GFH7-100GFH7-500 GFH7-1000GFH185-5ENA 78 / CXCL5ENA 78 (CXCL5) is a chemokine that recruits neutrophils. There are 2 variants of this protein. This version is amino acids 5-78 and the other variant is amino acids 8-78. ENA 78 is a non-glycosilated protein, containing 74 amino acids and with a molecular weight of 8.1 kDa. GFH185-20 GFH185-100 GFH185-500 GFH185-1000GFH178-5Eotaxin / CCL11�Eotaxin (or CCL11) is a chemokine that recruits eosinophils to the site of allergic reactions. Eotaxin signals through the GPCR, CCR3. Eotaxin is a non-glycosylated protein, containing 74 amino acids, with a molecular weight of 8.3 kDa. GFH178-20 GFH178-100 GFH178-500 GFH178-1000GFH179-5Eotaxin 3 / CCL26Eotaxin 3 (or CCL26) is a chemokine that is made by a variety of cells stimulated by IL-4 or IL-13. Eotaxin signals through the GPCR, CCR3, and acts to recruit eosinophils and basophils. Non-glycosylated protein, containing 71 amino acids, with a molecular weight of 8.4 kDa. GFH179-20 GFH179-100 GFH179-500 GFH179-1000GFH06-5Exodus-2 / CCL21�Exodus-2, also known as CCL21 and 6Ckine, is a chemokine that is strongly produced in the human lymph nodes and spleen. Exodus-2 signals through the chemokine receptor CCR7 to regulate thymocyte and activated T cell migration, but is not chemotactic for monocytes. Exodus-2 also mediates the homing of lymphocytes to the lymphatic system. Human and mouse Exodus-2 share > 85% amino acid identity.GFH06-20 GFH06-100 GFH06-500 GFH06-1000GFM35-5�Exodus�-2, also known as CCL21 and 6Ckine, is a novel chemokine produced at high levels in human lymph node tissue and the spleen. 6Ckine signals through the CCR7 receptor to recruit thymocytes and activated T cells in vitro, but is not known to be chemotactic for monocytes. Human and mouse Exodus-2 share >85% amino acid identity. Recombinant mouse Exodus�-2 is a nonglycosylated protein.GFM35-20 GFM35-100 GFM35-500 GFM35-1000GFH29-10FGF-1�FGF-1 is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of angiogenesis. It binds to heparin, which potentiates its biological activity and protects it from proteolysis. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages, and also has chemotactic and mitogenic activities. Other homologous FGF belonging to the same family are int-2 (FGF-3), FGF-5, FGF-6, K-FGF and KGF (keratinocyte growth factor = FGF-7). All factors are products of different genes, some of which are Oncogene products (FGF-3, FGF-4, FGF-5). Recombinant Human FGF-1 is a single, non-glycosylated, polypeptide chain.GFH29-50 GFH29-100 G< FH29-500 GFH29-1000GFM48-10Recombinant FGF-1 is one of over 20 members of the FGF family. The fibroblast growth factors play a central role in prenatal development and growth and regeneration of cells during the proliferation and differentiation stages. Mouse FGF-1 is non-glycosylated heparin binding protein.GFM48-50 GFM48-100 GFM48-500 GFM48-1000GFH28-10 FGF-2 (147) A single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of angiogenesis. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor. Recombinant Human FGF-b (FGF-2) produced is a single, non-glycosylated, polypeptide chain. GFH28-50 GFH28-500 GFH28-1000 GFH28AF-10FGF-2 (147) (AF)�A single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of angiogenesis. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor. Recombinant Human FGF-b (FGF-2) produced is a single, non-glycosylated, polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH28AF-50 GFH28AF-100 GFH28AF-500 GFH28AF-1000 GFH146-10 FGF-2 (154) �A single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of angiogenesis. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor. Recombinant Human FGF-2 is a single, non-glycosylated, polypeptide chain. GFH146-50 GFH146-100 GFH146-500 GFH146-1000 GFH146AF-10FGF-2 (154) (AF)zA single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of angiogenesis. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor. Recombinant Human FGF-b (FGF-2) is a single, non-glycosylated, polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH146AF-50 GFH146AF-100 GFH146AF-500 GFH146AF-1000GFM12-10FGF-2�Fibroblast Growth Factors, FGFs, are a 22 member family of proteins known to be involved in angiogenesis, wound healing and embryonic development. As a family, they bind to heparin and signal through four receptor tyrosine kinases called, FGFR1, 2, 3 and 4. Although the mechanism remains unclear, FGF-basic is a critical component in keeping embryonic stem cells undifferentiated in cell culture systems. Recombinant mouse FGF basic is a non-glycosylated protein.GFM12-50 GFM12-100 GFM12-500 GFM12-1000GFR2-10:Fibroblast Growth Factors (FGFs) are a 22 member family of proteins known to be involved in angiogenesis, wound healing and embryonic development. As a family, they bind to heparin and signal through four receptor tyrosine kinases called, FGFR1, 2, 3 and 4. Recombinant rat FGF-basic is a non-glycosylated protein.GFR2-50GFR2-100GFR2-500 GFR2-1000 GFR2AF-10 FGF-2 (AF)�Fibroblast Growth Factors (FGFs) are a 22 member family of proteins known to be involved in angiogenesis, wound healing and embryonic development. As a family, they bind to heparin and signal through four receptor tyrosine kinases called, FGFR1, 2, 3 and<  4. Recombinant rat FGF-basic is a non-glycosylated protein. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFR2AF-50 GFR2AF-100 GFR2AF-500 GFR2AF-1000GFH31-5FGF-4�Fibroblast Growth Factor 4 (FGF-4) is a growth factor predominantly expressed during embryonic development, playing a key role in limb development. In culture, FGF-4 has been shown to be an important growth factor for fibroblasts and endothelial cells. Human FGF-4 shares high homology and cross-reactivity with the mouse protein. Recombinant human FGF-4 is a non-glycosylated protein.GFH31-25 GFH31-100 GFH31-500 GFH31-1000GFH187-2 FGF-7 / KGFSFibroblast Growth Factor 7 (FGF-7) is a growth factor predominantly expressed during embryonic development, playing a key role in limb development. In culture, FGF-7 might be important for epithelial cell proliferation. Recombinant Human FGF-7 is a non-glycosilated protein containing 164 amino acids and with a molecular weight of 19 kDa. GFH187-10 GFH187-100 GFH187-500 GFH187-1000 GFH187AF-2FGF-7 / KGF (AF) GFH187AF-10 GFH187AF-100 GFH187AF-500 GFH187AF-1000GFH176-5FGF-8�Fibroblast Growth Factor 8 (FGF-8) is a critical factor in embryonic development of the brain structure and also required for normal development of the eye, ear and limbs. FGF-8 has broad functions that involve proliferation, differentiation and cell migration. Inappropriate expression of FGF-8 is linked to increased tumor growth and angiogenesis. There is 100% homology between human and mouse FGF-8. FGF-8 is a non-glycosylated protein containing 194 amino acids, with a total molecular weight of 22.5 kDa. GFH176-25 GFH176-100 GFH176-500 GFH176-1000 GFH176AF-5 FGF-8 (AF) GFH176AF-25 GFH176AF-100 GFH176AF-500 GFH176AF-1000GFM72-5GFM72-25 GFM72-100 GFM72-500 GFM72-1000 GFM72AF-5 GFM72AF-25 GFM72AF-100 GFM72AF-500 GFM72AF-1000GFM13-2FGF-9@Fibroblast growth factor 9 (FGF-9) is a steroid-regulated mitogen and survival factor for nerve and mesenchymal cells, it is an autocrine/paracrine growth factor considered to be important for the growth and survival of motorneurons and prostate. Recombinant Mouse FGF-9 is a single, non-glycosylated, polypeptide chain.GFM13-10 GFM13-100 GFM13-500 GFM13-1000GFR27-2GFR27-10 GFR27-100 GFR27-500 GFR27-1000GFH183-5FGF-10(Fibroblast Growth Factor 10 (FGF-10) is a growth factor involved in a broad range of functions that include tissue repair, morphogenesis, proliferation, embryonic development, among others. FGF-9 is a non-glycosylated protein containing 170 amino acids, with a total molecular weight of 19.2 kDa. GFH183-25 GFH183-100 GFH183-500 GFH183-1000 GFH183AF-5 FGF-10 (AF) GFH183AF-25 GFH183AF-100 GFH183AF-500 GFH183AF-1000GFH148-5FGF-21�Fibroblast Growth Factors (FGFs) are a 22 member family of proteins known to be involved in angiogenesis, wound healing and embryonic development. As a family, they bind to heparin and signal through four receptor tyrosine kinases called, FGFR1, 2, 3 and 4. FGF-21 is most closely related to FGF-19 and shows low binding to heparin and is highly diffusible. Recombinant human FGF-21 is a non-glycosylated protein. GFH148-20 GFH148-100 GFH148-500 GFH148-1000GFH68-5FGF-22iHuman FGF-22 is a member of the FGF-7 subfamily of growth factors. Human FGF-22 shares 86% homology to Mouse FGF-22, and is synthesized by multiple cell lines including neurons, keratinocytes and skeletal muscle myotubes. It is believed to function as an organizer of the presynaptic apparatus. Recombinant Human FGF-22 is a nonglycosylated polypeptide protein.GFH68-20 GFH68-100 GFH68-500 GFH68-1000GFH21-2FLT-3-LG�This ligand binds to Fms-Like Tyrosine Kinase-3 (FLT-3). Human FLT-3 Ligand also stimulates the proliferation of cells expressing murine FLT-3 receptors. The effects of FLT-3 Ligand are synergized by coexpression of G-CSF, GM-CSF, M-CSF, IL-3 and SCF. FLT-3 ligand promotes long-term expansion and differentiation of human pro-B-cells in the presence of IL-7 or in combination of IL-7 and IL-3. Recom< binant Human FLT-3 Ligand is a non-glycosylated, polypeptide chain. GFH21-10 GFH21-100 GFH21-500 GFH21-1000 GFH21AF-2 FLT-3-LG (AF) GFH21AF-10 GFH21AF-100 GFH21AF-500 GFH21AF-1000GFM6-2 FMS-related Tyrosine Kinase 3 Ligand (FLT-3 Ligand) is a growth factor important for the proliferation of hematopoietic cells. FLT-3 Ligand binds to, and transmits signals through, the receptor tyrosine kinase known as FLT-3. FLT-3 Ligand promotes long-term expansion and differentiation of human pro-B cells in the presence of IL-7 or in combination of IL-7 and IL-3. Human FLT-3 Ligand can stimulate the proliferation of cells expressing murine FLT-3 receptors. Recombinant mouse FLT-3 Ligand is a non-glycosylated protein.GFM6-10GFM6-100GFM6-500 GFM6-1000GFH41-5 Follistatin�Follistatin is an autocrine acting protein that is expressed by many tissues, but at noteably higher levels in the ovary and skin. Follistatin functions to negatively regulate the signaling of a wide variety of TGF-beta family members (activin, BMPs, myostatin, GDF-11 and TGF-beta 1). Mechanistically, follistatin works as an antagonist by complexing with TGF-beta family members to prevent them from interacting with their signaling receptors. Recombinant human Follistatin is a non-glycosylated protein.GFH41-20 GFH41-100 GFH41-500 GFH41-1000GFM24-5GFM24-20 GFM24-100 GFM24-500 GFM24-1000GFH174-5 Fractalkine�Fractalkine, also known as CX3CL1, is an atypical chemokine that was the first of a fourth chemokine motif (CX3C). It is thought to function as a T cell and monocyte chemoattractant and is produced by non-hematopoietic cells. Fractalkine is made in a soluble and membrane bound form in activated endothelial cells which is thought to promote adhesion of leukocytes. Recombinant human Fractalkine is a non-glycosylated protein. GFH174-20 GFH174-100 GFH174-500 GFH174-1000GFH156-5gACRP-30gRecombinant human globular ACRP-30 is a natural product produced when processed from the full length adiponectin molecule. Produced by adipocytes, this plasma protein exists in high concentrations (0.05%) as a serum protein. ACPR-30 plays an important role in hyperclycemia and insulin resistance. Recombinant Human ACRP-30 is a non-glycosylated polypeptide. GFH156-25 GFH156-100 GFH156-500 GFH156-1000GFH30-10 Galectin-1+Human Galectin-1 belongs to a large family of carbohydrate-binding proteins that contain structural similarities in there carboyhydrate recognition domains. Galectin-1, also known as L-14, BHL or galaptin, can be either monomeric or homodimeric, and is found in a wide varity of cells and tissue types. Galectin-1 controls cell growth and proliferation and induces apoptosis of activated T cells. It can also modulate cytokine secretion or inhibit pro-inflammatory cytokine production. Galectin-1 plays an important role in acute and chronic inflammation.GFH30-50 GFH30-100 GFH30-500 GFH30-1000 GFH154-10 Galectin-3�Recombinant Human Galectin-3 is a member of a large family of carbohydrate-binding proteins. Also known as Mac-2, L29 and CBP35, Human Galectin-3 is expressed by a wide range of cell types including activated T- cells, tumor cells, macrophages, osteoclasts, fibroblasts and epithelial cells. Galectin-3 exhibits proinflammatory activities both in vitro and in vivo. Galectin-3 also chemoattracts monocytes and macrophages. Increased circulating levels of Galectin-3 correlate with several types of cancer, suggesting Galectin -3 is involved in tumor growth and metastasis. Human and Mouse Galectin-3 share 80% homology by amino acid sequence. Human Galectin-3 is a recombinant polypeptide chain. GFH154-50 GFH154-100 GFH154-500 GFH154-1000GFH72-2G-CSF�Human G-CSF induces the survival, proliferation and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. The synthesis of G-CSF can be induced by bacterial endotoxins, TNF, IL-1 a< nd GM-CSF. Prostaglandin E2 inhibits the synthesis of G-CSF. In epithelial, endothelial and fibroblastic cells secretion of G-CSF is induced by IL-17. Human and mouse G-CSF are cross-reactive. Recombinant Human G-CSF is a single, non-glycosylated polypeptide chain.GFH72-10 GFH72-100 GFH72-500 GFH72-1000 GFH72AF-2 G-CSF (AF) GFH72AF-10 GFH72AF-100 GFH72AF-500 GFH72AF-1000GFM14-2�G-CSF is a glycoprotein containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. The synthesis of G-CSF can be induced by bacterial endotoxins, TNF, IL-1 and GM-CSF. Prostaglandin E2 inhibits the synthesis of G-CSF. In epithelial, endothelial, and fibroblastic cells secretion of G-CSF is induced by IL-17. Recombinant Mouse G-CSF is a single, non- glycosylated, polypeptide chain.GFM14-10 GFM14-100 GFM14-500 GFM14-1000GFH71-10GDF-5 / BMP-14�Growth/Differentiation Factor 5 (GDF-5), or BMP-14, is very closely related to bone morphogenetic protein (BMP) and a member of the TGF beta super family of proteins. It is expressed in the developing central nervous system and is important for neuron survival for skeletal and joint development. Mouse and human GDF-5 are 98% identical. Recombinant Human GDF-5 is a non-glycosylated disulfide linked homodimer polypeptide chain.GFH71-50�Growth/Differentiation Factor 5 (GDF-5), or BMP 14, is very closely related to bone morphogenetic protein (BMP) and a member of the TGF� super family of proteins. It is expressed in the developing central nervous system and is important for neuron survival for skeletal and joint development. Mouse and human GDF-5 are 98% identical. Recombinant Human GDF-5 is a non-glycosylated disulfide linked homodimer polypeptide chain. GFH71-100 GFH71-500 GFH71-1000GFH57-5GDF-11 / BMP-11}Growth differentiation factor 11 (GDF-11 or BMP-11) is an important developmental factor that regulates muscular and neural development. In adults, GDF-11 is suspected to promote the reversal of cardiac hypertrophy by the regeneration of cardiomyocytes. GDF-11 is a non-glycosylated homodimer, containing two 109 amino acids chains, with each having a molecular weight of 12.5 kDa.GFH57-20 GFH57-100 GFH57-500 GFH57-1000 GFH57AF-5GDF-11 / BMP-11 (AF) GFH57AF-20 GFH57AF-100 GFH57AF-500 GFH57AF-1000GFH171-5GDF-15�Growth and Differentiation Factor 15 (GDF-15) is a TGF beta family member, made by the placenta and heart tissues, that has a role in regulating inflammatory and apoptotic pathways. GDF-15 has become an emerging marker of early heart disease and has the potential of being used as a molecule for screening patients for early heart failure. Recombinant human GDF-15 D is a non-glycosylated, disulfide linked homodimer. There is a His to an Asp substitution at position 7. GFH171-20 GFH171-100 GFH171-500 GFH171-1000GFH172-5GDF-15 D GFH172-20 GFH172-100 GFH172-500GFH2-2GDNFGlial-derived Neurotrophic Factor (GDNF) is a neurotrophic factor that is closely related to other neurotrophic factors, such as neurturin, persephin, and artemin, by a common structural feature called the cysteine-knot. GDNF signals through a multicomponent system of receptors that includes RET and GFR�1-4, to romote dopamine uptake, survival and differentiation of neurons. Recombinant human GDNF is a non-glycosylated homodimer, containing two 135 amino acid chains and with a total molecular weight of 30.4 kDa.GFH2-10GFH2-100GFH2-500 GFH2-1000GFH2AF-2 GDNF (AF) GFH2AF-10 GFH2AF-100 GFH2AF-500 GFH2AF-1000GFM37-2�Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a neurotrophic factor that is closely related to other neurotrophic factors, such as Neurturin, Persephin, and Artemin, by a common structural feature called the cysteine-knot. GDNF signals through a multicomponent system of receptors that include< s RET and GFR�1-4, to promote dopamine uptake, survival and differentiation of neurons. Recombinant mouse GDNF is a non-glycosylated homodimer.GFM37-10 GFM37-100 GFM37-500 GFM37-1000 GFM37AF-28Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a neurotrophic factor that is closely related to other neurotrophic factors, such as Neurturin, Persephin, and Artemin, by a common structural feature called the cysteine-knot. GDNF signals through a multicomponent system of receptors that includes RET and GFR�1-4, to promote dopamine uptake, survival and differentiation of neurons. Recombinant mouse GDNF is a non-glycosylated homodimer. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFM37AF-10 GFM37AF-100 GFM37AF-500 GFM37AF-1000GFR10-2�Glial�Cell Line-Derived�Neurotrophic�Factor, or�GDNF, is a�neurotrophic�factor that is closely related to other�neurotrophic�factors such as�Neurturin,�Persephin, and�Artemin, by a common structural feature called the�cysteine-knot.�GDNF�signals through a�multicomponent�system of receptors that includes receptors known as RET, and�GFR�1-4�to promote dopamine uptake, survival and differentiation of neurons. Recombinant rat�GDNF�is a�non-glycosylated�homodimer.GFR10-10 GFR10-100 GFR10-500 GFR10-1000 GFR10AF-2 GFR10AF-10 GFR10AF-100 GFR10AF-500 GFR10AF-1000GFH8-5GM-CSF"Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. GM-CSF receptors shows significant homologies with other receptors for hematopoietic growth factors, including IL-2 beta, IL-3, IL-6, IL-7, EPO and the Prolactin receptors. Recombinant Human GM-CSF is a single, non-glycosylated polypeptide chain. GFH8-20GFH8-100GFH8-500 GFH8-1000GFH8AF-5 GM-CSF (AF) GFH8AF-20 GFH8AF-100 GFH8AF-500 GFH8AF-1000GFM15-5�Mouse GM-CSF is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. GM-CSF receptors shows significant homologies with other receptors for hematopoietic growth factors, including IL-2 beta, IL-3, IL-6, IL-7, EPO and the Prolactin receptors. Recombinant mouse GM-CSF is a single, non-glycosylated, polypeptide chain.GFM15-20 GFM15-100 GFM15-500 GFM15-1000 GFM15AF-2 GFM15AF-20 GFM15AF-100 GFM15AF-500 GFM15AF-1000GFR3-5"Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is hematopoietic factor produced by entothelial cells, monocytes, fibroblasts and T cells in response to a number of inflammatory mediators. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. Human and mouse GM-CSF show no cross-reactivity. Recombinant rat GM-CSF is a non-glycosylated protein.GFR3-20GFR3-100GFR3-500 GFR3-1000GFH32-5Gro-alpha / CXCL1�GRO-alpha, also known as CXCL1, is a chemokine thought to have mitogenic properties and chemoattract neutrophils. Secreted by macrophages, epithelial cells, neutrophils and melanomas, GRO-alpha signals through chemokines receptor CXCL2 and has been implicated to be important in the processes of spinal co< rd formation, inflammation, angiogenesis, tumorigenesis, and wound healing. Recombinant human GRO-alpha is a single non-glycosylated peptide chain.GFH32-25 GFH32-100 GFH32-500 GFH32-1000GFM23-5�GRO-alpha, also known as CXCL1, is a chemokine thought to have mitogenic properties and chemoattract neutrophils. Secreted by macrophages, epithelial cells, neutrophils and melanomas, GRO-alpha signals through chemokine receptor, CXCR2, and has been implicated in the processes of spinal cord formation, inflammation, angiogenesis, tumorigenesis, and wound healing. Recombinant mouse GRO-alpha is a non-glycosylated protein.GFM23-20 GFM23-100 GFM23-500 GFM23-1000GFH123-2Gro-beta / CXLC2cThree human MGSA/GRO genes encode 3 highly related chemokines, MGSA/GRO alpha, -beta and -gamma. All 3 MGSA/GRO proteins bind to the same receptors, but with different affinities, and stimulate a number of biological responses including chemotaxis, angiogenesis, and growth regulation. Recombinant Human GRO-beta is a single, non-glycosylated polypeptide. GFH123-10 GFH123-100 GFH123-500 GFH123-1000GFH170-2Gro-gamma / CXCL3Growth Regulated Proteins (GRO) are a group of three proteins, GRO-alpha, -beta and  gamma, that are encoded by three distinct genes. All 3 GRO proteins can bind to the same receptors, but with different affinities, and stimulate a number of biological responses including chemotaxis, angiogenesis, and growth regulation. More specifically, GRO-gamma (also called CXCL3), can act through chemokine receptor CXCR2 to promote monocyte migration and adhesion. Recombinant human GRO-gamma is a non-glycosylated protein. GFH170-10 GFH170-100 GFH170-500 GFH170-1000 GFH40-100Growth Hormone�Growth Hormone (GH) stimulates growth and cell reproduction and regeneration in humans and other animals. Although GH is used to treat several growth disorders, it is thought to be a very complex hormone with many of its functions yet to be uncovered. GFH40-500 GFH40-1000 GFH40-5000 GFH40-10000 GFH180-10HB-EGF�Heparin Binding EGF-like Growth Factor (HB-EGF) is a growth factor expressed by monocytes and macrophages. HB-EGF mediates its effects via EGFR, ERBB2 and ERBB4 and has higher binding affinity to the EGFR than EGF itself. It is a mitogen for fibroblasts and smooth muscle cells, but not endothelial cells. HB-EGF is a non-glycosylated protein, containing 87 amino acids, with a molecular weight of 9.9 kDa. GFH180-50 GFH180-100 GFH180-500 GFH180-1000 GFH180AF-10 HB-EGF (AF) GFH180AF-50 GFH180AF-100 GFH180AF-500 GFH180AF-1000GFH54-20 IFN-alpha 2axInterferon-alpha 2a (IFN-alpha 2a) is a Type I interferon made by leukocytes during viral infection. It has anti-viral and non-proliferative activity induced by JAK1-STAT signaling. IFN-alpha 2s are the most widely used type for therapeutic purposes. IFN-alpha 2b is a variant of IFN� 2a that differs by one amino acid. Recombinant human IFN� 2a is a non-glycosylated protein. GFH54-100 GFH54-250 GFH54-500 GFH54-1000GFH52-20 IFN-alpha 2b�Interferon-alpha 2b (IFN-alpha 2b) is a Type I interferon made by leukocytes during viral infection. It has anti-viral and non-proliferative activity induced by JAK1-STAT signaling. IFN-alphas are the most widely used type for therapeutic purposes. IFN-alpha 2b is a variant of IFN-alpha 2a that differs by one amino acid. Recombinant human IFN-alpha 2b is a non-glycosylated protein. GFH52-100 GFH52-250 GFH52-500 GFH52-1000GFH77-20 IFN-gamma�Interferon-gamma (IFN-gamma) is a major immune-modulating molecule produced mainly by T cells and natural killer cells activated by antigens, mitogens or alloantigens. Most immune cells express IFN-gamma receptors and respond to IFN-gamma induced signaling by up-regulating MHC class I expression. Human IFN-gamma does not show cross-reactivity with mouse. Recombinant human IFN-gamma is a non-glycosylated protein. GFH77-100 GFH77-250 GFH77-500 GFH77-1000 GFH77AF-20IFN-gamma (AF) GFH77AF-100 GFH77AF-250 GFH77AF-500 GFH77AF-1000GFM16-20�The major interferon is produced by mitogenically or antigenically stimulated lymphocyte< s. It is structurally different from type I interferon and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease. IFN-gamma is produced mainly by T-cells and natural killer cells activated by antigens, mitogens, or alloantigens. It is produced by lymphocytes expressing the surface antigens CD4 and CD8. The synthesis of IFN-gamma is induced, among other things, by IL-2, FGF-2, and EGF. Recombinant Murine IFN-gamma is a single, non-glycosylated, polypeptide chain. GFM16-100 GFM16-250 GFM16-500 GFM16-1000GFR4-20�The major interferon is produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease. IFN-gamma is produced mainly by T-cells and natural killer cells activated by antigens, mitogens, or alloantigens. It is produced by lymphocytes expressing the surface antigens CD4 and CD8. The synthesis of IFN-gamma is induced, among other things, by Interleukin-2, FGF-2, and EGF. Recombinant Rat IFN-gamma is a single, non-glycosylated, polypeptide chain. GFR4-100GFR4-250GFR4-500 GFR4-1000GFH34-20IGF-1�IGF-1 is a well-characterized basic peptide believed to be secreted by the liver and circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. IGF-1 has a major, but not absolute, dependence on Somatotropin. It is believed to be mainly active in adults in contrast to Insulin-like Growth Factor 2, which is a major fetal growth factor. Recombinant Human IGF-1 is a single, non-glycosylated, polypeptide chain. GFH34-100 GFH34-1000 GFH34-5000 GFH34AF-20 IGF-1 (AF) GFH34AF-100 GFH34AF-1000 GFH34AF-5000GFM5-10�IGF-1 is a well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. IGF-1 has a major, but not absolute, dependence on Somatotropin. It is believed to be mainly active in adults in contrast to Insulin like Growth Factor 2, which is a major fetal growth factor. Recombinant mouse IGF-1 is a single, non-glycosylated, polypeptide chain. GFM5-50GFM5-100GFM5-500 GFM5-1000GFR1-10�IGF-1 is a well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. IGF-1 has a major, but not absolute, dependence on Somatotropin. It is believed to be mainly active in adults in contrast to Insulin like Growth Factor 2, which is a major fetal growth factor. Recombinant Rat IGF-1 is a single, non-glycosylated, polypeptide chain.GFR1-50GFR1-100GFR1-500 GFR1-1000GFH14-10IGF-26IGF is a well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. Insulin like Growth Factor 2 is a major fetal growth factor. Recombinant Human IGF-2 is a single, non-glycosylated, polypeptide chain.GFH14-50 GFH14-100 GFH14-500 GFH14-1000GFH182-5IHH�Indian Hedgehog (IHH) is a developmental factor found in the gut, cartilage and bones of an embryo. IHH acts through the patched (PTC) receptor and induces transcriptional changes important for bone development and include the up regulation of parathyroid hormone-related protein (PTHRP). IHH is a non-glycosylated protein, containing 177 amino acids, with a molecular weight of 20 kDa. GFH182-25 GFH182-100 GFH182-500 GFH182-1000 GFH182AF-5IHH (AF) GFH182AF-25 GFH182AF-100 GFH182AF-500 GFH182AF-1000GFM73-5TIndian Hedgehog (IHH) is a developmental factor found in the gut, cartilage and bones of an embryo. IHH acts through the patched (PTC) receptor and induces transcriptional changes important for bone development and include the up regulation of parathyroid hormone-related<  protein (PTHRP). There is 100% identity between human and mouse IHH.GFM73-25 GFM73-100 GFM73-500 GFM73-1000 GFM73AF-5 GFM73AF-25 GFM73AF-100 GFM73AF-500 GFM73AF-1000GFH173-2 IL-1 alphaInterleukin-1 alpha (IL-1 alpha) is constitutively expressed by epithelial cells, but can also be produced by most other cells upon stimulation. IL-1 alpha and IL-1 beta are two distinct and independently regulated gene products that comprise IL-1 and signal through the Type 1 IL-1 receptor (IL-1R1). Although IL-1 alpha is cell associated and IL-1 beta is secreted, they have nearly identical biological activity in that they induce adhesion molecule expression on epithelial cells, control fever induction, and play a role in arthritis and septic shock. Signaling activated by the IL-1R1 promotes these activities through a MYD88 signaling pathway similar to those associated with Toll receptors. Recombinant human IL-1 alpha is a non-glycosylated single chain protein. GFH173-10 GFH173-100 GFH173-500 GFH173-1000GFH167-2 IL-1 beta%Interleukin-1 beta (IL-1 beta) is a proinflammatory cytokine produced in response to inflammatory agents by a variety of cells, including monocytes, macrophages, and dendric cells (DCs). IL-1 beta and IL-1 alpha are two distinct and independently regulated gene products that comprise IL-1 and signal through the Type 1 IL-1 receptor (IL-1R1). Although IL-1 alpha is cell associated and IL-1 beta is secreted, they have nearly identical biological activity in that they induce adhesion molecule expression on epithelial cells, control fever induction, and play a role in arthritis and septic shock. Signaling activated by the IL-1R1 promotes these activities through a MYD88 signaling pathway similar to those associated with Toll receptors. Recombinant human IL-1 beta is a non-glycosylated single chain. GFH167-10 GFH167-100 GFH167-500 GFH167-1000 GFH167AF-2IL-1 beta (AF) GFH167AF-10 GFH167AF-100 GFH167AF-500 GFH167AF-1000GFM68-2'Interleukin-1 beta (IL-1 beta) is a proinflammatory cytokine produced in response to inflammatory agents by a variety of cells, including monocytes, macrophages, and dendritic cells (DCs). IL-1 beta and IL-1 alpha are two distinct and independently regulated gene products that comprise IL-1 and signal through the Type 1 IL-1 receptor (IL-1R1). Although IL-1 alpha is cell associated and IL-1 beta is secreted, they have nearly identical biological activity in that they induce adhesion molecule expression on epithelial cells, control fever induction, and play a role in arthritis and septic shock. Signaling activated by the IL-1R1 promotes these activities through a MYD88 signaling pathway similar to those associated with Toll receptors. Recombinant mouse IL-1 beta is a non-glycosylated single chain.GFM68-10 GFM68-100 GFM68-500 GFM68-1000GFR30-21Interleukin-1 beta (IL-1 beta) is a proinflammatory cytokine produced in response to inflammatory agents by a variety of cells, including monocytes, macrophages, and dendritic cells (DCs). IL-1 beta and IL-1 alpha are two distinct and independently regulated gene products that comprise IL-1 and signal through the Type 1 IL-1 receptor (IL-1R1). Although IL-1 alpha is cell associated and IL-1 beta is secreted, they have nearly identical biological activity in that they induce adhesion molecule expression on epithelial cells, control fever induction, and play a role in arthritis and septic shock. Signaling activated by the IL-1R1 promotes these activities through a MYD88 signaling pathway similar to those associated with Toll receptors. Recombinant Rat IL-1 beta is a non-glycosylated single polypeptide chain.GFR30-10 GFR30-100 GFR30-500 GFR30-1000GFH12-10IL-2IL-2 is an immunomodulatory cytokine produced by stimulated T-cells. Its activity is signaled via interaction with the IL-2R receptor. Recombinant IL-2 is a single, non-glycosylated polypeptide chain. Recombinant human IL-2 has a Ser substitute for Cysteine at position 126.GFH12-50 GFH12-100 GFH12-500 GFH12-1000 GFH12AF-10 IL-2 (AF) GFH12AF-50 GFH12AF-100 GFH12AF-500 GFH12AF-1000GFM17-5�Mo< use Interleukin-2, also know as T-cell Growth Factor, is an immunomodulatory cytokine produced by stimulated T-cells. Its activity is signaled via interaction with the IL-2R receptor. Recombinant IL-2 is a single, non-glycosylated polypeptide chain.GFM17-20 GFM17-100 GFM17-500 GFM17-1000GFR38-2BInterleukin-2 (IL-2) is an immunomodulatory cytokine that is produced by lymphocytes. IL-2 signals through the IL-2R receptor to induce activated T cell proliferation and promote T cell differentiation. IL-2 also stimulates the proliferation and differentiation of B cells, natural killer cells, monocytes and macrophages.GFR38-20 GFR38-100 GFR38-500 GFR38-1000 GFR38AF-2 GFR38AF-20 GFR38AF-100 GFR38AF-500 GFR38AF-1000GFH80-2IL-3.Interleukin-3 (IL-3) is a cytokine produced by activated T-cells and mast cells that is active on a broad range of hematopoietic cells and in the nervous system and appears to be important in several chronic inflammatory diseases. Recombinant Human IL-3 is a single, non-glycosylated polypeptide chain.GFH80-10 GFH80-100 GFH80-500 GFH80-1000 GFH80AF-2 IL-3 (AF)�Interleukin-3 (IL-3) is a cytokine produced by activated T-cells and mast cells that is active on a broad range of hematopoietic cells and in the nervous system and appears to be important in several chronic inflammatory diseases. Recombinant Human IL-3 is a single, non-glycosylated polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH80AF-10 GFH80AF-100 GFH80AF-500 GFH80AF-1000GFM1-2.Interleukin-3 (IL-3) is a cytokine produced by activated T-cells and mast cells that is active on a broad range of hematopoietic cells and in the nervous system and appears to be important in several chronic inflammatory diseases. Recombinant mouse IL-3 is a single, non-glycosylated polypeptide chain.GFM1-10GFM1-100GFM1-500 GFM1-1000GFM1AF-2�Interleukin-3 (IL-3) is a cytokine produced by activated T-cells and mast cells that is active on a broad range of hematopoietic cells and in the nervous system and appears to be important in several chronic inflammatory diseases. Recombinant mouse IL-3 is a single, non-glycosylated polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFM1AF-10 GFM1AF-100 GFM1AF-500 GFM1AF-1000GFH9-5IL-4�Interleukin-4 (IL-4), produced primarily by CD4(+) T cells, is an immunomodulatory cytokine, which can inhibit the growth of tumour cells. IL-4 has been known as a Th2 cytokine and can act on B cells, T cells, and monocytes. IL-4 exhibits antitumor activity in rodent experimental gliomas, which is likely mediated by the actions of IL-4 on a variety of immune cells present in and around the tumor masses. Recombinant Human IL-4 produced in E. coli is a single, non-glycosylated polypeptide chain.GFH9-20GFH9-100GFH9-500 GFH9-1000GFH9AF-5 IL-4 (AF)nInterleukin-4 (IL-4), produced primarily by CD4(+) T cells, is an immunomodulatory cytokine, which can inhibit the growth of tumour cells. IL-4 has been known as a Th2 cytokine and can act on B cells, T cells, and monocytes. IL-4 exhibits antitumor activity in rodent experimental gliomas, which is likely mediated by the actions of IL-4 on a variety of immune cells present in and around the tumor masses. Recombinant Human IL-4 produced in E. coli is a single, non-glycosylated polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH9AF-20 GFH9AF-100 GFH9AF-500 GFH9AF-1000GFM18-5�Mouse Interleukin-4, also known as BCDF or BCGF, is a pleiotropic immunoregulatory cytokine. IL-4 activity is mediated through the IL-4R receptor. Recombinant IL-4 is a single, non-glycosylated polypeptide chain.GFM18-20 GFM18-100 GFM18-500 GFM18-1000 GFM18AF-5PMouse Interleukin-4, also known as BCDF or BCGF, is a pleiotropic immunoregulatory cytokine. IL-4 activity is mediated through the IL-4R receptor. Recombinant IL-4 is a single, non< -glycosylated polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFM18AF-20 GFM18AF-100 GFM18AF-500 GFM18AF-1000GFH191-2IL-5�Interleukin-5 (IL-5) is a hematopoietic growth factor expressed in Th2, mast cells and eosinophils. IL-5 acts through its receptor, the IL-5 receptor (IL-5R) and is involved in B cell growth and eosinophil activation. Human and mouse IL-5 are cross-reactive. Recombinant human IL-5 is a non-glycosilated homodimer containing two 116 amino acid chains and with a molecular weight of 26.6 kDa. GFH191-10 GFH191-100 GFH191-500 GFH191-1000 GFH191AF-2 IL-5 (AF) GFH191AF-10 GFH191AF-100 GFH191AF-500 GFH191AF-1000GFM20-5�Mouse Interleukin-5 (IL-5) is a glycoprotein also known as EDF and TRF. It is involved in B-cell growth and eosinophil activation. IL-5 has been shown to be expressed in Th2, mast cells and eosinophils and is regulated by GATA-3, in addition to other transcription factors. IL-5 signals its biological effect through interaction with the IL-5 receptor (IL-5R). Recombinant mIL-5 is comprised of two chains forming a disulfide-linked homodimer.GFM20-25 GFM20-100 GFM20-500 GFM20-1000 GFM20AF-5�Interleukin-5 (IL-5) is a hematopoietic growth factor expressed in Th2, mast cells and eosinophils. IL-5 acts through its receptor, the IL-5 receptor (IL-5R) and is involved in B cell growth and eosinophil activation. IL-5 has been shown to be and is regulated cross-reactive. IL-5 is a non-glycosylated, disulfide-linked homodimer, containing two 113 amino acid chains, with a total molecular weight of 26.2 kDa. GFM20AF-25 GFM20AF-100 GFM20AF-500 GFM20AF-1000GFH10-5IL-6�Interleukin-6 (IL-6) is an important proinflammatory and immunoregulatory cytokine expressed by T cells, macrophages and muscle cells. IL-6 signals through a receptor complex containing two receptors, IL-6R� and gp130. IL-6 has an important function in promoting fever and can serve to stimulate an immune response to trauma. IL-6 is often used for growth of hybridoma cell lines. Human IL-6 is active on mouse and rat cells. Recombinant human IL-6 is a non-glycosylated protein.GFH10-20 GFH10-100 GFH10-500 GFH10-1000 GFH10AF-5 IL-6 (AF) GFH10AF-20 GFH10AF-100 GFH10AF-500 GFH10AF-1000GFM2-2hInterleukin-6 (IL-6), also know as BCDG, BCGF and BSF-2, is an important proinflammatory and immunoregulatory cytokine expressed by various cells. Interleukin-6 has been shown to inhibit the growth of early stage and to promote the proliferation of advanced stage melanoma cells in vitro. Recombinant Mouse IL-6 is a single, non-glycosylated polypeptide chain.GFM2-10GFM2-100GFM2-500 GFM2-1000GFR9-23Interleukin-6 (IL-6) is an important proinflammatory and immunoregulatory cytokine expressed by various cells has been shown to inhibit the growth of early stage and to promote the proliferation of advanced stage melanoma cells in vitro. Recombinant Rat IL-6 is a single, non-glycosylated polypeptide chain.GFR9-10GFR9-100GFR9-500 GFR9-1000GFR9AF-2�Interleukin-6 (IL-6) is an important proinflammatory and immunoregulatory cytokine expressed by various cells has been shown to inhibit the growth of early stage and to promote the proliferation of advanced stage melanoma cells in vitro. Recombinant Rat IL-6 is a single, non-glycosylated polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFR9AF-10 GFR9AF-100 GFR9AF-500 GFR9AF-1000GFH11-2IL-7 Interleukin-7 (IL-7), which is constitutively produced particularly by stromal cells from the bone marrow and thymus, plays a crucial role in T cell homeostasis. This cytokine is implicated in thymopoiesis since it sustains thymocyte proliferation and survival. It regulates peripheral naive T cell survival by modulating the expression of the anti-apoptotic molecule Bcl-2, and sustains peripheral T cell expansion in response to antigenic stimulation. Recombinant Human IL-7 is a single, non-glycosylated polypeptide chain.GFH11-1< 0 GFH11-100 GFH11-500 GFH11-1000GFM3-2�Interleukin 7 (IL-7) is a hematopoietic cytokine that is constitutively produced by stromal cells from the bone marrow and thymus. IL-7 signals through the IL-7R to promote the differentiation of hematopoietic stem cells to lymphoid precursor cells, which give rise to T cells, B cell s, and natural killer cells. Human and mouse IL-7 show species cross-reactivity. Recombinant mouse IL-7 is a non-glycosylated protein, containing 172 amino acids, with a molecular weight of 17.4 kDa.GFM3-10GFM3-100GFM3-500 GFM3-1000GFH175-5 IL-8 / CXCL8gInterleukin-8 (IL-8 or CXCL8) is an inflammatory chemokine of the CXC family that can be produced by a variety of cells but is predominantly studied in the context of macrophages and epithelial cells. IL-8 is a ligand for GPCRs, CXCR1 and CXCR2, and acts to recruit innate immune cells as well as induce phagocytosis. IL-8 is also able to induce Angiogenesis. GFH175-25 GFH175-100 GFH175-500 GFH175-1000GFP8-53Interleukin-8 (IL-8 or CXCL8) is a member of the CXC cytokine family and is produced by macrophages, epithelial, smooth muscle and endothelial cells. IL-8 binds the G protein-coupled serpentine receptors CXCR1 and CXCR2. IL-8 recruits innate immune cells, induces phagocytosis and stimulate angiogenesis. GFP8-20GFP8-100GFP8-500 GFP8-1000GFP8AF-5IL-8 / CXCL8 (AF) GFP8AF-20 GFP8AF-100 GFP8AF-500 GFP8AF-1000GFH82-2IL-97Interleukin-9 (IL-9) is known to regulate many cell types involved in T- helper type 2 responses classically associated with asthma, including B- and T- lymphocytes, mast cells, eosinophils and epithelial cells. Growing evidence obtained from human genomic analysis and antigen-challenged transgenic mice suggests that IL-9 is a candidate factor in immunoglobulin E (IgE) production and thus is thought to be associated with bronchial inflammation and bronchial hyperresponsiveness (BHR). Recombinant Human IL-9 is a single, non-glycosylated single polypeptide chain.GFH82-10 GFH82-100 GFH82-500 GFH82-1000GFM19-28Interleukin-9 (IL-9) is known to regulate many cell types involved in T-helper type 2 responses classically associated with asthma, including B- and T-lymphocytes, mast cells, eosinophils and epithelial cells. Growing evidence obtained from human genomic analysis and antigen-challenged transgenic mice suggests that interleukin-9 is a candidate factor in immunoglobulin E (IgE) production and thus is thought to be associated with bronchial inflammation and bronchial hyperresponsiveness (BHR). Recombinant Mouse IL-9 is a non-glycosylated, single polypeptide chain. GFM19-10 GFM19-100 GFM19-500 GFM19-1000GFH83-2IL-10ZInterleukin-10 (IL-10) is produced by murine T-cells following their stimulation by lectins. The main source for B-cell-derived Interleukin-10 in mice are Ly-1 B-cells that express CD5 and CD11. Murine keratinocytes also produce IL-10. In humans, IL-10 is produced by activated CD8(+) peripheral blood T-cells, by T-helper CD4(+) T-cell clones (resembling Th0, Th1, and Th2) after both antigen-specific and polyclonal activation, by B-cell lymphomas and by monocytes following cell activation by bacterial lipopolysaccharides and mast cells. B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt2 s lymphoma constitutively secrete large quantities of IL-10 into the conditioned medium. The synthesis of IL-10 by monocytes is inhibited by IL-4 and IL-10. IL-10 Human Recombinant is a single, non-glycosylated polypeptide chain.GFH83-10 GFH83-100 GFH83-500 GFH83-1000 GFH83AF-2 IL-10 (AF)�Interleukin-10 (IL-10) is an anti-inflammatory�cytokine�mainly produced by macrophages and�Th2�cells. IL-10 functions by inhibiting pro-inflammatory cytokines made by macrophages and regulatory T cells including�IFN-gamma,�TNF-alpha, IL-2, IL-3, IL-4, and GM-CSF. IL-10 is also known to suppress antigen presentation on antigen presenting cells. While human IL-10 can act on mouse cells, mouse IL-10 cannot act on human cells. Recombinant human IL-10 is a�non-glycosylated�protein. GFH83AF-10 GFH83AF-100< GFH83AF-500 GFH83AF-1000GFM84-2gInterleukin-10 (IL-10) is an anti-inflammatory cytokine produced by macrophages and type 2 T helper (Th2) cells. IL-10 inhibits the production of pro-inflammatory cytokines such as interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF), made by macrophages and regulatory T cells. IL-10 also suppresses antigen presentation on antigen presenting cells and enhances the survival, proliferation and antibody production of B cells. Mouse IL-10 is not active on human cells. GFM84-10 GFM84-100 GFM84-500 GFM84-1000 GFM84AF-2 GFM84AF-10 GFM84AF-100 GFM84AF-500 GFM84AF-1000GFH84-2IL-11�Interleukin-11 (IL-11) is a pleotropic cytokine closely related to IL-6 in function, but is overall one of the lesser characterized interleukins. In hematopoietic cell populations, IL-11 is thought to inducemegakaryocyte differentiation. In non-hematopoietic populations, IL-11 is thought to be able to stimulate hepatic acute-phase proteins. Human IL-11 can stimulate murine cells. Recombinant Human IL-11 is a single, non-glycosylated polypeptide chain.GFH84-10 GFH84-100 GFH84-500 GFH84-1000GFM64-2�Interleukin-11 (IL-11) is a pleotropic cytokine closely related to IL-6 in function, but is overall one of the lesser characterized interleukins. In hematopoietic cell populations, IL-11 is thought to inducemegakaryocyte differentiation. In non-hematopoietic populations, IL-11 is thought to be able to stimulate hepatic acute-phase proteins. Recombinant Mouse IL-11 is a single, non-glycosylated polypeptide chain.GFM64-10 GFM64-100 GFM64-500 GFM64-1000 GFM64AF-2 IL-11 (AF)Interleukin-11 (IL-11) is a pleotropic cytokine closely related to IL-6 in function, but is overall one of the lesser characterized interleukins. In hematopoietic cell populations, IL-11 is thought to inducemegakaryocyte differentiation. In non-hematopoietic populations, IL-11 is thought to be able to stimulate hepatic acute-phase proteins. Recombinant Mouse IL-11 is a single, non-glycosylated polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFM64AF-10 GFM64AF-100 GFM64AF-500 GFM64AF-1000GFM25-2IL-12�Interleukin-12 (IL-12) is an important mediator of cellular-immunity produced by dendritic cells, macrophages and B cells when stimulated with antigen. IL-12 is involved in differentiating precursor helper T cells to Th1 and/or Th2 subtypes and promotes the production of IFN gamma and TNF alpha. Mouse IL-12 is active on human and mouse cells. Recombinant mouse IL-12 is a glycosylated, disulfide-linked heterodimer. It is containing one p35 subunit (35 kDa) and one p40 subunit (40 kDa).GFM25-10 GFM25-100 GFM25-500 GFM25-1000GFH85-2IL-13�Interleukin-13 (IL-13) is a multifunctional cytokine whose net principle action is to diminish inflammatory responses. IL-13 is an important cytokine secreted from type 2 helper T lymphocytes. It is essential for modulating IgE synthesis by human B cells. Previous studies showed that polymorphisms in the IL-13 gene were associated with serum total IgE or allergic asthma. IL-13 is a pleiotropic cytokine, which shares many biological functions with IL-4. The receptor subunits of IL-13 consist of IL- 4Ralpha, IL-13Ralpha1 and IL-13Ralpha2. Recombinant Human IL-13 is a variant of native IL-13, containing 115 amino acids (additional Gln at position 113) and a molecular weight of 12.6 kDa.�GFH85-10 GFH85-100 GFH85-500 GFH85-1000GFM22-2`Interleukin-13 (IL-13) is an important cytokine secreted from Th2 cells. The functions attributed to IL-13 overlap significantly with those of IL-4 (induces IgE secretion from B cells and inhibits expression of inflammatory cytokines such as IL-1 beta, TNF-alpha, IL-8 and IL-6), but differs from IL-4 in that IL-13 seems to link inflammatory response of immune cells to the pathophysiological changes in the surrounding non-immune cells. The receptor subu< nits of IL-13 consist of IL-4R�, IL-13R�1 and IL-13R�2. Human and mouse IL-13 are cross-reactive. Recombinant mouse IL-13 is a non-glycosylated protein.GFM22-10 GFM22-100 GFM22-500 GFM22-1000GFH86-2IL-15WInterleukin-15 (IL-15) is a pleiotropic pro-inflammatory cytokine that promotes activation of T cells, neutrophils and macrophages, and is critical to dendritic cell function in several model systems. IL-15 has been shown to play a role in several inflammatory disorders, including rheumatoid arthritis, psoriasis and pulmonary inflammatory diseases. Emerging data suggest that IL-15 may serve as a good therapeutic target as there appears to be a beneficial effect of IL-15 neutralization in models of psoriasis and diabetes. Recombinant human IL-15 is a single, non-glycosylated polypeptide chain.GFH86-10 GFH86-100 GFH86-500 GFH86-1000GFM7-2�Interleukin-15 (IL-15) is a pleiotropic pro-inflammatory cytokine that is expressed in several inflammatory disorders, including rheumatoid arthritis, psoriasis and pulmonary inflammatory diseases. IL-15 promotes activation of T cells, neutrophils and macrophages, and is critical to dendritic cell function in several model systems. Recent emerging data suggest that IL-15 may serve as a useful therapeutic target across a range of disease states. Advances in the past year highlight the beneficial effect of IL-15 neutralization in models of psoriasis and diabetes. Further evidence for IL-15 expression and effector function has emerged across a range of rheumatic disorders, including juvenile inflammatory arthritis, rheumatoid arthritis and Kawasaki disease. IL-15 is a gamma-common cytokine, which plays an important role in the development, survival and proliferation of NK, NK T and CD8+ T cells. Recombinant Mouse IL-15 is a single, non-glycosylated polypeptide chain. GFM7-10GFM7-100GFM7-500 GFM7-1000GFM7AF-2 IL-15 (AF) GFM7AF-10 GFM7AF-100 GFM7AF-500 GFM7AF-1000GFH144-2IL-16�Human IL-16 is produced primarily by CD4(+) and CD8(+) T cells and acts as a chemoattractant for lymphocytes, monocytes, eosinophils, dendritic cells and Langerhans cells. Additionally, IL-16 has been reported to upregulate IL-2 receptor (CD25), induce progression of cells to the G(1) phase and suppress HIV & SIV replication. Human and murine IL-16 share a high degree of structural and functional similarity. GFH144-10 GFH144-100 GFH144-500 GFH144-1000GFM49-2�Mouse IL-16 was originally described as Lymphocyte Chemoattractant Factor (LCF), is produced primarily by CD4(+) and CD8(+) T cells and acts as a chemoattractant for lymphocytes, monocytes, eosinophils, dendritic cells and Langerhans cells. Additionally, IL-16 has been reported to upregulate IL-2 receptor (CD25), induce progression of cells into G(1) and suppresses HIV & SIV replication. B-cells, eosinophils, macrophages, epithelial cells, fibroblasts, microglial cells and keratinocytes have also been shown to express IL-16. Human and mouse IL-16 share a high degree of structural and functional similarity. Recombinant mouse IL-16 is a non-glycosylated protein.GFM49-10 GFM49-100 GFM49-500 GFM49-1000GFH87-5IL-17AZHuman Interleukin-17A (IL-17A), also known as CTLA-8, is a proinflammatory cytokine member of a six-species family of proteins (IL-17A-17F). IL-17A is secreted mainly by activated CD4+ and CD8+ T lymphocytes and acts through its receptor, IL-17R, to induce the expression of many mediators of inflammation, most strikingly, those that are involved in the proliferation, maturation and chemotaxis of neutrophils. Elevated levels of IL-17A have been associated with several conditions, including rheumatoid arthritis, airway inflammation, allograft rejection, inflammatory bowel disease, psoriasis, cancer and multiple sclerosis. There is 58% identity between the amino acid sequence of human and mouse IL-17A. Recombinant human IL-17A is a non-glycosylated disulfide-joined homodimer containing two 137 amino acid chains and having a molecular mass of 31 kDa.GFH87-25 GFH87-100 GFH87-500 GFH87-1000GFM59-5`Mouse Interleukin-17A (IL-17A), also known as<  CTLA-8, is a proinflammatory cytokine member of a six-species family of proteins (IL-17A-17F). Mouse IL-17A protein is a homodimer consisting of two 134 amino acids peptides. IL-17A is secreted mainly by activated CD4+ and CD8+ T lymphocytes and acts through its receptor, IL-17R, to induce the expression of many mediators of inflammation, most strikingly, those that are involved in the proliferation, maturation and chemotaxis of neutrophils. Elevated levels of IL-17A have been associated with several conditions, including rheumatoid arthritis, airway inflammation, allograft rejection, inflammatory bowel disease, psoriasis, cancer and multiple sclerosis. There is 58% identity between the amino acid sequence of human and mouse IL-17A. Recombinant mouse IL-17A is a non-glycosylated, disulfide-linked homodimer.GFM59-25 GFM59-100 GFM59-500 GFM59-1000GFR24-5#Rat IL-17A (IL-17), also known as CTLA-8, is a proinflammatory cytokine member of a six-species family of proteins (IL-17A-17F). Rat IL-17A protein is a homodimer. IL-17A is secreted mainly by activated CD4+ and CD8+ T lymphocytes and acts through its receptor, IL-17R, to induce the expression of many mediators of inflammation, most strikingly, those that are involved in the proliferation, maturation and chemotaxis of neutrophils. Elevated levels of IL-17A have been associated with several conditions, including rheumatoid arthritis, airway inflammation, allograft rejection, inflammatory bowel disease, psoriasis, cancer and multiple sclerosis. There is 58% identity between the amino acid sequence of human and rat IL-17A. Recombinant rat IL-17A is a non-glycosylated disulfide-joined homodimer.GFR24-25 GFR24-100 GFR24-500 GFR24-1000GFH161-5IL-17A/F�Heterodimeric interleukin-17A/F is a member of the IL-17 family of six homodimeric proteins (IL-17A-17F). Recent IL-17A/IL-17F co-expression studies in HEK-293 cells revealed the presence of a biologically active heterodimer, IL-17A/F. Activated CD4+ T cells have also been shown to produce human IL-17A/F. Activity studies reveal hIL-17A to be the most potent, followed by hIL-17A/F and hIL-17F 100 fold lower than hIL-17A. IL-17A/F is thought to induce neutrophilia and chemokine expression via the IL-17RA receptor. Recombinant human IL-17A/F is a heterodimeric non-glycosylated polypeptide comprised of one monomeric subunit each of h-IL-17A and h-IL-17F. GFH161-25 GFH161-100 GFH161-500 GFH161-1000GFM61-5�Heterodimeric interleukin-17A/F is a member of the IL-17 family of six homodimeric proteins (IL-17A-17F). Recent IL-17A/IL-17F co-expression studies in HEK-293 cells revealed the presence of a biologically active heterodimer, IL-17A/F. Activated CD4+ T cells have also been shown to produce human IL-17A/F. Activity studies reveal hIL-17A to be the most potent, followed by hIL-17A/F and hIL-17F 100 fold lower than hIL-17A. IL-17A/F is thought to induce neutrophilia and chemokine expression via the IL-17RA receptor. Recombinant mouse IL-17A/F is a heterodimeric non-glycosylated polypeptide comprised of one monomeric subunit each of m-IL-17A and m-IL-17F.GFM61-25 GFM61-100 GFM61-500 GFM61-1000GFR29-5�Heterodimeric interleukin-17A/F is a member of the IL-17 family of six homodimeric proteins (IL-17A-17F). Recent IL-17A/IL-17F co-expression studies in HEK-293 cells revealed the presence of a biologically active heterodimer, IL-17A/F. Activated CD4+ T cells have also been shown to produce human IL-17A/F. Activity studies reveal hIL-17A to be the most potent, followed by hIL-17A/F and hIL-17F 100 fold lower than hIL-17A. IL-17A/F is thought to induce neutrophilia and chemokine expression via the IL-17RA receptor.Recombinant rat IL-17A/F produced in E.coli is a heterodimeric non-glycosylated polypeptide comprised of one monomeric subunit each of r-IL-17A and r-IL-17F.GFR29-25 GFR29-100 GFR29-500 GFR29-1000GFH149-5IL-17E / IL-25�Recombinant Human Interleukin-17E is a disulfide-linked homodimer comprised of two single, non-glycosylated polypeptide amino acid chains containing 146 amino acids each. There are six known members of thi< s family, IL-17A through IL-17F. GFH149-25 GFH149-100 GFH149-500 GFH149-1000GFM60-5FMouse Interleukin-17E (IL-17E) or interleukin-25 (IL-25) is a proinflammatory cytokine member of a six-species family of proteins (IL-17A-F). IL-17E stimulates secretion of IL-8 and induces activation of NF-kappa B by binding to the receptor IL-17RB. Recombinant mouse IL-17E is a non-glycosylated, disulfide-linked homodimer.GFM60-25 GFM60-100 GFM60-500 GFM60-1000 GFM60AF-5IL-17E / IL-25 (AF) GFM60AF-25 GFM60AF-100 GFM60AF-500 GFM60AF-1000GFR25-2�Rat IL-17E (IL-17) is a proinflammatory cytokine member of a six-species family of proteins (IL-17A- 17F). Recombinant rat IL-17E is a non-glycosylated disulfide-joined homodimer.GFR25-10 GFR25-100 GFR25-500 GFR25-1000GFH152-5IL-17F�Recombinant Human Interleukin-17F is a non-glycosylated protein consisting of two 134 amino acid polypeptide chains that are cysteine linked homodimeric polypeptide chains. GFH152-25 GFH152-100 GFH152-500 GFH152-1000GFM62-5Interleukin-17F (IL-17F) is one of six members of the IL-17 family (IL-17A-F) secreted by activated CD4+ T cells and monocytes. Similar to IL-17A, IL-17F binds to the IL-17 RC receptor and promotes the production of IL-6, IL-8, G-CSF and increases matrix turnover rates. IL-17F is also thought to inhibit angiogenesis and induce endothelial cells to produce IL-2, MCP-1 and TGF- beta 1. Recombinant mouse IL-17F is a non-glycosylated, disulfide-linked homodimer containing two 134 amino acid chains and with a total molecular weight of 30 kDa.GFM62-25 GFM62-100 GFM62-500 GFM62-1000 GFM62AF-5 IL-17F (AF) GFM62AF-25 GFM62AF-100 GFM62AF-500 GFM62AF-1000GFR28-5�Interleukin-17F (IL-17F) is one of six members of the IL-17 family (IL-17A-F) secreted by activated CD4+ T cells and monocytes. Similar to IL-17A, IL-17F binds to the IL17 RC receptor and promotes the production of IL-6, IL-8, G-CSF and increases matrix turnover rates. IL-17F is also thought to inhibit angiogenesis and induce endothelial cells to produce IL-2, MCP-1 and TGF-�1. Recombinant rat IL-17F is a non-glycosylated, disulfide-linked homodimer.GFR28-25 GFR28-100 GFR28-500 GFR28-1000GFH88-2IL-19@Interleukin-19 (IL-19) is a novel cytokine that was initially identified during a sequence data base search aimed at finding potential Interleukin-10 homologs. Interleukin-19 shares 21% amino acid identity with IL-10. The exon/intron structure of IL-19 is similar to that of the human IL-10 gene, comprising five exons and four introns within the coding region of the IL-19 cDNA. IL-19 shares a receptor complex with IL-20, indicating that the biological activities of these two cytokines overlap and that both may play an important role in regulating development and proper functioning of the skin. Unlike IL-10, which forms an intercalated dimer, the molecule of IL-19 is a monomer made of seven amphipathic helices, A-G, creating a unique helical bundle. Recombinant Human IL-19 is a single, non-glycosylated polypeptide chain. GFH88-10 GFH88-100 GFH88-500 GFH88-1000 GFH88AF-2 IL-19 (AF)�Interleukin-19 (IL-19) is a member of the IL-10 family produced by resting B cells and monocytes. IL-19 is thought to be up-regulated when monocytes are treated with GM-CSF or LPS. IL-19 shares a receptor complex with IL-20, and acts to induce IL-6 and TNF-� production by monocytes and promotes the Th2response. Recombinant human IL-19 is a non-glycosylated protein. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH88AF-10 GFH88AF-100 GFH88AF-500 GFH88AF-1000GFM75-2�Interleukin-19 (IL-19) is produced by resting B cells and monocytes. IL-19 can be up-regulated when monocytes are treated with GM-CSF or LPS. IL-19 shares a receptor complex with IL-20. It acts to induce IL-6 and TNF-alpha production by monocytes as well as to promote a Th2 response. Recombinant mouse IL-19 is a non-glycosylated protein, containing 153 amino acids, with a molecular weight of 17.7 kDa.GFM75-10 GFM75-100 GFM75-500 GFM75-1000 GFM75AF-2 GFM75AF-10< GFM75AF-100 GFM75AF-500 GFM75AF-1000GFH89-2IL-20The newly discovered cytokine interleukin-20 (IL-20) is structurally related to IL-10, yet it appears to be an autocrine factor for keratinocytes that regulates their participation in inflammation. Recombinant Human IL-20 is a homodimeric, non-glycosylated polypeptide chain.GFH89-10 GFH89-100 GFH89-500 GFH89-1000GFH90-2IL-21 Interleukin-21 (IL-21), expressed by activated CD4(+) T cells, is the newest member of the common gamma-chain family of cytokines, which includes IL-2, IL-4, IL-7, IL-9, IL-13, and IL-15. Its private receptor, IL-21R, is expressed on T, B, and NK cells. Within the B cell lineage, IL-21 regulates IgG1 production and cooperates with IL-4 for the production of multiple Ab classes in vivo. IL- 21R has been shown to activate the Janus kinase/signal transducers and activators of transcription signaling pathway upon ligand binding. Initial studies have demonstrated that IL-21 has pleiotropic effects on the proliferation, differentiation, and effector functions of B, T, natural killer, and dendritic cells. Recombinant Human IL-21 is a single, non-glycosilated polypeptide chain.GFH90-10 GFH90-100 GFH90-500 GFH90-1000 GFH90AF-2 IL-21 (AF)�Interleukin-21 (IL-21), expressed by activated CD4(+) T cells, is the newest member of the common gamma-chain family of cytokines, which includes IL-2, IL-4, IL-7, IL-9, IL-13, and IL-15. Its private receptor, IL-21R, is expressed on T, B, and NK cells. Within the B cell lineage, IL-21 regulates IgG1 production and cooperates with IL-4 for the production of multiple Ab classes in vivo. IL- 21R has been shown to activate the Janus kinase/signal transducers and activators of transcription signaling pathway upon ligand binding. Initial studies have demonstrated that IL-21 has pleiotropic effects on the proliferation, differentiation, and effector functions of B, T, natural killer, and dendritic cells. Recombinant Human IL-21 is a single, non-glycosilated polypeptide chain. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH90AF-10 GFH90AF-100 GFH90AF-500 GFH90AF-1000GFM70-2Interleukin-21 (IL-21), expressed by activated CD4(+) T cells, is the newest member of the common gamma-chain family of cytokines, which also includes IL-2, IL-4, IL-7, IL-9, and IL-13. Its private receptor, IL-21R, is expressed on T, B, and NK cells. Within the B cell lineage, IL-21 regulates IgG1 production and cooperates with IL-4 for the production of multiple Ab classes in vivo. IL-21R has been shown to activate the Janus kinase/signal transducers and activators of transcription signaling pathways upon ligand binding. Initial studies have demonstrated that IL-21 has pleiotropic effects on the proliferation, the differentiation, and the effector functions of B, T, natural killer, and dendritic cells. Recombinant mouse IL-21 is a single, non-glycosylated polypeptide chain. GFM70-10 GFM70-100 GFM70-500 GFM70-1000GFH91-2IL-22pRecombinant Human IL-22, also known as IL-TIF, was first identified by its ability to induce IL-9 production in mast cells and T-cells. It is expessed in CD23 activated T-cells and many organs upon LPS stimulation. IL-22 signals via the IL-22R and IL-10Rbeta receptors. Recombinant human IL-22 is a non-disulfide-linked homodimeric, non-glycosylated polypeptide chain.GFH91-10 GFH91-100 GFH91-500 GFH91-1000GFM77-2XInterleukin-22 (IL-22) is produced by activated dendritic cells and T lymphocytes. IL-22 signals via the IL-22R and IL-10R beta receptors to act as a potent mediator of the cellular inflammatory response and wound healing. Recombinant mouse IL-22 is a non-glycosylated protein containing 147 amino acids and with a molecular weight of 16.8 kDa.GFM77-10 GFM77-100 GFM77-500 GFM77-1000 GFM77AF-2 IL-22 (AF) GFM77AF-10 GFM77AF-100 GFM77AF-500 GFM77AF-1000GFH162-5IL-27/IL-35 (EBI-3)�Epstein-Barr Virus Induced Gene-3 (EBI-3) is a secreted glycoprotein belonging to the hematopoietin receptor family and related to the p40 subunit of IL-12. I< t was identified by its induced expression in B-lymphocytes in response to Epstein-Barr virus infection. EBI-3 forms heterodimers with p28 to form IL-27 and with p35 to form IL-35. Both IL-27 and IL-35 have anti-inflammatory and regulatory activity. Recombinant Human EBI-3 is a non-glycosylated polypeptide chain. GFH162-20 GFH162-100 GFH162-500 GFH162-1000 GFH162AF-5IL-27/IL-35 (EBI-3) (AF) GFH162AF-20 GFH162AF-100 GFH162AF-500 GFH162AF-1000GFM57-2 IL-27(EBI-3)�Epstein-Barr Virus Induced Gene-3 (EBI-3), is a secreted glycoprotein belonging to the hematopoietin receptor family and related to the p40 subunit of IL-12. It was identified by its induced expression in B-lymphocytes in response to Epstein-Barr virus infection. EBI-3 forms heterodimers with p28 to form IL-27 and with p35 to form IL-35. Both IL-27 and IL-35 have anti-inflammatory and regulatory activity. Recombinant Mouse EBI is a non-glycosylated polypeptide chain. GFM57-10 GFM57-100 GFM57-500 GFM57-1000GFM50-2 IL-27/p28�Recombinant Mouse IL-27/p28 Subunit, also known as IL-30, is a member of the IL-12 family of cytokines. When combined with EBI-3 (Epstein-Barr virus induced gene 3), the heterodimer formed is IL-27. Mouse p28 is a proinflammatory cytokine inducing immunomodulatory effects. Current research is underway to delineate specific biological functions. Recombinant mouse p28 is a single-chain peptide.GFM50-10 GFM50-100 GFM50-500 GFM50-1000 GFM50AF-2IL-27/p28 (AF) GFM50AF-10 GFM50AF-100 GFM50AF-500 GFM50AF-1000GFH169-5IL-29Interleukin-29 (IL-29), also known as IFN�1, is a type III interferon produced by virally infected cells. It is thought to play an important role in host defenses against multiple microbes and shares homology with IL-28. Recombinant human IL-29 is a non-glycosylated protein. GFH169-20 GFH169-100 GFH169-500 GFH169-1000GFM71-2IL-31kInterleukin-31 (IL-31) is an immunoregulatory cytokine that is mainly expressed by activated TH2 cells. IL-31 signals through the IL-31 Receptor (IL-31RA) and the oncostain receptor (OSMR), which are expressed on monocytes, epithelial cells, and keratinocytes. IL-31 has a role in inflammatory skin diseases. Recombinant mouse IL-31 is a non-glycosylated protein.GFM71-10 GFM71-100 GFM71-500 GFM71-1000GFH151-2 IL-32 alpha�Human IL-32 alpha is one of approximately 6 splice variants of a gene cloned from the human lung carcinoma stable transfectant, A549-Rbeta. IL-32 alpha has been shown to induce IL-8, TNF-a, and MIP-2 production from human and mouse macrophage cell lines. It is upregulated in activated T- and NK-cells, and IFN-g-treated epithelial cells. Human recombinant IL-32 alpha is a non-glycosylated polypeptide. GFH151-10 GFH151-100 GFH151-500 GFH151-1000GFH145-2IL-33:Interleukin-33 (IL-33) is a member of the IL-1 cytokine family and is constitutively expressed in smooth muscle cells and the airway epithelium. IL-33 signals through receptors, IL-1RL1 and IL-1RAP, to induce type 2 cytokine production in polarized Th2 cells. Recombinant human IL-33 is a non-glycosylated protein. GFH145-10 GFH145-100 GFH145-500 GFH145-1000GFM36-2:Interleukin-33 (IL-33) is a member of the IL-1 cytokine family and is constitutively expressed in smooth muscle cells and the airway epithelium. IL-33 signals through receptors, IL-1RL1 and IL-1RAP, to induce type 2 cytokine production in polarized Th2 cells. Recombinant mouse IL-33 is a non-glycosylated protein.GFM36-10 GFM36-100 GFM36-500 GFM36-1000 GFM36AF-2 IL-33 (AF)�Interleukin-33 (IL-33) is a member of the IL-1 cytokine family and is constitutively expressed in smooth muscle cells and the airway epithelium. IL-33 signals through receptors, IL-1RL1 and IL-1RAP, to induce type 2 cytokine production in polarized Th2 cells. Recombinant mouse IL-33 is a non-glycosylated protein. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFM36AF-10 GFM36AF-100 GFM36AF-500 GFM36AF-1000GFH49-2IL-35 HeterodimerGFH49-10�Interleukin-35 (IL-35)�is a member of IL-12 cytokine family and < is produced by regulatory T-cells (Tregs). This heterodimeric cytokine is comprised of one p35 subunit (also a subunit of IL-12) and one EBI3 subunit (also a subunit of IL-27). IL-35 signals through IL-12Rbeta2 and gp130 heterodimers and homodimers to induce a suppression of inflammatory responses. Recombinant human IL-35 is a single chain product, containing 442 amino acids, with a predicted molecular weight of 49 kDa (observed molecular weight of approximately 75-95 KDa reduced and approximately 65-75 kDa unreduced). From N terminus to C terminus, the molecule is comprised of a poly His tag, the EBI3 subunit, a G rich linker and the p35 subunit. GFH49-100GFH127-5IP-10 / CXCL10�Among CXC chemokines, CXCL10 has been identified to play an important role in several endocrinological autoimmune diseases such as Hashimoto2 s thyroiditis, Graves2 disease and Type 1 diabetes mellitus. The chemokine IP-10 (interferon-inducible protein of 10 kDa, CXCL10) is a chemoattractant for CXCR3+ T cells, binds to the G protein-coupled receptor CXCR3, which is found mainly on activated T cells and NK cells, and plays an important role in Th1-type inflammatory diseases. IP-10 also binds to glycosaminoglycans (GAGs), an interaction thought to be important for its sequestration on endothelial and other cells. Recombinant Human IP-10 is a single, non-glycosylated, polypeptide chain. GFH127-25 GFH127-100 GFH127-500 GFH127-1000GFM38-5�Among CXC chemokines, CXCL10 has been identified to play an important role in several endocrinological autoimmune diseases such as Hashimoto2 s thyroiditis, Graves2 disease and Type 1 diabetes mellitus.The chemokine IP-10 (interferon-inducible protein of 10 kDa, CXCL10) is a chemoattractant for CXCR3+ T cells, binds to the G protein-coupled receptor CXCR3, which is found mainly on activated T cells and NK cells, and plays an important role in Th1-type inflammatory diseases. IP-10 also binds to glycosaminoglycans (GAGs), an interaction thought to be important for its sequestration on endothelial and other cells. Recombinant Mouse IP-10 is a single, non- glycosylated, polypeptide chain.GFM38-25 GFM38-100 GFM38-500 GFM38-1000GFG2-5The chemokine IP-10 (or CXCL10) is a chemokine made by monocytes, endothelial cells and fibroblasts in response to treatment with IFN�. IP-10 functions as a chemoattractant to cells expressing the G protein-coupled receptor, CXCR3, which is found mainly on activated T cells and NK cells. IP-10 plays an important role in Th1 type inflammatory diseases and autoimmune diseases such as, Hashimoto's thyroiditis, Graves' disease and Type 1 diabetes mellitus. Recombinant guinea pig IP-10 is a non-glycosylated protein.GFG2-25GFG2-100GFG2-500 GFG2-1000GFH128-5 ITAC / CXCL11rITAC, or CXCL11, is one of three chemokines known to bind the receptor CXCR3 (the two others being CXCL9 (Mig) and CXCL10 (IP-10)). CXCL11 differs from the other CXCR3 ligands in that it has a higher receptor affinity and it acts as a stronger agonist. CXCL11 takes on the canonical chemokine fold but exhibits greater conformational flexibility than has been observed for related chemokines under the same sample conditions. Unlike related chemokines such as IP-10 and IL-8, ITAC does not appear to form dimers at mM concentrations. Recombinant Human ITAC produced in E. coli is a single, non-glycosylated, polypeptide chain. GFH128-20 GFH128-100 GFH128-500 GFH128-1000 GFH37-200Leptin200 ugbLeptin inhibits food intake and stimulates energy expenditure. Leptin also has thermogenic actions and regulates enzymes of fatty acid oxidation. Severe hereditary obesity in rodents and humans is caused by defects in leptin production. In addition to its critical role in the physiologic regulation of body weight leptin has a variety of other physiologic and pathologic functions resembling those of cytokines. These functions include the regulation of hematopoiesis, angiogenesis, wound healing, inflammation, and immune responses. Leptin Human Recombinant is a single, non-glycosylated, polypeptide chain. GFH37-1000 GFH37-5000 GFH37-10000 GFM2< 6-200aLeptin inhibits food intake and stimulates energy expenditure. Leptin also has thermogenic actions and regulates enzymes of fatty acid oxidation. Severe hereditary obesity in rodents and humans is caused by defects in leptin production. In addition to its critical role in the physiologic regulation of body weight leptin has a variety of other physiologic and pathologic functions resembling those of cytokines. These functions include the regulation of hematopoiesis, angiogenesis, wound healing, inflammation, and immune responses. Recombinant Mouse Leptin is a single, non-glycosylated, polypeptide chain. GFM26-1000 GFM26-5000 GFM26-10000 GFR14-200_Leptin inhibits food intake and stimulates energy expenditure. Leptin also has thermogenic actions and regulates enzymes of fatty acid oxidation. Severe hereditary obesity in rodents and humans is caused by defects in leptin production. In addition to its critical role in the physiologic regulation of body weight leptin has a variety of other physiologic and pathologic functions resembling those of cytokines. These functions include the regulation of hematopoiesis, angiogenesis, wound healing, inflammation, and immune responses. Recombinant Rat Leptin is a single, non-glycosylated, polypeptide chain. GFR14-1000 GFR14-5000 GFR14-10000GFH200-5LIF�Leukemia Inhibitory Factor (LIF) is a lymphoid factor that promotes long-term maintenance of pluripotent embryonic stem cells by suppressing spontaneous differentiation. Recombinant Human Leukemia inhibitory factor (hLIF) contains a single non-glycosylated polypeptide chain. hLIF is purified by proprietary techniques using HPLC and FPLC chromatography. The sample purity is better than 95% on SDS page. Its biological activity has been determined. GFH200-20 GFH200-100 GFH200-500 GFH200-1000 GFH47AF-5LIF (AF)FHuman Leukemia Inhibitory Factor (LIF) is member of the IL-6 family and is made by a variety of tissues. Human LIF signals through gp130 to activiate STAT3 in human ESCs. In mouse ESCs, LIF promotes self-renewal and pluripotentcy, but in human cells there is no indication that LIF has the same function. Instead, FGF-basic (FGF-2) and Activin A are used to promote self-renewal and pluripotent potential. Recombinant human LIF is a non-glycosylated protein. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH47AF-25 GFH47AF-100 GFH47AF-500 GFH47AF-1000GFM200-5�Leukemia Inhibitory Factor (LIF) is a lymphoid factor that promotes long-term maintenance of pluripotent embryonic stem cells by suppressing spontaneous differentiation. Recombinant Mouse LIF contains a single non-glycosylated polypeptide chain. GFM200-20 GFM200-100 GFM200-500 GFM200-1000 GFM200AF-5 GFM200AF-20 GFM200AF-100 GFM200AF-500 GFM200AF-1000GFH13-5 MCP-1 / CCL2(Monocyte Chemotactic Protein 1 (MCP-1), also known as CCL2, is thought to be produced by injured or infected tissues. MCP-1 signals through G protein-coupled receptors, CCR2 and CCR4, to recruit memory T cells, monocytes and dendritic cells. Recombinant human MCP-1 is a non-glycosylated protein.GFH13-20 GFH13-100 GFH13-500 GFH13-1000GFM39-2(Monocyte Chemotactic Protein 1 (MCP-1), also known as CCL2, is thought to be produced by injured or infected tissues. MCP-1 signals through G protein-coupled receptors, CCR2 and CCR4, to recruit memory T cells, monocytes and dendritic cells. Recombinant mouse MCP-1 is a non-glycosylated protein.GFM39-10 GFM39-100 GFM39-500 GFM39-1000GFR22-2&Monocyte Chemotactic Protein 1 (MCP-1), also known as CCL2, is thought to be produced by injured or infected tissues. MCP-1 signals through G protein-coupled receptors, CCR2 and CCR4, to recruit memory T cells, monocytes and dendritic cells. Recombinant rat MCP-1 is a non-glycosylated protein.GFR22-10 GFR22-100 GFR22-500 GFR22-1000GFH130-2 MCP-2 / CCL8EMonocyte Chemotactic Protein 2 (MCP-2), also known as CCL8, is implicated in allergic responses through its ability to activate mast cells, eosinophils, and basophils. MCP-2 is known to signal < through several G protein-coupled receptors including, CCR1, CCR2B, and CCR5. Recombinant human MCP-2 is a non-glycosylated protein. GFH130-10 GFH130-100 GFH130-500 GFH130-1000GFM63-5EMonocyte Chemotactic protein 2 (MCP-2), also known as CCL8, is implicated in allergic responses through its ability to activate mast cells, eosinophils, and basophils. MCP-2 is known to signal through several G protein-coupled receptors including, CCR1, CCR2B, and CCR5. Recombinant mouse MCP-2 is a non-glycosylated protein.GFM63-20 GFM63-100 GFM63-500 GFM63-1000GFH131-2 MCP-3 / CCL7BMonocyte Chemotactic Protein 3 (MCP-3), also called CCL7, is produced by macrophages and some tumor cell lines. MCP-3 signals through three different G protein-coupled receptors, CCR1, CCR2, and CCR3. CCL7 chemoattracts monocytes and can regulate macrophage function. Recombinant human MCP-3 is a non-glycosylated protein. GFH131-10 GFH131-100 GFH131-500 GFH131-1000GFM40-2�Mouse MCP-3, also known as CCL7 and SCYA7, is produced in a variety of tumor cells and has been shown to induce chemotaxis in monocytes, basophils, NK cells and dendrocytes. Recombinant mouse MCP-3 is a non-glycosylated, polypeptide chain.GFM40-10 GFM40-100 GFM40-500 GFM40-1000GFR7-2LMonocyte Chemotactic Protein 3 (MCP-3), also called CCL7, is a chemokine produced by macrophages and some tumor cell lines. MCP-3 signals through three different G protein-coupled receptors, CCR1, CCR2, and CCR3. CCL7 chemoattracts monocytes and can regulate macrophage function. Recombinant rat MCP-3 is a non-glycosylated protein.GFR7-10GFR7-100GFR7-500 GFR7-1000GFH132-5 MCP-4 / CCL13�Monocyte Chemotactic Protein 4 (MCP-4), also called CCL13, is induced by inflammatory proteins such as IL-1 and TNF�. MCP-4 is a ligand for three different G protein coupled receptors, CCR2, CCR3 and CCR5. MCP-4 activates signaling in monocytes, T lymphocytes, eosinophils and basophils and this signaling is associated with the allergic response. Recombinant human MCP-4 is a non-glycosylated protein. GFH132-20 GFH132-100 GFH132-500 GFH132-1000GFH3-2MCSF~Macrophage colony stimulating factor (MCSF) is one of the glycoproteins called colony-stimulating factors (CSFs). A mononuclear phagocyte colony-stimulating factor (MCSF) synthesized by mesenchymal cells. The compound stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series. Some clinical investigations have shown autologous production of MCSF various human cell lines in vitro and by tumors in vivo. Recombinant Human MCSF is a disulfide linked homodimer, non-glycosylated, polypeptide chain containing two 159 amino acid chains and with a total molecular weight of 36.8 kDa.GFH3-10GFH3-100GFH3-500 GFH3-1000GFH3AF-2 MCSF (AF) GFH3AF-10 GFH3AF-100 GFH3AF-500 GFH3AF-1000GFM8-2GFM8-10~Macrophage colony stimulating factor (MCSF) is one of the glycoproteins called colony-stimulating factors (CSFs). A mononuclear phagocyte colony-stimulating factor (MCSF) synthesized by mesenchymal cells. The compound stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series. Some clinical investigations have shown autologous production of MCSF various human cell lines in vitro and by tumors in vivo. Recombinant Mouse MCSF is a disulfide linked homodimer, non-glycosylated, polypeptide chain containing two 156 amino acid chains and with a total molecular weight of 36.8 kDa.GFM8-100GFM8-500 GFM8-1000GFM8AF-2 GFM8AF-10 GFM8AF-100 GFM8AF-500 GFM8AF-1000GFR33-2�Macrophage Colony Stimulating Factor (MCSF) is a hematopoietic growth factor produced by a wide variety of cells. MCSF is known to stimulate differentiation of hematopoietic stem cells to monocyte-macrophage cell populations in culture. MCSF acts through the CSF receptor 1. Recombinant rat MCSF is a non-glycosylated homodimer containing two 155 amino acid chains and with a total molecular weight of 36.2 kDa.GFR33-10 GFR33-100 GFR33-500 GFR33-1000 GFR33AF-2 GFR33AF-10 GFR33AF-100 GFR33AF-500 GFR33AF-100< 0GFH153-5MIF�Recombinant Human MIF (migration inhibitory factor) acts as an inflammatory mediator consisting of two alpha-helices and six beta-strands, four of which form a beta-sheet structure. The remaining two beta-strands interact with other MIF molecules forming a trimer in solution. Human MIF acts on fibroblasts by inducing IL-1, IL-8 and MMP expression. MIF stimulates NO production and TNF-alpha release following IFN-gamma activation on macrophages. Human MIF is a non-glycosylated polypeptide. GFH153-25 GFH153-100 GFH153-500 GFH153-1000GFM78-51MIF is a pro-inflammatory cytokine that acts by inducing IL-1, IL-8 and MMP expression. MIF stimulates no production and TNF-alpha release following IFN-gamma activation of macrophages. Recombinant mouse MIF is a non-glycosylated protein containing 115 amino acids and with a molecular weight of 12.5 kDa.GFM78-25 GFM78-100 GFM78-500 GFM78-1000 GFM78AF-5MIF (AF) GFM78AF-25 GFM78AF-100 GFM78AF-500 GFM78AF-1000GFH184-5 MIG / CXCL9�MIG is a chemokine produced by cells stimulated by IFN-gamma. It signals through CXCR3 to recruit T cells. MIG is a non-glycosylated protein containing 103 amino acids and with a molecular weight of 11.7 kDa. GFH184-20 GFH184-100 GFH184-500 GFH184-1000GFH15-5MIP-1 alpha / CCL3�Macrophage Inflammatory Protein-1 alpha (MIP-1 alpha), also known as CCL3, is produced by macrophages and is thought to induce inflammatory responses, including superoxide production by neutrophils. MIP-1 alpha can exist as a naturally occurring heterodimer with MIP-1 beta and has been shown to have antiviral activity against HSV-1. Recombinant human MIP-1 alpha is a non-glycosylated protein.GFH15-20 GFH15-100 GFH15-500 GFH15-1000GFM42-2�Macrophage Inflammatory Protein-1 alpha (MIP-1 alpha), also known as CCL3, is produced by macrophages and is thought to induce inflammatory responses, including superoxide production by neutrophils. MIP-1 alpha can exist as a naturally occurring heterodimer with MIP-1 beta and has been shown to have antiviral activity against HSV-1. Recombinant mouse MIP-1 alpha is a non-glycosylated protein.GFM42-10 GFM42-100 GFM42-500 GFM42-1000GFR23-5�Macrophage Inflammatory Protein-1 alpha (MIP-1 alpha), also known as CCL3, is produced by macrophages and is thought to induce inflammatory responses, including superoxide production by neutrophils. MIP-1 alpha can exist as a naturally occurring heterodimer with MIP-1 beta and has been shown to have antiviral activity against HSV-1. Recombinant rat MIP-1 alpha is a non-glycosylated protein. GFR23-20 GFR23-100 GFR23-500 GFR23-1000GFH134-2MIP-1 beta / CCL4Macrophage Inflammatory Protein-1 beta (MIP-1 beta), also known as CCL4, is produced by macrophages and thought to induce inflammatory responses, including superoxide production by neutrophils. MIP-1 alpha and MIP-1 beta can exist as a naturally occurring heterodimer has been shown to have antiviral activity against HSV-1. Recombinant human MIP-1 beta is a non-glycoslated protein. GFH134-10 GFH134-100 GFH134-500 GFH134-1000GFM43-2Macrophage Inflammatory Protein-1 beta (MIP-1 beta), also known as CCL4, is produced by macrophages and thought to induce inflammatory responses, including superoxide production by neutrophils.MIP-1 alpha and MIP-1 beta can exist as a naturally occurring heterodimer has been shown to have antiviral activity against HSV-1. Recombinant mouse MIP-1 beta is a non-glycosylated protein.GFM43-10 GFM43-100 GFM43-500 GFM43-1000GFM80-5 MIP-2 / CXCL2Macrophage Inflammatory Protein 2 (MIP-2), also known as CXCL2, is a small cytokine that is secreted by monocytes and neutrophils at sites of inflammation. MIP-2 functions through the chemokine receptor CXCR2 to act as a chemotactic agent for leukocytes and hematopoietic cells.GFM80-20 GFM80-100 GFM80-500 GFM80-1000GFH147-5MIP-3 alpha / CCL20�Macrophage Inflammatory Protein-3 alpha (MIP-3 alpha), also called CCL20, is expressed in the liver, lungs, lymph nodes and peripheral blood lymphocytes. MIP-3 alpha is strongly up regulated by inflammatory signals, and dow< n regulated by the anti-inflammatory cytokine IL-10. MIP3 alpha signals through the G protein-coupled receptor, CCR6, and acts as a chemoattractant to lymphocytes anddendritic cells. Recombinant human MIP-3 alpha is a non-glycosylated protein. GFH147-20 GFH147-100 GFH147-500 GFH147-1000GFM51-5�Macrophage Inflammatory Protein-3 alpha (MIP-3 alpha), also called CCL20, is expressed in the liver, lungs, lymph nodes and peripheral blood lymphocytes. MIP-3 alpha is strongly up regulated by inflammatory signals, and down regulated by the anti-inflammatory cytokine IL-10. MIP3 alpha signals through the G protein-coupled receptor, CCR6, and acts as a chemoattractant to lymphocytes anddendritic cells. Recombinant mouse MIP-3 alpha is a non-glycosylated protein.GFM51-20 GFM51-100 GFM51-500 GFM51-1000GFH135-5MIP-3 beta / CCL19�Macrophage Inflammatory Protein-3 beta (MIP-3 beta), also called CCL19, is a chemokine that is expressed in the thymus, lymph nodes and activated bone marrow stromal cells. MIP-3 beta signals through the G protein-coupled receptor, CCR7, to regulate normal lymphocyte recirculation and homing of T and B cells to the lymph nodes. Human MIP-3 beta shows activity on mouse cells. Recombinant human MIP-3 beta is a non-glycosylated protein. GFH135-20 GFH135-100 GFH135-500 GFH135-1000GFM44-5�Macrophage Inflammatory Protein-3 beta (MIP-3 beta), also called CCL19, is a chemokine that is expressed in the thymus, lymph nodes and activated bone marrow stromal cells. MIP-3 beta signals through the G protein-coupled receptor, CCR7, to regulate normal lymphocyte recirculation and homing of T and B cells to the lymph nodes. Human MIP-3 beta shows activity on mouse cells. Recombinant mouse MIP-3 beta is a non-glycosylated protein.GFM44-20 GFM44-100 GFM44-500 GFM44-1000GFH136-2 MIP-4 / CCL18JMacrophage Inflammatory Protein-4 (MIP-4), also called CCL18, is a chemokine expressed in the lymph nodes, lungs, placenta and bone marrow. Although the MIP-4's receptor remains undetermined, MIP-4 is known to act as a chemoattractant for activated and non-activated T cells. Recombinant human MIP-4 is a non-glycosylated protein. GFH136-10 GFH136-100 GFH136-500 GFH136-1000GFH22-2 Myostatin~Myostatin (GDF8) is a member of the transforming growth factor beta superfamily that is essential for proper regulation of skeletal muscle mass. Myostatin is a secreted protein that negatively regulates skeletal muscle mass determining both muscle fiber number and size. The myostatin pathway is conserved and regulates muscle mass in a number of animal species ranging from fish to humans. Inhibition of myostatin using a variety of therapeutic approaches can increase muscle mass in a number of animal models of human disease, including muscular dystrophy. Recombinant Human Myostatin is a homodimer, non-glycosylated polypeptide chain.GFH22-10 GFH22-100 GFH22-500 GFH22-1000GFH142-5Myostatin Propeptide�Myostatin (GDF-8), a member of the TGF-beta superfamily, is a potent and specific negative regulator of skeletal muscle mass. In serum, myostatin circulates as part of a latent complex containing myostatin propeptide and/or follistatin-related gene. The myostatin propeptide is known to bind and inhibit myostatin in vitro. This interaction is relevant in vivo, with a majority (>70%) of myostatin in serum bound to its propeptide. The myostatin propeptide is negative regulator of myostatin in vivo. GFH142-25 GFH142-100 GFH142-500 GFH142-1000GFH38-5NGF-beta�Nerve Growth Factor (NGF-beta) is a neurotrophic factor related to BDNF, NT-3 and NT-4. NGF-beta acts through its receptor beta-NGFR, and is involved in the development and maintenance of the sensory and sympathetic nervous systems. NGF-beta is also involved in the growth, differentiation and survival of B lymphocytes. Human, mouse and rat proteins show cross-reactivity. Recombinant human NGF-beta is a non-covalently linked homodimer.GFH38-20 GFH38-100 GFH38-500 GFH38-1000 GFH38AF-5 NGF-beta (AF) GFH38AF-20 GFH38AF-100 GFH38AF-500 GFH38AF-1000GFM11-5�Nerve Growth Factor (NGF) is the fi< rst of a series of neurotrophic factors that were found to influence the growth and differentiation of sympathetic and sensory neurons. It is comprised of alpha, beta, and gamma subunits. The beta subunit is responsible for its growth stimulating activity. The synthesis of NGF in astrocytes is enhanced by various other cytokines: IL-1, TNF-alpha, PDGF and TGF beta. Mouse NGF-beta is non-glycosylated, non-covalently linked homodimer.GFM11-20 GFM11-100 GFM11-500 GFM11-1000GFH46-10 NRG1-beta�Neuregulin 1-beta (NRG1-beta) is one of many isoforms of NRG that contains a soluble EGF-like domain. Alpha and beta variants are distinguished by difference in length at the C terminus. The EGF-like domain signals through receptors ErbB2, ErbB3, and ErbB4 to act as a growth factor. NRG isoforms are particularly important for nervous system and cardiovasucular development. Recombinant human NRG1-beta is a non-glycosylated protein.GFH46-50 GFH46-100 GFH46-500 GFH46-1000GFH99-2NT-3'Neurotrophin-3 (NT-3) is an important member of the nerve growth factor (NGF) family of proteins behind BDNF and NGF. It is thought to promote the survival or differentiation of existing and new neurons in the central nervous system and synapses. These functions are thought to be communicated by TrkC, a receptor tryrosine kinase thought induce NT-3-specific signaling. In addition, NT-3 is thought to also bind TrkB and low affinity nerve growth factor receptor (LNGFR). Recombinant human NT-3 is a non-glycosylated, non-covalently linked homodimer.GFH99-10 GFH99-100 GFH99-500 GFH99-1000GFM21-2Neurotrophin-3 (NT-3) is an important member of the nerve growth factor (NGF) family of proteins behind BDNF and NGF. It is thought to promote the survival or differentiation of existing and new neurons in the central nervous system and synapses. These functions are thought to be communicated by TrkC, a receptor tryrosine kinase thought to induce NT-3-specific signaling. In addition, NT-3 is thought to also bind TrkB and low affinity nerve growth factor receptor (LNGFR). Recombinant mouse NT-3 is a non-glycosylated protein.GFM21-10 GFM21-100 GFM21-500 GFM21-1000GFH33-2NT-4�Neurotrophin-4 (NT-4) is an important member of the nerve growth factor (NGF) family of proteins along with NT-3, BDNF and NGF. Neurotrophins act in a paracrine and/or autocine manner to control neuronal numbers and dendrite outgrowth. These functions are thought to be communicated by TrkB, a receptor tryrosine kinase that NT-4 shares with BDNF. Recombinant human NT-4 is a non-glycosylated, non-covalently linked homodimer.GFH33-10 GFH33-100 GFH33-500 GFH33-1000GFH140-2OmentindOmentin is a member of the adipokine family of cytokines typically made and secreted by adipose tissue that surrounds internal organs and also by the small intestine. Omentin enhances insulin-stimulated glucose uptake in adipocytes and is considered to be a link between obesity and Type 2 Diabetes. Recombinant human Omentin is a non-glycosylated protein. GFH140-10 GFH140-100 GFH140-500 GFH140-1000 GFH140AF-2 Omentin (AF)�Omentin is a member of the adipokine family of cytokines typically made and secreted by adipose tissue that surrounds internal organs and also by the small intestine. Omentin enhances insulin-stimulated glucose uptake in adipocytes and is considered to be a link between obesity and Type 2 Diabetes. Recombinant human Omentin is a non-glycosylated protein. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH140AF-10 GFH140AF-100 GFH140AF-500 GFH140AF-1000GFH356-2 Oncostatin M�Oncostatin M is a growth regulator produced by a variety of cells and has a wide range of attributed functions. Several of these functions include: inhibition of tumor cell line proliferation, liver development/regeneration, regulation of cytokine production (hematopoiesis and inflammation), bone development and possibly nervous system development. Oncostatin M is a non-glycosylated protein, containing 210 amino acids, with a molecular weight of 23.8 < kDa. GFH356-10 GFH356-100 GFH356-500 GFH356-1000 GFH356AF-2Oncostatin M (AF) GFH356AF-10 GFH356AF-100 GFH356AF-500 GFH356AF-1000GFH16-2PDGF-AA�Platelet Derived Growth Factor (PDGF) is a mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication. The synthesis of PDGF can be induced by IL-1, IL-6, TNF-alpha, TGF-beta and EGF. Recombinant Human PDGF-AA is a homodimeric, non-glycosylated, polypeptide chain.GFH16-10 GFH16-100 GFH16-500 GFH16-1000 GFH16AF-2 PDGF-AA (AF) GFH16AF-10 GFH16AF-100 GFH16AF-500 GFH16AF-1000GFM54-2DRecombinant Mouse Platelet Derived Growth Factor-AA (PDGF-AA) is a disulfide linked dimer comprised of 2 polypeptide chains. Belonging to a family of PDGF s including PDGF-AA, PDGF-BB and PDGF-AB, they play an important role as a mitogen for a number of cell types. Recombinant Mouse PDGF-AA is a non-glycosylated homodimer.GFM54-10 GFM54-100 GFM54-500 GFM54-1000GFH17-2PDGF-ABPlatelet-Derived Growth Factor (PDGF) is a mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication.The synthesis of PDGF can be induced by IL-1, IL-6, TNF-alpha, TGF-beta and EGF. Recombinant Human PDGF-AB is a heterodimeric, non-glycosylated, polypeptide chain containing 234 amino acids consisting of 13.3 kDa alpha-chain and 12.2 kDa beta-chain.GFH17-10 GFH17-100 GFH17-500 GFH17-1000 GFH17AF-2 PDGF-AB (AF) GFH17AF-10 GFH17AF-100 GFH17AF-500 GFH17AF-1000GFH18-2PDGF-BB�Platelet Derived Growth Factor - BB (PDGF-BB) is a mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication. The synthesis of PDGF can be induced by IL-1, IL-6, TNF-alpha, TGF-beta and EGF. PDGF-BB Human Recombinant is a homodimeric, non-glycosylated, polypeptide chain.GFH18-10 GFH18-100 GFH18-500 GFH18-1000 GFH18AF-2 PDGF-BB (AF) GFH18AF-10 GFH18AF-100 GFH18AF-500 GFH18AF-1000GFM58-2�Recombinant Mouse Platelet Derived Growth Factor-BB (PDGF-BB) is part of a family of PDGFs incuding AA, AB and BB. All of them are disulfide-linked homodimers and play an important role in the mitogenic activity for connective tissue, blood, bone and cartilage cells. Recombinant Mouse PDGF-BB is a nonglycosylated polypeptide consisting of two PDGF-B chains. The final protein is a disulfide-linked homodimer.GFM58-10 GFM58-100 GFM58-500 GFM58-1000GFH81-5 PersephinPersephin is a neurotrophic factor that promotes survival and growth of dopaminergic and motor neurons, but not peripheral neurons. Persephin is a non-glycosylated, disulfide-linked homodimer, containing two 97 amino acid chains, each with a molecular weight of 10.4 kDa.GFH81-20 GFH81-100 GFH81-500 GFH81-1000 GFH81AF-5Persephin (AF) GFH81AF-20 GFH81AF-100 GFH81AF-500 GFH81AF-1000GFH55-5 Pleiotrophin^Pleiotrophin, or PTN, is a growth factor that has mitogenic effects on fibroblast, epithelial, and endothelial cells as well as induces neurite outgrowth. PTN is made by many tissues, but predominantly by the tissues of the nervous system during development. PTN shows a high affinity for heparin. Recombinant human PTN is a non-glycosylated protein.GFH55-20 GFH55-100 GFH55-500 GFH55-1000 GFH55AF-5Pleiotrophin (AF) GFH55AF-20 GFH55AF-100 GFH55AF-500 GFH55AF-1000GFH164-2 Procalcitonin�Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. Levels of unprocessed procalcitonin rise significantly after bacterial infection, trauma or shock. Reco< mbinant Human Procalcitonin is a single, non-glycosylated, polypeptide chain. GFH164-10 GFH164-100 GFH164-500 GFH164-1000GFH45-10 Prolactin�Prolactin (PRL) is a hormone that is made and secreted by the pituitary gland and acts in an endocrine, paracrine and autocrine manner. The prolactin receptor is expressed on many cell types and is linked to JAK kinase signaling pathways. PRL s primary function is to regulate lactation, but it is known to have many other regulation functions. These functions include roles in the immune system, cell growth, apoptosis, and differentiation. Recombinant human Prolactin is a non-glycosylated protein.GFH45-50 GFH45-100 GFH45-500 GFH45-1000GFR11-10�Prolactin (PRL) is a hormone that is made and secreted by the pituitary gland and acts in an endocrine, paracrine and autocrine manner. The prolactin receptor is expressed on many cell types and is linked to JAK kinase signaling pathways. Prolactin primary function is to regulate lactation, but it is known to have many other regulation functions, including roles in the immune system, cell growth, apoptosis, and differentiation.GFR11-50 GFR11-100 GFR11-500 GFR11-1000 GFR11AF-10Prolactin (AF) GFR11AF-50 GFR11AF-100 GFR11AF-500 GFR11AF-1000GFH19-2 RANK Ligand�Receptor Activator of NF-�B Ligand (RANK Ligand) is a cell-bound marker (CD254) related to the TNF family of proteins. RANK Ligand plays a critical role in bone metabolism, particularly osteoclast differentiation. In addition, RANK Ligand is expressed by some T cells is thought to promote dendritic cell maturation. Recombinant soluble human RANK Ligand is a non-glycosylated protein.GFH19-10 GFH19-100 GFH19-500 GFH19-1000 GFH19AF-2RANK Ligand (AF) GFH19AF-10 GFH19AF-100 GFH19AF-500 GFH19AF-1000GFM4-2�Receptor Activator of NF-kB Ligand (RANK Ligand) is a cell-bound marker (CD254) related to the TNF family of proteins. RANK Ligand plays a critical role in bone metabolism, particularly osteoclast differentiation. In addition, RANK Ligand is expressed by some T cells is thought to promote dendritic cell maturation. Recombinant mouse RANK Ligand is a non-glycosylated protein containing 174 amino acids and with a molecular weight of 19.9 kDa.GFM4-10GFM4-100GFM4-500 GFM4-1000GFM4AF-2 GFM4AF-10 GFM4AF-100 GFM4AF-500 GFM4AF-1000GFH138-5Rantes�Regulated Upon Activation Normal T cell Express Sequence (RANTES), also called CCL5, is a chemokine produced by T cells three to five days after activation. RANTES is a promiscuous chemokine that signals through several G protein-coupled receptors, CCR5, CCR3, CCR1 and US28 (a viral receptor encoded by human CMV). The main function of RANTES is to recruit immune cells to the site of inflammation. Recombinant human RANTES is a non-glycosylated protein. GFH138-20 GFH138-100 GFH138-500 GFH138-1000GFM45-5�Regulated Upon Activation Normal T cell Express Sequence (RANTES), also called CCL5, is a chemokine produced by T cells three to five days after activation. RANTES is a promiscuous chemokine that signals through several G protein-coupled receptors including, CCR5, CCR3, CCR1 and US28 (a viral receptor encoded by human CMV). The main function of RANTES is to recruit immune cells to the site of inflammation. Recombinant mouse RANTES is a non-glycosylated protein.GFM45-20 GFM45-100 GFM45-500 GFM45-1000GFR26-5�Regulated Upon Activation Normal T cell Express Sequence (RANTES), also called CCL5, is a chemokine produced by T cells three to five days after activation. RANTES is a promiscuous chemokine that signals through several G protein-coupled receptors, CCR5, CCR3, CCR1 and US28 (a viral receptor encoded by human CMV). The main function of RANTES is to recruit immune cells to the site of inflammation. Recombinant rat RANTES is a non-glycosylated protein.GFR26-20 GFR26-100 GFR26-500 GFR26-1000GFM56-5 RELM alpha�Recombinant Mouse Resistin-Like Molecule-alpha (RELM alpha) is a cytokine member to a unique family of proteins including RELM beta and Resistin. Also known as FIZZ1, RELM alpha and Resistin are secreted by adipocytes, where a< s RELM beta is secreted by intestinal epithelial cells, all sharing a high conserved C-terminal region with 10 Cysteine residues. Mouse RELM alpha is a non-glycosylated polypeptide.GFM56-25 GFM56-100 GFM56-500 GFM56-1000GFH160-5 RELM beta�Resistin-Like Molecule beta (RELM beta) is a member of a family of secreted proteins containing a conserved cystein-rich C-terminus. The RELM family consists of resistin (also called FIZZ3), RELM alpha (FIZZ1), RELM beta (FIZZ2) and RELM gamma. Only resistin and RELM beta were found in humans whereas all four RELM family members were identified in rodents. Recombinant human RELM beta consists of two non-glycosylated polypeptide chains. GFH160-25 GFH160-100 GFH160-500 GFH160-1000 GFH160AF-5RELM beta (AF) GFH160AF-25 GFH160AF-100 GFH160AF-500 GFH160AF-1000GFM69-5�RELM beta (Resistin-Like Molecule-beta) is a member of a recently identified family of secreted proteins containing a conserved cystein-rich C-terminus. The RELM family consists of resistin (also called FIZZ3), RELM alpha (FIZZ1), RELM beta (FIZZ2) and RELM gamma. Only resisistin and RELM beta were found in humans whereas all four RELM family members were identified in rodents. Recombinant Human RELM beta is a non-glycosylated polypeptide chain.GFM69-25 GFM69-100 GFM69-500 GFM69-1000GFH107-5Resistin�Resistin is a peptide hormone belonging to the class of cysteine-rich secreted proteins which is termed the RELM family and is also described as ADSF (Adipose Tissue-Specific Secretory Factor) and FIZZ3 (Found in Inflammatory Zone). Resistin is produced by adipocytes and may be an important link between obesity and insulin resistance. Recombinant human Resistin is a disulfide-linked homodimer. GFH107-25 GFH107-100 GFH107-500 GFH107-1000GFM30-5�Resistin is a peptide hormone belonging to the class of cysteine�-rich secreted proteins which is termed the RELM family and is also described as ADSF (Adipose Tissue�-Specific Secretory Factor) and FIZZ3 (Found in Inflammatory Zone). Mouse resistin is produced by adipocytes and may be an important link between obesity and insulin resistance. Recombinant mouse resistin is a non-glycosylated, disulfide�-linked homodimer.GFM30-25 GFM30-100 GFM30-500500 ug GFM30-1000GFH4-2SCFwStem Cell Factor (SCF) is a cytokine made by fibroblasts and endothelial cells. SCF binds to the receptor known as c-Kit (CD117) and is thought to play a critical role in the maintenance or survival of hematopoietic stem cells. Human SCF shows no activity on murine cells, but murine and rat SCF are active on human cells. Recombinant human SCF is a non-glycosylated protein.GFH4-10GFH4-100GFH4-500 GFH4-1000GFH4AF-2 SCF (AF) �Stem Cell Factor (SCF) is a cytokine made by fibroblasts and endothelial cells. SCF binds to the receptor known as c-Kit (CD117) and is thought to play a critical role in the maintenance or survival ofhematopoietic stem cells. Human SCF shows no activity on murine cells, but murine and rat SCF are active on human cells. Recombinant human SCF is a non-glycosylated protein. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH4AF-10 GFH4AF-100 GFH4AF-500 GFH4AF-1000GFM9-2�Stem Cell Factor (SCF) is a cytokine made by fibroblasts and endothelial cells. SCF binds to the receptor known as c-Kit (CD117) and is thought to play a critical role in the maintenance or survival of hematopoietic stem cells. Human SCF shows no activity on murine cells, but murine and rat SCF are active on human cells. Mouse SCF is a single, non-glycosylated polypeptide chain containing 164 amino acids and having a molecular mass of 18.3 kDa.GFM9-10GFM9-100GFM9-500 GFM9-1000GFR32-2uStem Cell Factor (SCF) is a cytokine made by fibroblasts and endothelial cells. SCF binds to the receptor known as c-Kit (CD117) and is thought to play a critical role in the maintenance or survival of hematopoietic stem cells. Human SCF shows no activity on murine cells, but murine and rat SCF are active on human cells. Recombinant rat SCF is a non-glyco< sylated protein.GFR32-10 GFR32-100 GFR32-500 GFR32-1000GFH20-2 SDF-1 alpha�Stromal Cell Derived Factor-1 alpha (SDF-1 alpha), also called CXCL12, is one of two splice variants made by a wide variety of cells when stimulated by inflammatory cytokines such as, TNF, IL-1 or LPS. SDF-1 alpha signals through the G protein-couple receptor, CXCR4, to recruit activated leukocytes. Human and mouse SDF-1� share 99% sequence identity. Recombinant human SDF-1 alpha is a non-glycosylated protein.GFH20-10 GFH20-100 GFH20-500 GFH20-1000GFM46-2�Stromal Cell Derived Factor-1 alpha (SDF-1 alpha) is one of two splice variants made by a wide variety of cells when stimulated by inflammatory cytokines such as, TNF, IL-1 or LPS. SDF-1 alpha signals through the G protein-couple receptor, CXCR4, to recruit activated leukocytes. Human and mouse SDF-1 alpha share 99% sequence identity. Recombinant mouse SDF-1 alpha is a non-glycosylated protein.GFM46-10 GFM46-100 GFM46-500 GFM46-1000GFH159-2 SDF-1 betaRecombinant Human Stromal Derived Growth Factor-1 beta (SDF-1 beta) is an important chemoattractant for T-lymphocytes and monocytes. The human amino acid sequence shares 100% homology to the feline SDF-1 beta. Recombinant SDF-1 beta is a polypeptide chain. GFH159-10 GFH159-100 GFH159-500 GFH159-1000GFM67-2�Recombinant Mouse Stromal Derived Growth Factor-1 beta, also called CXCL12, is one of two splice variants made by a wide variety of cells when stimulated by inflammatory cytokines such as TNF, IL-1 or LPS. SDF-1 beta signals through the G protein-couple receptor, CXCR4, to recruit activated leukocytes. Recombinant mouse SDF-1 beta is a non-glycosylated protein containing 72 amino acids and with a molecular weight of 8.5 kDa.GFM67-10 GFM67-100 GFM67-500 GFM67-1000GFF1-2MStromal Derived Growth Factor-1 (SDF-1) alpha and beta, also known as CXCL12, are two alternative splice variants from the same gene. SDF-1 alpha and SDF-1 beta are important chemoattractants for T-lymphocytes and monocytes which signal through CXCR4. The human, mouse and feline amino acid sequences have 99-100% sequence identity. GFF1-10GFF1-100GFF1-500 GFF1-1000GFH168-5SHHPRecombinant Human Sonic Hedgehog is a member of a small group of secreted proteins that are essential for development in both vertebrates and invertebrates. Three mammalian hedgehog genes (sonic, desert, indian) share about 60% homology. The Cys at position 25 has been substituted with Ile. Human SHH is a non-glycosylated polypeptide. GFH168-25 GFH168-100 GFH168-1000GFM55-5�Recombinant Mouse Sonic Hedgehog is a member of a small group of secreted proteins that are essential for development in both vertebrates and invertebrates. Three mammalian hedgehog genes (sonic, desert, Indian) share about 60% homology. The Mouse Sonic Hedgehog is 99% homologous to the human gene. Cysteine at position 25 has been substituted with Ile. Mouse SHH is a non-glycosylated polypeptide. The protein is modified with a HIS tag.GFM55-25 GFM55-100 GFM55-500 GFM55-1000GFH42-5 TARC / CCL17�Thymus and activation regulated chemokine (TARC), also known as CCL17, is a chemokine produced by thymus tissue constitutively and activated PBMCs (mainly DCs). TARC signals through the CCR4 receptor to induce chemotaxis of Th2 cells. TARC is thought to be important in asthma and allergic diseases, along with bacterial and viral infections. Recombinant human TARC is a non-glycosylated protein.GFH42-20 GFH42-100 GFH42-500 GFH42-1000GFH39-5 TGF beta 1[Human Transforming Growth Factor beta 1 is a member of the TGF beta superfamily (TGF beta 1-5). Members of this family are known to exhibit regulatory activity in immunity and proliferation. It signals activity through Smad proteins via the TGF-b1 R1 & R2 receptors. Mature TGF beta 1 is a homodimeric protein consisting of two polypeptide chains.GFH39-20 GFH39-100 GFH39-500 GFH39-1000GFH1 ������������     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~�09-2 TGF beta 3at 4�C�Transforming growth factor-betas (TGF betas) are multifunctional peptides that regulate growth and differentiation in a variety of cells. The TGF-beta family of gr< owth modulators play critical roles in tissue development and maintenance. TGF-beta isoforms (TGF-beta 1, -beta 2 and -beta 3) have overlapping yet distinct biological actions and target cell specificities, both in developing and adult tissues. TGF beta 3 is a new isoform of the TGF beta superfamily and is presumed to play an important role in wound repair and scarring. TGF-beta 3 is believed to be involved in osteoblast proliferation, chemotaxis, and collagen synthesis. Recombinant Human TGF-b 3 is a disulfide-linked homodimer. GFH109-10 GFH109-100 GFH109-500 GFH109-1000 GFH109AF-2TGF beta 3 (AF)4Transforming growth factor-betas (TGF betas) are multifunctional peptides that regulate growth and differentiation in a variety of cells. The TGF-beta family of growth modulators play critical roles in tissue development and maintenance. TGF-beta isoforms (TGF-beta 1, -beta 2 and -beta 3) have overlapping yet distinct biological actions and target cell specificities, both in developing and adult tissues TGF beta 3 is a new isoform of the TGF beta superfamily and is presumed to play an important role in wound repair and scarring. TGF-beta 3 is believed to be involved in osteoblast proliferation, chemotaxis, and collagen synthesis. Recombinant Human TGF-b 3 is a disulfide-linked homodimer. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH109AF-10 GFH109AF-100 GFH109AF-500 GFH109AF-1000GFM27-2XThe Transforming Growth Factors (TGFs) are multifunctional peptides that regulate growth and differentiation in a variety of cells. Recent data suggests that individual TGF-� isoforms (TGF-�1, -�2 and -�3) have overlapping, yet distinct biological actions and target cell specificities, both in developing and adult tissues. TGF-�3 is a new isoform that is presumed to play an important role in wound repair and scarring. TGF-�3 is also thought to be involved in osteoblast proliferation, chemotaxis, and collagen synthesis. Recombinant mouse TGF-�3 is a non-glycosylated, disulfide-linked homodimer.GFM27-10 GFM27-100 GFM27-500 GFM27-1000 GFM27AF-2 GFM27AF-10 GFM27AF-100 GFM27AF-500 GFM27AF-1000 GFH111-10 TNF-alpha�TNF is secreted by macrophages, monocytes, neutrophils, T-cells, NK- cells following their stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-alpha while CD8 cells secrete little or no TNF-alpha. The synthesis of TNF-alpha is induced by many different stimuli including interferons, IL2, GM-CSF. Recombinant Human Tumor Necrosis Factor-alpha is a single, non-glycosylated polypeptide. GFH111-50 GFH111-100 GFH111-500 GFH111-1000 GFH111AF-10TNF-alpha (AF) GFH111AF-50 GFH111AF-100 GFH111AF-500 GFH111AF-1000GFM31-52Tumor Necrosis Factor alpha (TNF-alpha) is an inflammatory cytokine secreted by macrophages, monocytes, neutrophils, T cells, NK-cells following their stimulation by bacterial LPS. TNF-alpha activates signals through two receptors: TNF-R1, which is expressed on most cell types, and TNF-R2, which is expressed mainly on immune cells. TNF-alpha can have many functions including to stimulate of phagocytosis in macrophages, to chemoattract neutrophils, to increase insulin resistance and to induce fever. Recombinant mouse TNF-alpha is a non-glycosylated protein.GFM31-20 GFM31-100 GFM31-500 GFM31-1000GFR18-5TNF is secreted by macrophages, monocytes, neutrophils, T-cells, NK-cells following their stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-alpha while CD8 cells secrete little or no TNF-alpha. The synthesis of TNF-alpha is induced by many different stimuli including interferons, IL2, GM-CSF. Recombinant rat TNF-alpha is a single, non-glycosylated, polypeptide chain. GFR18-20 GFR18-100 GFR18-500 GFR18-1000GFH35-5TNF-Receptor Type 1�TNF-alpha Receptor 1, also known as CD120a or TNF-R1, is expressed in most tissues and is activated by soluble and membrane-bound TNF-a. Activation of TNF-R1 is known to induce inflammation and apoptotic cell death, important for inhibition of tumorigenesis and viral replication, through < NF-�B and MAPK pathways. The soluble form of human recombinant TNF-alpha Receptor 1 is a non-glycosylated polypeptide chain.GFH35-20 GFH35-100 GFH35-500 GFH35-1000GFH5-2TPOtThrombopoietin (TPO) is a growth factor that is produced by the liver and kidney. TPO acts through the TPO receptor to promote megakaryocyte maturation and differentiation, which leads to the production of platelets. Recombinant human TPO is a non-glycosylated protein, containing the 174 amino acids of the receptor binding domain and having a molecular mass of 18.6 kDa.GFH5-10GFH5-100GFH5-500 GFH5-1000GFH5AF-2TPO (AF)�Thrombopoietin (TPO) is a growth factor that is produced by liver and kidney tissue. TPO acts through the TPO receptor to promote megakaryocyte maturation and differentiation, which leads to the production of platelets. Recombinant human TPO is a non-glycosylated protein. Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFH5AF-10 GFH5AF-100 GFH5AF-500 GFH5AF-1000GFM32-2VThrombopoietin (TPO) is a growth factor that is produced by the liver and kidney. TPO acts through the TPO receptor to promote megakaryocyte maturation and differentiation, which leads to the production of platelets. Recombinant mouse TPO is a non-glycosylated protein, containing 174 amino acids (which comprise the receptor binding domain).GFM32-10 GFM32-100 GFM32-500 GFM32-1000 GFM32AF-2�Thrombopoietin (TPO) is a growth factor that is produced by the liver and kidney. TPO acts through the TPO receptor to promote megakaryocyte maturation and differentiation, which leads to the production of platelets. Recombinant mouse TPO is a non-glycosylated protein, containing 174 amino acids (which comprise the receptor binding domain). Animal Free: This product is produced with no animal-derived raw products, animal free equipment and animal free protocols. GFM32AF-10 GFM32AF-100 GFM32AF-500 GFM32AF-1000 GFH115-10TRAILzRecombinant Human soluble TRAIL (also called TNF-related apoptosis-inducing Ligand, TNFSF10, Apo2 Ligand and TL2) is produced by a wide variety of cell types and is shown to be a cytotoxic protein that induces apoptosis in tumor cells through activation of the DR4 and DR5 receptors. Recombinant human TRAIL is produced in E.coli as a single, non-glycosylated polypeptide chain. GFH115-50 GFH115-100 GFH115-500 GFH115-1000GFH165-2TSLP�Human Thymic Stromal Lymphopoietin (H-TSLP) is produced in several tissues including heart, liver and prostate. TSLP shares similar biological activities to IL-7 including enhancement of STAT3 and STAT5. TSLP induces the release of T-cell chemokines from monocytes and affects increased growth of dendritic cells. H-TSLP is also signals through the IL-7 receptor and TSLP-R receptor pathways. GFH165-10 GFH165-100 GFH165-500 GFH165-1000GFM52-2VEGF-120[Vascular Endothelial Growth Factor-A (VEGF-A) was originally isolated from tumor cells and is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability, VEGF-A may play a role in stimulating vasodilatation via nitric oxide-dependent pathways. Mouse VEGF-A has several variants, one being VEGF-120. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95%. Recombinant mouse VEGF-120 is an alternative spliced version of Mouse VEGF-165, consisting of a non-glycosylated homodimer.GFM52-10 GFM52-100 GFM52-500 GFM52-1000GFH116-2VEGF-121VEGF-A was originally isolated from tumor cells. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating vasodilation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Recombinant Human VEGF-121 is a double, non-glycosylated, polypeptide chain. GFH116-10 GFH116-100 GFH116-500 GFH116-1000 GFH116AF-2 VEGF-121 (AF) GFH116AF-10 GFH116AF-100 GFH116AF-500 GFH116AF-1000GFH44-2VEGF-165lVascular endothelial growth<� factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells, it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating vasodilation via nitric oxide-dependent pathways. VEGF-A has several variants, VEGF-165 being the most abundant. Recombinant human VEGF-165 is a non-glycosylated homodimer, containing two 165 amino acids, with a total molecular weight of 38.2 kDa.GFH44-10 GFH44-100 GFH44-500 GFH44-1000 GFH44AF-2 VEGF-165 (AF) GFH44AF-10 GFH44AF-100 GFH44AF-500 GFH44AF-1000GFM34-2*Vascular endothelial growth factor-A (VEGF-A) was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells, it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating vasodilation via nitric oxide-dependent pathways. VEGF-A has several variants, VEGF-165 being the most abundant. Recombinant mouse VEGF-165 is a non-glycosylated homodimer.GFM34-10 GFM34-100 GFM34-500 GFM34-1000GFR31-2!Vascular Endothelial Growth Factor-A (VEGF-A) was originally isolated from tumor cells and is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability, VEGF-A may play a role in stimulating vasodilatation via nitric oxide-dependent pathways. VEGF-A has several variants, VEGF-165 being the most abundant. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95%. Recombinant rat VEGF-165 is a disulfide linked homodimer.GFR31-10 GFR31-100 GFR31-500 GFR31-1000GFH50-5VisfatinbVisfatin is an adipokine produced by visceral adipose tissue. Other adipokines include leptin, adiponectin, resistin, chemerin, omentin and vaspin. Visfatin has been shown to act as a pro-inflammatory factor for PBMCs and may mimic the effects of insulin on adipocytes, monocytes and hepatocytes. Recombinant human Visfatin is a non-glycosylated protein.GFH50-25 GFH50-100 GFH50-500 GFH50-1000GFM77-5Wnt-3a (15 ng/ul)Wnt-3a signalling has been implicated in the control of differentiation of stem cells. Wnt proteins have been shown to regulate cell-to-cell interactions during embryogenesis, more specifically regulating mesoderm differentiation and osteogenesis. The Wnts have also been shown to have putative roles in the regulation of adult stem cells. Recombinant murine Wnt-3a is active in human cells. Recombinant murine Wnt-3a is a monomeric glycoprotein. Murine Wnt-3a migrates at an apparent molecular weight of approximately 35 kDa.GFM77-25 GFM77-250����; �r����\�[�1Q+� �w���D&�uz}��A �G���<��B ����� � ��� �X% ��-f>.O�_�r��-��������Q���&u7=H Y�i�za�)������I����i"13�C�T�eQv����q�9������Y ! �. �? yP Aa r т �� a� )� �� �� ��  d����MbP?_*+��%;����&ffffff�?'ffffff�?(�?)�?�" dU333333�?333333�?�&� U} A} �"B} `B} � C} � C} � A} @A} H'B} $ DX�@;@;@;�@�������������������������������������������������������������������������������������������������������������������������������      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~��������������������������������������������������������������������������������������������������������������������������������������;�@;�@;�@;�@;�@ ;�@ ;�@ ;�@ ;�@ ;@;@;�@;�@;�@;�@;�@;�@;�@;�@;�@;�@;�@;�@;�@;�@;�@;�@;�@� E� F� F� G� G� H� H� I� J� K � K ~ L8�@� L � J � J � K� A� K� K~ L��@� L � J � J � K� M� N� K~ L�@� L � J� J� K� M� N� K ~ L��@� L � J� J� K� M� N� K~ L�@� L � J� J� K� M� N� K ~ L��@� L � J� J� K� M� N� K~ L��@� L � J � J � K� M � N!� K"� O#� L � J� JK� M$� N!� K%� O#� L � J� J K� A&� P'� N(~ Q8�@� L � J � J � K)� R*� P'� P+~ Q8�@� L � J � J � K)� R,� P-� P(~ Q8�@� L � J � J � K)� R.� P/� P+~ Q8�@� L � J � J � K)� A0� S1� R2~ Q�@� L � R� R3� P4� J5� K6� K7~ LL�@� L � R� R3� P4� J8� K9� K7~ L��@� L � R� R3� P4� J:� K9� K;~ L-�@� L � R� R3� P<� S=� S>� R2~ Q��@� L � R� R3� P<� J?� K@� K7~ LƷ@� L � R� R3� P<� JA� K@� K;~ L��@� L � R� R3� PB� SC� SD� R2~ Q��@� L � R� J� PE� JF� KD� K7~ T�@� L � R� J� PE� JG� KD� K;~ L>�@� L � R� J� PE� JH� KI� KJ~ Q�@� L � R� J� KK� JL� KI� KM~ L��@� L � R� J� KK� JN� PO� KP~ L�@� L � R� R� KQ� MR� PS� NT~ L���@� L � RU� J� PV� MW� UX� NT~ L���@� L � RU� J� PV� MY� VZ� NT~ L���@� L � RU� J� PV� W[� W\� M]~ L��@� L � RU� JP� W^� W_� M]~ L��@� L � RU� JP�Dplppppppppllppppppppppppppppppppl ;�@!;�@";�@#;�@$;�@%;�@&;�@';�@(;�@);�@*;�@+;@,;@-;@.;@/;@0;@1;@2;@3;@4;@5;@6;@7;@8;@9;@:;@;;@<;@=;@>;@?;@� W`� Wa� M]~ L��@� L � RU� J P� !Wb� !Wc� !M]~ !L�@� !L � !RU� !J!P� "Wd� "We� "Mf~ "L��@� "L � "R� "J � "Sg� #Wh� #Wi� #Mf~ #L��@� #L � #R� #J � #Sg� $Wj� $Wk� $Mf~ $L��@� $L � $R� $J � $Sg� %Wl� %Wm� %Mn~ %L��@� %L � %R� %J� %Sg� &Wo� &Wm� &Mp~ &L��@� &L � &R� &J� &Sg� 'Wq� 'Wr� 'Mn~ 'L��@� 'L � 'R� 'J� 'Sg� (Ws� (Wr� (Mp~ (L��@� (L � (R� (J� (Sg� )Wt� )Wu� )Mn~ )L��@� )L � )R� )J� )Sg� *Wv� *Wu� *Mp~ *L��@� *L � *R� *J� *Sg� +Mw� +Px� +Ny~ +Q�@� +L � +X� +Y� +Nz� ,M{� ,Px� ,N|~ ,QƧ@� ,L � ,X� ,Y� ,Nz� -M}� -Px� -P~~ -Q��@� -L � -X� -Y� -Nz� .J� .K�� .K�~ .C;�@� .L � .J� .R�� .K�� /R�� /P�� /P�~ /Q<�@� /L � /R�� /Y� /P�� 0R�� 0P�� 0P�~ 0QC�@� 0L � 0R�� 0Y� 0P�� 1R�� 1P�� 1P�~ 1Q��@� 1L � 1R�� 1Y� 1P�� 2R�� 2P�� 2P�~ 2Q>�@� 2L � 2R� 2R�� 2P�� 3R�� 3P�� 3P�~ 3QB�@� 3L � 3R�� 3Y� 3P�� 4R�� 4P�� 4P%~ 4Q� 4L � 4R�� 4Y4P� 5R�� 5P�� 5P�~ 5Q��@� 5L � 5R�� 5Y� 5P�� 6R�� 6P�� 6P�~ 6Q��@� 6L � 6R�� 6Y� 6P�� 7R�� 7P�� 7P�~ 7Q�@� 7L � 7R� 7R�� 7P�� 8R�� 8P�� 8P�~ 8Q>�@� 8L � 8R� 8R�� 8P�� 9R�� 9Z�� 9P�~ 9Q�@� 9L � 9R� 9R�� 9P�� :R�� :P�� :P�~ :Q>�@� :L � :R�� :Y� :P�� ;R�� ;P�� ;P�~ ;Q<�@� ;L � ;R�� ;Y� ;P�� <R�� <P�� <P�~ <Q<�@� <L � <R�� <Y� <P�� =R�� =P�� =P�~ =Q<�@� =L � =R�� =Y� =P�� >R�� >P�� >P�~ >Q;�@� >L � >R� >R�� >P�� ?R�� ?P�� ?P�~ ?Q��@� ?L � ?R�� ?Y� ?P��Dtlllpppppppppppppppppplpppppppppp@;@A;@B;@C;@D;@E;@F;@G;@H;@I;@J;@K;@L;@M;@N;@O;@P;@Q;@R;@S;@T;@U;@V;@W;@X;@Y;@Z;@[;@\;@];@^;@_;@� @R�� @P�� @P�~ @Q�@� @L � @R�� @Y� @P�� AS�� AS�� AS�~ AQ@�@� AL � AX� AS�� AS�� BS�� BS�� BS�~ BQ��@� BL � BX� BS�� BS�� CS�� CS�� CS�~ CQ@�@� CL � CX� CS�� CS�� DS�� DS�� DS�~ DQ��@� DL � DX� DS�� DS�� ES�� ES�� ES�~ EQ�o�@� EL � EX� ES�� ES�� FS�� FS�� FS�~ FQ��@� FL � FX� FS�� FS�� GS�� GS�� GS�~ GQ@�@� GL � GX� GS�� GS�� HS�� HS�� HS�~ HQ��@� HL � HX� HS�� HS�� IS�� IS�� IS�~ IQ��@� IL � IX� IS�� IS�� JS�� JS�� JS�~ JQ��@� JL � JX� JS�� JS�� KS�� KS�� KS�~ KQ��@� KL � KX� KS�� KS�� LS�� LS�� LS�~ LQ@�@� LL � LX� LS�� LS�� MS�� MS�� MS�~ MQ��@� ML � MX� MS�� MS�� NS�� NS�� NS�~ NQ�@� NL � NX� NS�� NS�� OS�� OS�� OS�~ OQ@�@� OL � OX� OS�� OS�� PS�� PS�� PS�~ PQ��@� PL � PX� PS�� PS�� QS�� QS�� QS�~ QQ8�@� QL � QX� QS�� QS�� RS�� RS�� RS�~ RQ��@� RL � RX� RS�� RS�� SS�� SS�� SS�~ SQ=�@� SL � SX� SS�� SS�� TS�� TS�� TS�~ TQ@�@� TL � TX� TS�� TS�� US�� US�� US�~ UQ��@� UL � UX� US�� US�� VS�� VS�� VS�~ VQ��@� VL � VX� VS�� VS�� WS�� WS�� WS�~ WQ@�@� WL � WX� WS�� WS�� XS�� XS�� XS�~ XQ��@� XL � XX� XS�� XS�� YS�� YS�� YS�~ YQ8�@� YL � YX� YS�� YS�� ZS�� ZS�� ZS�~ ZQ9�@� ZL � ZX� ZS�� ZS�� [S�� [S�� [S�~ [Q@�@� [L � [X� [S�� [S�� \S�� \S�� \S�~ \Q��@� \L � \X� \S�� \S�� ]S�� ]S�� ]S�~ ]Q�@� ]L � ]X� ]S�� ]S�� ^S�� ^S�� ^S�~ ^Q@�@� ^L � ^X� ^S�� ^S�� _S�� _S�� _S�~ _Q��@� _L � _X� _S�� _S��D�lppppppppppppppppppppppppppppppp`;@a;@b;@c;@d;@e;@f;@g;@h;@i;@j;@k;@l;@m;@n;@o;@p;@q;@r;@s;@t;@u;@v;@w;@x;@y;@z;@{;@|;@};@~;@;@� `S�� `S�� `S�~ `Q���@� `L � `X� `S�� `S�� aS�� aS�� aS�~ aQ@�@� aL � aX� aS�� aS�� bS� bS�� bS�~ bQ��@� bL � bX� bS�� bS�� cS� cS�� cS�~ cQ��@� cL � cX� cS�� cS�� dS� dS� dS~ dQ@�@� dL � dX� dS�� dS� eS� eS� eS�~ eQ��@� eL � eX� eS�� eS� fS� fS� fS~ fQ��@� fL � fX� fS�� fS� gS � gS� gS�~ gQE�@� gL � gX� gS�� gS� hS � hS� hS�~ hQ��@� hL � hX� hS�� hS� iS � iS � iS�~ iQ@�@� iL � iX� iS�� iS � jS� jS � jS�~ jQ��@� jL � jX� jS�� jS � kS� kS � kS�~ kQ��@� kL � kX� kS�� kS � lS� lS � lS~ lQ��@� lL � lX� lS�� lS � mS� mS � mS�~ mQ��@� mL � mX� mS�� mS � nS� nS� nS�~ nQ@�@� nL � nX� nS�� nS� oS� oS� oS~ oQ��@� oL � oX� oS�� oS� pS� pS� pS~ pQ�@� pL � pX� pS�� pS� qS� qS� qS�~ qQ�@� qL � qX� qS�� qS� rS� rS� rS�~ rQ@�@� rL � rX� rS�� rS� sS� sS� sS�~ sQ��@� sL � sX� sS�� sS� tS� tS� tS�~ tQ��@� tL � tX� tS�� tS� uS� uS� uS�~ uQ��@� uL � uX� uS�� uS� vS� vS � vS�~ vQ@�@� vL � vX� vS�� vS!� wS"� wS � wS�~ wQ��@� wL � wX� wS�� wS!� xS#� xS � xS~ xQ�@� xL � xX� xS�� xS!� yS$� yS � yS~ yQ��@� yL � yX� yS�� yS!� zS%� zS � zS�~ zQ�n�@� zL � zX� zS�� zS!� {S&� {S'� {S�~ {Q@�@� {L � {X� {S�� {S(� |S)� |S'� |S�~ |Q��@� |L � |X� |S�� |S(� }S*� }S'� }S�~ }Q��@� }L � }X� }S�� }S(� ~S+� ~S'� ~S�~ ~QD�@� ~L � ~X� ~S�� ~S(� S,� S'� S�~ Q��@� L � X� S�� S(�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �S-� �S.� �S�~ �Q@�@� �L � �X� �S�� �S/� �S0� �S.� �S�~ �Q��@� �L � �X� �S�� �S/� �S1� �S.� �S�~ �Q�@� �L � �X� �S�� �S/� �S2� �S3� �S�~ �Q@�@� �L � �X� �S�� �S4� �S5� �S3� �S�~ �Q��@� �L � �X� �S�� �S4� �S6� �S3� �S�~ �Q�@� �L � �X� �S�� �S4� �S7� �S3� �S�~ �QC�@� �L � �X� �S�� �S4� �S8� �S9� �S�~ �Q@�@� �L � �X� �S�� �S:� �S;� �S9� �S�~ �Q��@� �L � �X� �S�� �S:� �S<� �S9� �S�~ �Q��@� �L � �X� �S�� �S:� �S=� �S9� �S�~ �Q�@� �L � �X� �S�� �S:� �S>� �S9� �S�~ �Q�@� �L � �X� �S�� �S:� �S?� �S@� �S�~ �Q@�@� �L � �X� �S�� �SA� �SB� �S@� �S�~ �Q��@� �L � �X� �S�� �SA� �SC� �S@� �S�~ �Q8�@� �L � �X� �S�� �SA� �SD� �S@� �S�~ �Q?�@� �L � �X� �S�� �SA� �SE� �S@� �S~ �Q��@� �L � �X� �S�� �SA� �SF� �SG� �S�~ �Q@�@� �L � �X� �S�� �SH� �SI� �SG� �S�~ �Q��@� �L � �X� �S�� �SH� �SJ� �SG� �S�~ �Q��@� �L � �X� �S�� �SH� �SK� �SL� �S�~ �Q@�@� �L � �X� �S�� �SM� �SN� �SL� �S�~ �Q��@� �L � �X� �S�� �SM� �SO� �SL� �S�~ �QC�@� �L � �X� �S�� �SM� �SP� �SQ� �S�~ �Q@�@� �L � �X� �S�� �SR� �SS� �SQ� �S�~ �Q��@� �L � �X� �S�� �SR� �ST� �SQ� �S�~ �Q>�@� �L � �X� �S�� �SR� �SU� �SQ� �S�~ �Q@��@� �L � �X� �S�� �SR� �SV� �SW� �S�~ �Q@�@� �L � �X� �S�� �SX� �SY� �SW� �S�~ �Q��@� �L � �X� �S�� �SX� �SZ� �SW� �S�~ �Q;�@� �L � �X� �S�� �SX� �S[� �SW� �S�~ �Q���@� �L � �X� �S�� �SX� �[\� �S]� �S�~ �Q@�@� �L � �X� �S�� �X^�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �[_� �S]� �S�~ �Q��@� �L � �X� �S�� �X^� �[`� �S]� �S�~ �QE�@� �L � �X� �S�� �X^� �[a� �S]� �S�~ �Q��@� �L � �X� �S�� �X^� �[b� �S]� �S~ �Q��@� �L � �X� �S�� �X^� �Sc� �Sd� �S�~ �Q@�@� �L � �X� �S�� �Se� �Sf� �Sd� �S�~ �Q��@� �L � �X� �S�� �Se� �Sg� �Sd� �S�~ �Q��@� �L � �X� �S�� �Se� �Sh� �Sd� �S~ �Q�@� �L � �X� �S�� �Se� �Si� �Sd� �S�~ �Q���@� �L � �X� �S�� �Se� �Sj� �Sk� �S�~ �Q@�@� �L � �X� �S�� �Sl� �Sm� �Sk� �S�~ �Q��@� �L � �X� �S�� �Sl� �Sn� �Sk� �S�~ �QE�@� �L � �X� �S�� �Sl� �So� �Sk� �S�~ �Q� �@� �L � �X� �S�� �Sl� �Sp� �Sq� �S�~ �Q@�@� �L � �X� �S�� �Sr� �Ss� �Sq� �S�~ �Q��@� �L � �X� �S�� �Sr� �St� �Sq� �Su~ �Q��@� �L � �X� �S�� �Sr� �Sv� �Sw� �S�~ �Q@�@� �L � �X� �S�� �Sx� �Sy� �Sw� �S�~ �Q��@� �L � �X� �S�� �Sx� �Sz� �Sw� �S�~ �Q<�@� �L � �X� �S�� �Sx� �S{� �S|� �S�~ �Q@�@� �L � �X� �S�� �S}� �S~� �S|� �S�~ �Q��@� �L � �X� �S�� �S}� �S� �S|� �S�~ �Q�@� �L � �X� �S�� �S}� �S�� �S|� �S�~ �Q@�@� �L � �X� �S�� �S}� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q8�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q���@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �QC�@� �L � �X� �S�� �S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �QA�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q�i�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S������L��� PD173074�� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S��� PD173074�� �S�~ �Q�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S���PD184352� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �QB�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S������L���PD98059�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �QD�@� �L � �X� �S�� �S�� �S��S���PD98059�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S���+PI-103 hydrochloride� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S��D��+PI-103 hydrochloride� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �QL�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S������L���+PIK-75 hydrochloride� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q�@� �L � �X� �S�� �S�� �S��S���+PIK-75 hydrochloride� �S�~ �QD�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S��� Plerixafor� �S�~ �Q��@� �L � �X� �S�� �S��D�lpppppppp��pp�ppp�p�p�p�pppp�p�p�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �S��S��� Plerixafor� �S�~ �Q�@� �L � �X� �S�� �S�� �S��S��� Plerixafor� �S�~ �QD�@� �L � �X� �S�� �S�� �S��S��� Plerixafor� �S�~ �Q>�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S��D�� PP1� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S������L���Purmorphamine�� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S���Purmorphamine�� �S�~ �Q�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S��� Rapamycin� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S��� Rapamycin� �S�~ �Q�@� �L � �X� �S�� �S�� �S��S��� Rapamycin� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S��� Rapamycin� �S�~ �Q�d�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S������L���)Reboxetine mesylate� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S���)Reboxetine mesylate� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S���)Reboxetine mesylate� �S�~ �Q���@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S��D�� Reversine� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S��D�� Reversine� �S�~ �Q<�@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S������L���RG108�� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S���RG108�� �S�~ �Q��@� �L � �X� �S�� �S�� �S�� �S�� �S�~ �Q@�@� �L � �X� �S�� �S�� �S��S��� Rosiglitazone� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S��� Rosiglitazone� �S�~ �Q��@� �L � �X� �S�� �S�� �S��S��� Rosiglitazone� �S�~ �Q��@� �L � �X� �S�� �S��DWl���p�pppppp��p����p���p��p��p��;@;@;@;@;@;@;@;@;@ ;@ ;@ ;@ ;@ ;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@� S�� S�� S�~ Q@�@� L � X� S�� S�� S�� S�� S�~ Q��@� L � X� S�� S�� S�� S�� S�~ Q��@� L � X� S�� S�� S�� S�� S�~ Q��@� L � X� S�� S�� S�� S�� S�~ Q@�@� L � X� S�� S�� S�S���L��� SAHA� S�~ Q��@� L � X� S�� S�� S�S�� SAHA� S~ Q�@� L � X� S�� S�� S�S�� SAHA� S~ Q�@� L � X� S�� S�� S�S�� SAHA� S�~ Q�@� L � X� S�� S�� S�� S�� S�~ Q@�@� L � X� S�� S�� S� S�� S�~ Q��@� L � X� S�� S�� S� S�� S�~ QB�@� L � X� S�� S�� S� S�� S�~ Q9�@� L � X� S�� S�� S� S� S�~ Q@�@� L � X� S�� S� SS��D �SB216763� S�~ Q��@� L � X� S�� S� SS���L���SB216763� S�~ Q��@� L � X� S�� S� SS��SB216763� S�~ Q�@� L � X� S�� S� S S��SB216763� S�~ Q��@� L � X� S�� S� S � S � S�~ Q@�@� L � X� S�� S � S � S � S�~ Q��@� L � X� S�� S � S� S � S�~ Q��@� L � X� S�� S � S� S � S�~ Q��@� L � X� S�� S � S� S� S�~ Q@�@� L � X� S�� S� S� S� S�~ Q��@� L � X� S�� S� S� S� S�~ Q��@� L � X� S�� S� S� S� S�~ Q@�@� L � X� S�� S� SS���L��� Sorafenib� S�~ Q��@� L � X� S�� S� SS�� Sorafenib� S~ Q�@� L � X� S�� S� SS�� Sorafenib� S�~ Q��@� L � X� S�� S� S� S� S�~ Q@�@� L � X� S�� S� S� S� S�~ Q��@� L � X� S�� S� S� S� S�~ Q<�@� L � X� S�� S�DWlppppp����ppppp����pppppppp���pp ;@!;@";@#;@$;@%;@&;@';@(;@);@*;@+;@,;@-;@.;@/;@0;@1;@2;@3;@4;@5;@6;@7;@8;@9;@:;@;;@<;@=;@>;@?;@� S � S� S�~ QB�@� L � X� S�� S� !S!� !S� !S"~ !Q?�@� !L � !X� !S�� !S� "S#� "S$� "S�~ "Q��@� "L � "X� "S�� "S%� #S&#S��D"� Stauprimide� #S�~ #Q��@� #L � #X� #S�� #S%� $S'$S��D#� Stauprimide� $S�~ $Q>�@� $L � $X� $S�� $S%� %S(� %S)� %S�~ %Q@�@� %L � %X� %S�� %S*� &S+� &S)� &S�~ &Q��@� &L � &X� &S�� &S*� 'S,� 'S)� 'S�~ 'Q��@� 'L � 'X� 'S�� 'S*� (S-� (S)� (S�~ (Q�d�@� (L � (X� (S�� (S*� )S.� )S/� )S�~ )Q@�@� )L � )X� )S�� )S0� *S1*S��*�*,L��� StemRegenin 1� *S�~ *Q��@� *L � *X� *S�� *S0� +S2+S��* StemRegenin 1� +S�~ +Q:�@� +L � +X� +S�� +S0� ,S3,S��* StemRegenin 1� ,S�~ ,Q�@� ,L � ,X� ,S�� ,S0� -S4� -S5� -S�~ -Q@�@� -L � -X� -S�� -S6� .S7.S��.�.0L���SU5402� .S�~ .Q��@� .L � .X� .S�� .S6� /S8/S��.SU5402� /S�~ /Q��@� /L � /X� /S�� /S6� 0S90S��.SU5402� 0S�~ 0Q��@� 0L � 0X� 0S�� 0S6� 1S:� 1S;� 1S�~ 1Q@�@� 1L � 1X� 1S�� 1S<� 2S=2S��2�24L���SU6668� 2S�~ 2Q��@� 2L � 2X� 2S�� 2S<� 3S>3S��2SU6668� 3S�~ 3Q�@� 3L � 3X� 3S�� 3S<� 4S?4S��2SU6668� 4S�~ 4Q��@� 4L � 4X� 4S�� 4S<� 5S@� 5SA� 5S�~ 5Q@�@� 5L � 5X� 5S�� 5SB� 6SC6S��6�69L��� Sunitinib� 6S�~ 6Q��@� 6L � 6X� 6S�� 6SB� 7SD7S��6 Sunitinib� 7S"~ 7Q�@� 7L � 7X� 7S�� 7SB� 8SE8S��6 Sunitinib� 8S~ 8Q��@� 8L � 8X� 8S�� 8SB� 9SF9S��6 Sunitinib� 9S�~ 9Q��@� 9L � 9X� 9S�� 9SB� :SG� :SH� :S�~ :Q@�@� :L � :X� :S�� :SI� ;SJ� ;SH� ;S�~ ;Q��@� ;L � ;X� ;S�� ;SI� <SK� <SH� <S�~ <Q��@� <L � <X� <S�� <SI� =SL� =SH� =S�~ =Q�/�@� =L � =X� =S�� =SI� >SM� >SN� >S�~ >Q@�@� >L � >X� >S�� >SO� ?SP?S��?�?AL���TG101348� ?S�~ ?Q��@� ?L � ?X� ?S�� ?SO�Dylppp��ppppp���p���p���p����ppppp@;@A;@B;@C;@D;@E;@F;@G;@H;@I;@J;@K;@L;@M;@N;@O;@P;@Q;@R;@S;@T;@U;@V;@W;@X;@Y;@Z;@[;@\;@];@^;@_;@� @SQ@S��?TG101348� @S�~ @Q�@� @L � @X� @S�� @SO� ASRAS��?TG101348� AS�~ AQ�i�@� AL � AX� AS�� ASO� BSS� BST� BS�~ BQ@�@� BL � BX� BS�� BSU� CSVCS��C�CGL��� Thiazovivin�� CS�~ CQ��@� CL � CX� CS�� CSU� DSWDS��C Thiazovivin�� DS�~ DQC�@� DL � DX� DS�� DSU� ESX� ESY� ES�~ EQ@�@� EL � EX� ES�� ESZ� FS[FS��C!Trichostatin A�� FS�~ FQ@�@� FL � FX� FS�� FSZ� GS\GS��C!Trichostatin A�� GS�~ GQ��@� GL � GX� GS�� GSZ� HS]� HS^� HS�~ HQ@�@� HL � HX� HS�� HS_� IS`� IS^� IS�~ IQ��@� IL � IX� IS�� IS_� JSa� JS^� JS�~ JQ��@� JL � JX� JS�� JS_� KSb� KS^� KS�~ KQ�@� KL � KX� KS�� KS_� LSc� LSd� LS�~ LQ@�@� LL � LX� LS�� LSe� MSfMS��M�MOL��� U0126� MS�~ MQ��@� ML � MX� MS�� MSe� NSgNS��M U0126� NS�~ NQ�@� NL � NX� NS�� NSe� OShOS��M U0126� OS"~ OQ��@� OL � OX� OS�� OSe� PSi� PSj� PS�~ PQ@�@� PL � PX� PS�� PSk� QSlQS��Q�QSL��� Vandetanib� QS�~ QQ��@� QL � QX� QS�� QSk� RSmRS��Q Vandetanib� RS�~ RQ�@� RL � RX� RS�� RSk� SSnSS��Q Vandetanib� SS~ SQ��@� SL � SX� SS�� SSk� T[o� TSp� TS�~ TQ@�@� TL � TX� TS�� TSq� U[r� USp� US�~ UQ��@� UL � UX� US�� USq� V[s� VSp� VS�~ VQB�@� VL � VX� VS�� VSq� W[t� WSp� WS�~ WQE�@� WL � WX� WS�� WSq� X[u� XSp� XS�~ XQ��@� XL � XX� XS�� XSq� Y[v� YSp� YS~ YQ���@� YL � YX� YS�� YSq� ZSw� ZSx� ZS�~ ZQ@�@� ZL � ZX� ZS�� ZSy� [Sz[S��[�[]L���XAV939� [S�~ [Q��@� [L � [X� [S�� [Sy� \S{\S��[XAV939� \S�~ \Q:�@� \L � \X� \S�� \Sy� ]S|]S��[XAV939� ]S�~ ]Q��@� ]L � ]X� ]S�� ]Sy� ^S}� ^S~� ^S�~ ^Q@�@� ^L � ^X� ^S�� ^S� _S�_S��_�_aL���Y-27632� _S�~ _Q��@� _L � _X� _S�� _S�Dwl��p��p��ppppp���p���ppppppp���p`;@a;@b;@c;@d;@e;@f;@g;@h;@i;@j;@k;@l;@m;@n;@o;@p;@q;@r;@s;@t;@u;@v;@w;@x;@y;@z;@{;@|;@};@~;@;@� `S�`S��_Y-27632� `S�~ `Q���@� `L � `X� `S�� `S� aS�aS��_Y-27632� aS�~ aQ�;�@� aL � aX� aS�� aS� bP�� bP�� bR�~ bQ��@� bL � bS� bS�� bS�� cP�� cP�� cR�~ cQ�@� cL � cS� cS�� cS�� dP�� dP�� dR]~ dQ��@� dL � dS� dS�� dS�� eP�� eP�� eR�~ eQC�@� eL � eS� eS�� eS�� fP�� fP�� fR�~ fQ�n�@� fL � fS� fS�� fS�� gP�� gP�� gR�~ gQD�@� gL � gS� gS�� gS�� hP�� hP�� hR�~ hQ�@� hL � hS� hS�� hS�� iP�� iP�� iR]~ iQ���@� iL � iS� iS�� iS�� jP�� jP�� jR�~ jQ��@� jL � jS� jS�� jS�� kP�� kP�� kR�~ kQ��@� kL � kS� kS�� kS�� lP�� lP�� lR�~ lQ��@� lL � lS� lS�� lP�� mP�� mP�� mR�~ mQ�@� mL � mS� mS�� mP�� nP�� nP�� nR]~ nQ��@� nL � nS� nS�� nP�� oP�� oP�� oR�~ oQC�@� oL � oS� oS�� oP�� pP�� pP�� pR�~ pQ�n�@� pL � pS� pS�� pP�� qP�� qP�� qR�~ qQD�@� qL � qS� qS�� qP�� rP�� rP�� rR�~ rQ�@� rL � rS� rS�� rP�� sP�� sP�� sR]~ sQ���@� sL � sS� sS�� sP�� tP�� tP�� tR�~ tQ��@� tL � tS� tS�� tP�� uP�� uP�� uR�~ uQ��@� uL � uS� uS�� uP�� vP�� vP�� vR�~ vQ��@� vL � vS� vS�� vP�� wP�� wP�� wR�~ wQ�@� wL � wS� wS�� wP�� xP�� xP�� xR]~ xQ��@� xL � xS� xS�� xP�� yP�� yP�� yR�~ yQ��@� yL � yS� yS�� yP�� zP�� zP�� zR�~ zQ��@� zL � zS� zS�� zP�� {P�� {P�� {R�~ {QD�@� {L � {S� {S�� {P�� |P�� |P�� |R�~ |Q�@� |L � |S� |S�� |P�� }P�� }P�� }R]~ }Q���@� }L � }S� }S�� }P�� ~P�� ~P�� ~R�~ ~Q��@� ~L � ~S� ~S�� ~P�� P�� P�� R�~ Q��@� L � S� S�� P��D�l��ppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q@��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �\�� �P�� �Y]~ �Q�@� �L � �S� �S�� �S�� �\�� �P�� �Y�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q<�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �P�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �P�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q� �@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q@��@� �L � �S� �S�� �P�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �P�� �P� �P�� �R]~ �Q�@� �L � �S� �S�� �P�� �P� �P�� �R�~ �Q��@� �L � �S� �S�� �P��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P� �P�� �R�~ �Q��@� �L � �S� �S�� �P�� �P� �P� �R]~ �Q��@� �L � �S� �S�� �P� �P� �P� �R�~ �Q�@� �L � �S� �S�� �P� �P� �P� �R�~ �Q8�@� �L � �S� �S�� �P� �P� �P� �R�~ �Q��@� �L � �S� �S�� �P� �P � �P � �R]~ �QD�@� �L � �S� �S�� �P� �P � �P � �R�~ �Q�@� �L � �S� �S�� �P� �P � �P � �R�~ �Q�@� �L � �S� �S�� �P� �P � �P � �R�~ �QC�@� �L � �S� �S�� �P� �P� �P� �R]~ �Q��@� �L � �S� �S�� �P� �P� �P� �R�~ �Q�@� �L � �S� �S�� �P� �P� �P� �R�~ �Q8�@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P � �R]~ �QD�@� �L � �S� �S�� �S� �P� �P � �R�~ �Q�@� �L � �S� �S�� �S� �P� �P � �R�~ �Q�@� �L � �S� �S�� �S� �P� �P � �R�~ �QC�@� �L � �S� �S�� �S� �]� �]� �^f~ �Q��@� �L � �S� �S�� �]� �]� �]� �^~ �Q�@� �L � �S� �S�� �]� �]� �]� �^~ �Q��@� �L � �S� �S�� �]� �]� �]� �^�~ �QD�@� �L � �S� �S�� �]� �]� �]� �^ ~ �Q��@� �L � �S� �S�� �]� �P!� �P"� �R�~ �Q��@� �L � �S� �S�� �]#� �P$� �P"� �Rf~ �Q�@� �L � �S� �S�� �]#� �P%� �P"� �R]~ �Q�@� �L � �S� �S�� �]#� �P&� �P"� �R�~ �Q��@� �L � �S� �S�� �]#� �P'� �P"� �R�~ �Q�i�@� �L � �S� �S�� �]#� �P(� �P)� �R�~ �Q��@� �L � �S� �S�� �]*� �P+� �P)� �Rf~ �Q�@� �L � �S� �S�� �]*� �P,� �P)� �R]~ �Q�@� �L � �S� �S�� �]*� �P-� �P)� �R�~ �Q��@� �L � �S� �S�� �]*� �P.� �P)� �R�~ �Q�i�@� �L � �S� �S�� �]*�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P/� �P0� �R�~ �Q��@� �L � �S� �S�� �]1� �P2� �P0� �Rf~ �Q�@� �L � �S� �S�� �]1� �P3� �P0� �R]~ �Q�@� �L � �S� �S�� �]1� �P4� �P0� �R�~ �Q��@� �L � �S� �S�� �]1� �P5� �P0� �R�~ �Q�i�@� �L � �S� �S�� �]1� �P6� �P7� �R�~ �Q��@� �L � �S� �S�� �]8� �P9� �P7� �Rf~ �Q�@� �L � �S� �S�� �]8� �P:� �P7� �R]~ �Q�@� �L � �S� �S�� �]8� �P;� �P7� �R�~ �Q��@� �L � �S� �S�� �]8� �P<� �P7� �R�~ �Q�i�@� �L � �S� �S�� �]8� �P=� �P>� �R�~ �Q��@� �L � �S� �S�� �]?� �P@� �P>� �Rf~ �Q�@� �L � �S� �S�� �]?� �PA� �P>� �R]~ �Q��@� �L � �S� �S�� �]?� �PB� �P>� �R�~ �Q��@� �L � �S� �S�� �]?� �PC� �P>� �R�~ �Q�i�@� �L � �S� �S�� �]?� �PD� �P>� �R�~ �Q��@� �L � �S� �S�� �]E� �PF� �P>� �Rf~ �Q�@� �L � �S� �S�� �]E� �PG� �P>� �R]~ �Q�@� �L � �S� �S�� �]E� �PH� �P>� �R�~ �Q��@� �L � �S� �S�� �]E� �PI� �P>� �R�~ �Q�i�@� �L � �S� �S�� �]E� �PJ� �PK� �R�~ �Q��@� �L � �S� �S�� �]L� �PM� �PK� �R�~ �Q�@� �L � �S� �S�� �]L� �PN� �PK� �R]~ �Q�@� �L � �S� �S�� �]L� �PO� �PK� �R�~ �Q��@� �L � �S� �S�� �]L� �PP� �PK� �R�~ �Q��@� �L � �S� �S�� �]L� �PQ� �PK� �R�~ �Q��@� �L � �S� �S�� �]R� �PS� �PK� �R�~ �Q�@� �L � �S� �S�� �]R� �PT� �PK� �R]~ �Q�@� �L � �S� �S�� �]R� �PU� �PK� �R�~ �Q��@� �L � �S� �S�� �]R� �PV� �PK� �R�~ �Q��@� �L � �S� �S�� �]R� �PW� �PX� �R�~ �Q��@� �L � �S� �S�� �]Y� �PZ� �PX� �R�~ �Q�@� �L � �S� �S�� �]Y�D�lppppppppppppppppppppppppppppppp;@;@;@;@;@;@;@;@;@ ;@ ;@ ;@ ;@ ;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@� P[� PX� R�~ Q��@� L � S� S�� ]Y� P\� PX� R�~ Q��@� L � S� S�� ]Y� P]� P^� R�~ QD�@� L � S� S�� ]_� P`� P^� R�~ Q�@� L � S� S�� ]_� Pa� P^� R]~ Q��@� L � S� S�� ]_� Pb� P^� R�~ Q<�@� L � S� S�� ]_� Pc� P^� R�~ Q��@� L � S� S�� ]_� Pd� Pe� R�~ Q��@� L � S� S�� ]f� Pg� Pe� R�~ Q�@� L � S� S�� ]f� Ph� Pe� R]~ Q��@� L � S� S�� ]_� Pi� Pe� R�~ QC�@� L � S� S�� ]f� Pj� Pe� R�~ Q��@� L � S� S�� ]f� Pk� Pl� R�~ QD�@� L � S� S�� ]m� Pn� Pl� R�~ Q�@� L � S� S�� ]m� Po� Pl� R]~ Q6�@� L � S� S�� ]_� Pp� Pl� R�~ Q��@� L � S� S�� ]m� Pq� ]l� R�~ QC�@� L � S� S�� ]m� Pr� Ps� R�~ Q��@� L � S� S�� ]t� Pu� Ps� R�~ Q�@� L � S� S�� ]t� Pv� Ps� R]~ Q�@� L � S� S�� ]t� Pw� Ps� R�~ Q��@� L � S� S�� ]t� Px� Ps� R�~ Q��@� L � S� S�� ]t� ]y� ]s� ^�~ Q��@� L � S� S�� ]z� ]{� ]s� ^�~ Q�@� L � S� S�� _z� ]|� ]s� ^]~ Q�@� L � S� S�� _z� ]}� ]s� ^�~ Q��@� L � S� S�� _z� ]~� ]s� ^�~ Q��@� L � S� S�� _z� P� P�� R�~ QD�@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R]~ Q��@� L � S� S�� S�� P�� P�� R�~ Q<�@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S��D�lppppppppppppppppppppppppppppppp ;@!;@";@#;@$;@%;@&;@';@(;@);@*;@+;@,;@-;@.;@/;@0;@1;@2;@3;@4;@5;@6;@7;@8;@9;@:;@;;@<;@=;@>;@?;@� P�� P�� R�~ Q��@� L � S� S�� S�� !P�� !P�� !R�~ !Q�@� !L � !S� !S�� !S�� "P�� "P�� "R]"Q�$I�$�@� "L � "S� "S�� "S�� #P�� #P�� #R�~ #Q��@� #L � #S� #S�� #S�� $P�� $P�� $R�~ $Q�i�@� $L � $S� $S�� $S�� %P�� %P�� %R�~ %Q��@� %L � %S� %S�� %S�� &P�� &P�� &R�~ &Q�@� &L � &S� &S�� &S�� 'P�� 'P�� 'R]~ 'QB�@� 'L � 'S� 'S�� 'S�� (P�� (P�� (R�~ (Q��@� (L � (S� (S�� (S�� )P�� )P�� )R�~ )Q��@� )L � )S� )S�� )S�� *P�� *P�� *R�~ *QD�@� *L � *S� *S�� *S�� +P�� +P�� +R�~ +Q�@� +L � +S� +S�� +S�� ,P�� ,P�� ,R]~ ,Q��@� ,L � ,S� ,S�� ,S�� -P�� -P�� -R�~ -Q�%�@� -L � -S� -S�� -S�� .P�� .P�� .R�~ .Q��@� .L � .S� .S�� .S�� /P�� /P�� /R�~ /Q��@� /L � /S� /S�� /S�� 0P�� 0P�� 0R�~ 0Q�@� 0L � 0S� 0S�� 0S�� 1P�� 1P�� 1R]~ 1Q�@� 1L � 1S� 1S�� 1S�� 2P�� 2P�� 2R�~ 2Q��@� 2L � 2S� 2S�� 2S�� 3P�� 3P�� 3R�~ 3Q�i�@� 3L � 3S� 3S�� 3S�� 4P�� 4P�� 4R�~ 4QD�@� 4L � 4S� 4S�� 4S�� 5P�� 5P�� 5R�~ 5Q�@� 5L � 5S� 5S�� 5S�� 6P�� 6P�� 6R]~ 6Q��@� 6L � 6S� 6S�� 6S�� 7P�� 7P�� 7R�~ 7Q�/�@� 7L � 7S� 7S�� 7S�� 8P�� 8P�� 8R�~ 8Q@��@� 8L � 8S� 8S�� 8S�� 9P�� 9P�� 9R�~ 9Q��@� 9L � 9S� 9S�� 9S�� :P�� :P�� :R�~ :Q�@� :L � :S� :S�� :S�� ;P�� ;P�� ;R]~ ;Q�@� ;L � ;S� ;S�� ;S�� <P�� <P�� <R�~ <Q��@� <L � <S� <S�� <S�� =P�� =P�� =R�~ =Q�i�@� =L � =S� =S�� =S�� >P�� >P�� >R�~ >QD�@� >L � >S� >S�� >S�� ?P�� ?P�� ?R�~ ?Q�@� ?L � ?S� ?S�� ?S��D�lpptpppppppppppppppppppppppppppp@;@A;@B;@C;@D;@E;@F;@G;@H;@I;@J;@K;@L;@M;@N;@O;@P;@Q;@R;@S;@T;@U;@V;@W;@X;@Y;@Z;@[;@\;@];@^;@_;@� @P�� @P�� @R]~ @Q��@� @L � @S� @S�� @S�� AP�� AP�� AR�~ AQ� �@� AL � AS� AS�� AS�� BP�� BP�� BR�~ BQ@��@� BL � BS� BS�� BS�� CP�� CP�� CR�~ CQ��@� CL � CS� CS�� CS�� DP�� DP�� DR�~ DQ�@� DL � DS� DS�� DS�� EP�� EP�� ER]~ EQ�@� EL � ES� ES�� ES�� FP�� FP�� FR�~ FQ���@� FL � FS� FS�� FS�� GP�� GP�� GR�~ GQ��@� GL � GS� GS�� GS�� HP�� HP�� HR�~ HQ��@� HL � HS� HS�� HS�� IP�� IP�� IR�~ IQ�@� IL � IS� IS�� IS�� JP�� JP�� JR]~ JQ�@� JL � JS� JS�� JS�� KP�� KP�� KR�~ KQ���@� KL � KS� KS�� KS�� LP�� LP�� LR�~ LQ��@� LL � LS� LS�� LS�� MP�� MP�� MR�~ MQ��@� ML � MS� MS�� MW�� NP�� NP�� NR�~ NQ�@� NL � NS� NS�� NW�� OP�� OP�� OR]~ OQ�@� OL � OS� OS�� OW�� PP�� PP�� PR�~ PQ��@� PL � PS� PS�� PW�� QP�� QP�� QR�~ QQ�i�@� QL � QS� QS�� QW�� RP�� RP�� RR�~ RQD�@� RL � RS� RS�� RW�� SP�� SP�� SR�~ SQ�@� SL � SS� SS�� SW�� TP�� TP�� TR]~ TQ��@� TL � TS� TS�� TW�� UP�� UP�� UR�~ UQ�/�@� UL � US� US�� UW�� VP�� VP�� VR�~ VQ@��@� VL � VS� VS�� VW�� WP�� WP�� WR�~ WQ��@� WL � WS� WS�� WS�� XP�� XP�� XRf~ XQ�@� XL � XS� XS�� XS�� YP�� YP�� YR]~ YQ�@� YL � YS� YS�� YS�� ZP�� ZP�� ZR�~ ZQ��@� ZL � ZS� ZS�� ZS�� [P�� [P�� [R�~ [Q�i�@� [L � [S� [S�� [S�� \P�� \P�� \R�~ \Q��@� \L � \S� \S�� \S�� ]P�� ]P�� ]Rf~ ]Q�@� ]L � ]S� ]S�� ]S�� ^P�� ^P�� ^R]~ ^QC�@� ^L � ^S� ^S�� ^S�� _P�� _P�� _R�~ _Q���@� _L � _S� _S�� _S��D�lppppppppppppppppppppppppppppppp`;@a;@b;@c;@d;@e;@f;@g;@h;@i;@j;@k;@l;@m;@n;@o;@p;@q;@r;@s;@t;@u;@v;@w;@x;@y;@z;@{;@|;@};@~;@;@� `P�� `P�� `R�~ `Q��@� `L � `S� `S�� `S�� aP�� aP�� aR�~ aQ��@� aL � aS� aS�� aS�� bP�� bP�� bR�~ bQ�@� bL � bS� bS�� bS�� cP�� cP�� cR]~ cQ�@� cL � cS� cS�� cS�� dP�� dP�� dR�~ dQ���@� dL � dS� dS�� dS�� eP�� eP�� eR�~ eQ��@� eL � eS� eS�� eS�� fP�� fP�� fR�~ fQD�@� fL � fS� fS�� fS�� gP�� gP�� gR�~ gQ�@� gL � gS� gS�� gS�� hP�� hP�� hR]~ hQ��@� hL � hS� hS�� hS�� iP�� iP�� iR�~ iQ��@� iL � iS� iS�� iS�� jP�� jP�� jR�~ jQ�o�@� jL � jS� jS�� jS�� kP�� kP�� kR�~ kQ��@� kL � kS� kS�� kS�� lP�� lP�� lR�~ lQ�@� lL � lS� lS�� lS�� mP�� mP�� mR]~ mQ�@� mL � mS� mS�� mS�� nP�� nP�� nR�~ nQ���@� nL � nS� nS�� nS�� oP�� oP�� oR�~ oQ��@� oL � oS� oS�� oS�� p]�� p]�� p^�~ pQ��@� pL � pS� pS�� p_�� q]�� q]�� q^f~ qQ�@� qL � qS� qS�� q_�� r]�� r]�� r^]~ rQB�@� rL � rS� rS�� r_�� s]�� s]�� s^�~ sQ��@� sL � sS� sS�� s_�� t]�� t]�� t^�~ tQ��@� tL � tS� tS�� t_�� uP�� uP�� uR�~ uQ��@� uL � uS� uS�� u_�� vP�� vP�� vRf~ vQ�@� vL � vS� vS�� v_�� wP�� wP�� wR]~ wQB�@� wL � wS� wS�� w_�� xP�� xP�� xR�~ xQ��@� xL � xS� xS�� x_�� yP�� yP�� yR�~ yQ��@� yL � yS� yS�� y_�� zP�� zP�� zR�~ zQ��@� zL � zS� zS�� z_�� {P�� {P�� {Rf~ {Q�@� {L � {S� {S�� {_�� |P�� |P�� |R]|Q�$I�$�@� |L � |S� |S�� |_�� }P�� }P�� }R�~ }Q��@� }L � }S� }S�� }_�� ~P�� ~P�� ~R�~ ~Q�i�@� ~L � ~S� ~S�� ~_�� P�� P�� R�~ Q��@� L � S� S�� S�D�lpppppppppppppppppppppppppppptpp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P� �P�� �R�~ �Q�@� �L � �S� �S�� �S� �P� �P�� �R]~ �Q��&� �L � �S� �S�� �S� �P� �P�� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q�@� �L � �S� �S�� �S� �P � �P� �R]~ �Q�@� �L � �S� �S�� �S� �P � �P� �R�~ �Q��@� �L � �S� �S�� �S� �P � �P� �R�~ �Q��@� �L � �S� �S�� �S� �P � �P � �R�~ �Q��@� �L � �S� �S�� �S� �P� �P � �R�~ �Q�@� �L � �S� �S�� �S� �P� �P � �R]~ �Q�@� �L � �S� �S�� �S� �P� �P � �R�~ �Q��@� �L � �S� �S�� �S� �P� �P � �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q�@� �L � �S� �S�� �S� �P� �P� �R]~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q���@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �QD�@� �L � �S� �S�� �S� �P� �P� �R�~ �Q�@� �L � �S� �S�� �S� �P� �P� �R]~ �Q���@� �L � �S� �S�� �S� �P� �P� �R�~ �Q�i�@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P � �P� �R�~ �Q��@� �L � �S� �S�� �S!� �P"� �P� �R�~ �Q�@� �L � �S� �S�� �S!� �P#� �P� �R]~ �Q��@� �L � �S� �S�� �S!� �P$� �P� �R�~ �Q���@� �L � �S� �S�� �S!� �P%� �P� �R�~ �Q��@� �L � �S� �S�� �S!� �P&� �P'� �R�~ �Q��@� �L � �S� �S�� �S(� �P)� �P'� �R�~ �Q�@� �L � �S� �S�� �S*� �P+� �P'� �R]~ �Q�@� �L � �S� �S�� �S*�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P,� �P'� �R�~ �Q��@� �L � �S� �S�� �S*� �P-� �P'� �R�~ �Q��@� �L � �S� �S�� �S*� �P.� �P/� �R�~ �Q��@� �L � �S� �S�� �W0� �P1� �P/� �Rf~ �Q�@� �L � �S� �S�� �W0� �P2� �P/� �R]~ �Q9�@� �L � �S� �S�� �W0� �P3� �P/� �R�~ �Q���@� �L � �S� �S�� �W0� �P4� �P/� �R�~ �Q��@� �L � �S� �S�� �W0� �P5� �P6� �R�~ �QD�@� �L � �S� �S�� �W0� �P7� �P6� �Rf~ �Q�@� �L � �S� �S�� �W0� �P8� �P6� �R]~ �Q6�@� �L � �S� �S�� �W0� �P9� �P6� �R�~ �Q�i�@� �L � �S� �S�� �W0� �P:� �P6� �R�~ �Q@��@� �L � �S� �S�� �W0� �P;� �P<� �R�~ �Q��@� �L � �S� �S�� �S=� �P>� �P<� �Rf~ �Q�@� �L � �S� �S�� �S=� �P?� �P<� �R]~ �Q9�@� �L � �S� �S�� �S=� �P@� �P<� �R�~ �Q���@� �L � �S� �S�� �S=� �PA� �P<� �R�~ �Q��@� �L � �S� �S�� �S=� �PB� �PC� �R�~ �Q��@� �L � �S� �S�� �S=� �PD� �PC� �Rf~ �Q�@� �L � �S� �S�� �S=� �PE� �PC� �R]~ �Q9�@� �L � �S� �S�� �S=� �PF� �PC� �R�~ �Q���@� �L � �S� �S�� �S=� �PA� �PC� �R�~ �Q��@� �L � �S� �S�� �S=� �PG� �PH� �R�~ �Q��@� �L � �S� �S�� �PI� �PJ� �PH� �R�~ �Q�@� �L � �S� �S�� �PI� �PK� �PH� �R]~ �QB�@� �L � �S� �S�� �PI� �PL� �PH� �R�~ �Q��@� �L � �S� �S�� �PI� �PM� �PH� �R�~ �Q��@� �L � �S� �S�� �PI� �PN� �PO� �R�~ �QD�@� �L � �S� �S�� �PI� �PP� �PO� �R�~ �Q�@� �L � �S� �S�� �PI� �PQ� �PO� �R]~ �Q��@� �L � �S� �S�� �PI� �PR� �PO� �R�~ �Q�%�@� �L � �S� �S�� �PI� �PS� �PO� �R�~ �Q��@� �L � �S� �S�� �PI�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �PT� �PH� �R�~ �Q��@� �L � �S� �S�� �SU� �PV� �PH� �R�~ �Q�@� �L � �S� �S�� �SU� �PW� �PH� �R]~ �QB�@� �L � �S� �S�� �SU� �PX� �PH� �R�~ �Q��@� �L � �S� �S�� �SU� �PY� �PH� �R�~ �Q��@� �L � �S� �S�� �SU� �PZ� �PO� �R�~ �QD�@� �L � �S� �S�� �S[� �P\� �PO� �R�~ �Q�@� �L � �S� �S�� �S[� �P]� �PO� �R]~ �Q��@� �L � �S� �S�� �S[� �P^� �PO� �R�~ �Q�%�@� �L � �S� �S�� �S[� �P_� �PO� �R�~ �Q��@� �L � �S� �S�� �S[� �P`� �PH� �R�~ �Q��@� �L � �S� �S�� �Sa� �Pb� �PH� �R�~ �Q�@� �L � �S� �S�� �Sa� �Pc� �PH� �R]~ �QB�@� �L � �S� �S�� �Sa� �Pd� �PH� �R�~ �Q��@� �L � �S� �S�� �Sa� �Pe� �PH� �R�~ �Q��@� �L � �S� �S�� �Sa� �Pf� �PO� �R�~ �QD�@� �L � �S� �S�� �Sa� �Pg� �PO� �R�~ �Q�@� �L � �S� �S�� �Sa� �Ph� �PO� �R]~ �Q��@� �L � �S� �S�� �Sa� �Pi� �PO� �R�~ �Q�%�@� �L � �S� �S�� �Sa� �Pj� �PO� �R�~ �Q��@� �L � �S� �S�� �Sa� �Pk� �Pl� �R�~ �Q��@� �L � �S� �S�� �Sm� �Pn� �Pl� �Rf~ �Q�@� �L � �S� �S�� �Sm� �Po� �Pl� �R]~ �Q�@� �L � �S� �S�� �Sm� �Pp� �Pl� �R�~ �Q9�@� �L � �S� �S�� �Sm� �Pq� �Pl� �R�~ �Q>�@� �L � �S� �S�� �Sm� �Pr� �Ps� �R�~ �QD�@� �L � �S� �S�� �Sm� �Pt� �Ps� �Rf~ �Q�@� �L � �S� �S�� �Sm� �Pu� �Ps� �R]~ �Q��@� �L � �S� �S�� �Sm� �Pv� �Ps� �R�~ �Q���@� �L � �S� �S�� �Sm� �Pw� �Ps� �R�~ �Q��@� �L � �S� �S�� �Sm� �Px� �Pl� �R�~ �Q��@� �L � �S� �S�� �Sy� �Pz� �Pl� �Rf~ �Q�@� �L � �S� �S�� �Sy�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P{� �Pl� �R]~ �Q�@� �L � �S� �S�� �Sy� �P|� �Pl� �R�~ �Q9�@� �L � �S� �S�� �Sy� �P}� �Pl� �R�~ �Q>�@� �L � �S� �S�� �Sy� �P~� �Ps� �R�~ �QD�@� �L � �S� �S�� �Sy� �P� �Ps� �Rf~ �Q�@� �L � �S� �S�� �Sy� �P�� �Ps� �R]~ �Q��@� �L � �S� �S�� �Sy� �P�� �Ps� �R�~ �Q���@� �L � �S� �S�� �Sy� �P�� �Ps� �R�~ �Q��@� �L � �S� �S�� �Sy� �P�� �Pl� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �Pl� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �Pl� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �Pl� �R�~ �Q9�@� �L � �S� �S�� �S�� �P�� �Pl� �R�~ �Q>�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S��D�lppppppppppppppppppppppppppppppp;@;@;@;@;@;@;@;@;@ ;@ ;@ ;@ ;@ ;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@� P�� P�� R�~ Q�i�@� L � S� S�� S�� P�� P�� R]~ Q��@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� W�� P�� P�� R�~ Q�@� L � S� S�� W�� P�� P�� R]~ Q�@� L � S� S�� W�� P�� P�� R�~ Q��@� L � S� S�� W�� P�� P�� R�~ Q��@� L � S� S�� W�� P�� P�� R�~ QD�@� L � S� S�� W�� P�� P�� R�~ Q�@� L � S� S�� W�� P�� P�� R]~ Q��@� L � S� S�� W�� P�� P�� R�~ Q<�@� L � S� S�� W�� P�� P�� R�~ Q��@� L � S� S�� W�� P�� P�� Rf~ Q��@� L � S� S�� S�� P�� P�� R]~ Q�@� L � S� S�� S�� P�� P�� R~ Q��@� L � S� S�� S�� P�� P�� R�~ QD�@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� Rf~ Q��@� L � S� S�� S�� P�� P�� R]~ Q�@� L � S� S�� S�� P�� P�� R~ Q��@� L � S� S�� S�� P�� P�� R�~ QD�@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� Rf~ Q��@� L � S� S�� S�� P�� P�� R]~ Q�@� L � S� S�� S�� P�� P�� R~ Q�@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� Rf~ QD�@� L � S� S�� S��D�lppppppppppppppppppppppppppppppp ;@!;@";@#;@$;@%;@&;@';@(;@);@*;@+;@,;@-;@.;@/;@0;@1;@2;@3;@4;@5;@6;@7;@8;@9;@:;@;;@<;@=;@>;@?;@� P�� P�� R]~ Q�@� L � S� S�� S�� !P�� !P�� !R~ !Q<�@� !L � !S� !S�� !S�� "P�� "P�� "R�~ "Q��@� "L � "S� "S�� "S�� #P�� #P�� #R�~ #QC�@� #L � #S� #S�� #S�� $P�� $P�� $Rf~ $Q��@� $L � $S� $S�� $S�� %P�� %P�� %R]~ %Q�@� %L � %S� %S�� %S�� &P�� &P�� &R~ &Q�@� &L � &S� &S�� &S�� 'P�� 'P�� 'R�~ 'Q��@� 'L � 'S� 'S�� 'S�� (P�� (P�� (R�~ (Q��@� (L � (S� (S�� (S�� )P�� )P�� )Rf~ )Q��@� )L � )S� )S�� )S�� *P�� *P�� *R]~ *Q�@� *L � *S� *S�� *S�� +P�� +P�� +R~ +Q�@� +L � +S� +S�� +S�� ,P�� ,P�� ,R�~ ,Q��@� ,L � ,S� ,S�� ,S�� -P�� -P�� -R�~ -Q��@� -L � -S� -S�� -S�� .P�� .P�� .Rf~ .Q��@� .L � .S� .S�� .S�� /P�� /P�� /R]~ /Q�@� /L � /S� /S�� /S�� 0P�� 0P�� 0R�~ 0Q��@� 0L � 0S� 0S�� 0S�� 1P�� 1P�� 1R�~ 1QC�@� 1L � 1S� 1S�� 1S�� 2P�� 2P�� 2Rf~ 2QD�@� 2L � 2S� 2S�� 2S�� 3P�� 3P�� 3R]~ 3Q�@� 3L � 3S� 3S�� 3S�� 4P�� 4P�� 4R�~ 4QC�@� 4L � 4S� 4S�� 4S�� 5P�� 5P�� 5R�~ 5Q��@� 5L � 5S� 5S�� 5S�� 6P�� 6P�� 6R�~ 6Q��@� 6L � 6S� 6S�� 6S�� 7P�� 7P�� 7R�~ 7Q�@� 7L � 7S� 7S�� 7S�� 8P�� 8P�� 8R]~ 8Q�@� 8L � 8S� 8S�� 8S�� 9P�� 9P�� 9R�~ 9Q��@� 9L � 9S� 9S�� 9S�� :P�� :P�� :R�~ :Q��@� :L � :S� :S�� :S�� ;P�� ;P�� ;R�~ ;Q��@� ;L � ;S� ;S�� ;S�� <P�� <P�� <R�~ <Q�@� <L � <S� <S�� <S�� =P�� =P�� =R]~ =Q�@� =L � =S� =S�� =S�� >P�� >P�� >R�~ >Q��@� >L � >S� >S�� >S�� ?P�� ?P�� ?R�~ ?Q��@� ?L � ?S� ?S�� ?S��D�lppppppppppppppppppppppppppppppp@;@A;@B;@C;@D;@E;@F;@G;@H;@I;@J;@K;@L;@M;@N;@O;@P;@Q;@R;@S;@T;@U;@V;@W;@X;@Y;@Z;@[;@\;@];@^;@_;@� @P�� @P�� @R�~ @Q��@� @L � @S� @S�� @S�� AP�� AP�� AR�~ AQ�@� AL � AS� AS�� AS�� BP�� BP�� BR]~ BQ�@� BL � BS� BS�� BS�� CP�� CP�� CR�~ CQ��@� CL � CS� CS�� CS�� DP�� DP�� DR�~ DQC�@� DL � DS� DS�� DS�� EP�� EP�� ER�~ EQ��@� EL � ES� ES�� EW�� FP� FP�� FR�~ FQ�@� FL � FS� FS�� FW�� GP� GP�� GR]~ GQ�@� GL � GS� GS�� GW�� HP� HP�� HR�~ HQ��@� HL � HS� HS�� HW�� IP� IP�� IR�~ IQ���@� IL � IS� IS�� IW�� JP� JP� JR�~ JQD�@� JL � JS� JS�� JW�� KP� KP� KR�~ KQ�@� KL � KS� KS�� KW�� LP� LP� LR]~ LQ��@� LL � LS� LS�� LW�� MP� MP� MR�~ MQ�d�@� ML � MS� MS�� MW�� NP � NP� NR�~ NQ���@� NL � NS� NS�� NW�� OP � OP�� OR�~ OQ��@� OL � OS� OS�� OZ � PP � PP�� PR�~ PQ�@� PL � PS� PS�� PP � QP � QP�� QR]~ QQ�@� QL � QS� QS�� QP � RP� RP�� RR�~ RQ��@� RL � RS� RS�� RP � SP� SP�� SR�~ SQ���@� SL � SS� SS�� SP � TP� TP� TR�~ TQD�@� TL � TS� TS�� TP � UP� UP� UR�~ UQ�@� UL � US� US�� UP � VP� VP� VR]~ VQ��@� VL � VS� VS�� VP � WP� WP� WR�~ WQ�d�@� WL � WS� WS�� WP � XP� XP� XR�~ XQ���@� XL � XS� XS�� XP � YP� YP� YR�~ YQ��@� YL � YS� YS�� YS� ZP� ZP� ZR�~ ZQ�@� ZL � ZS� ZS�� ZS� [P� [P� [R]~ [QB�@� [L � [S� [S�� [S� \P� \P� \R�~ \Q��@� \L � \S� \S�� \S� ]P� ]P� ]R�~ ]Q��@� ]L � ]S� ]S�� ]S� ^P� ^P� ^R�~ ^Q��@� ^L � ^S� ^S�� ^S� _P� _P� _R�~ _Q�@� _L � _S� _S�� _S�D�lppppppppppppppppppppppppppppppp`;@a;@b;@c;@d;@e;@f;@g;@h;@i;@j;@k;@l;@m;@n;@o;@p;@q;@r;@s;@t;@u;@v;@w;@x;@y;@z;@{;@|;@};@~;@;@� `P � `P� `R]~ `Q�@� `L � `S� `S�� `S� aP!� aP� aR�~ aQ���@� aL � aS� aS�� aS� bP"� bP� bR�~ bQ��@� bL � bS� bS�� bS� cP#� cP$� cR�~ cQD�@� cL � cS� cS�� cS� dP%� dP$� dR�~ dQ�@� dL � dS� dS�� dS� eP&� eP$� eR]~ eQ��@� eL � eS� eS�� eS� fP'� fP$� fR�~ fQ��@� fL � fS� fS�� fS� gP(� gP$� gR�~ gQ�o�@� gL � gS� gS�� gS� hP)� hP� hR�~ hQ��@� hL � hS� hS�� hS*� iP+� iP� iR�~ iQ�@� iL � iS� iS�� iS*� jP,� jP� jR]~ jQB�@� jL � jS� jS�� jS*� kP-� kP� kR�~ kQ��@� kL � kS� kS�� kS*� lP.� lP� lR�~ lQ��@� lL � lS� lS�� lS*� mP/� mP� mR�~ mQ��@� mL � mS� mS�� mS0� nP1� nP� nR�~ nQ�@� nL � nS� nS�� nS0� oP2� oP� oR]~ oQB�@� oL � oS� oS�� oS0� pP3� pP� pR�~ pQ��@� pL � pS� pS�� pS0� qP4� qP� qR�~ qQ��@� qL � qS� qS�� qS0� rP5� rP6� rR�~ rQ��@� rL � rS� rS�� rS7� sP8� sP6� sR�~ sQ�@� sL � sS� sS�� sS7� tP9� tP6� tR]~ tQ�@� tL � tS� tS�� tS7� uP:� uP6� uR�~ uQ�@� uL � uS� uS�� uS7� vP;� vP6� vR�~ vQ��@� vL � vS� vS�� vS7� wP<� wP=� wR�~ wQD�@� wL � wS� wS�� wS7� xP>� xP=� xR�~ xQ�@� xL � xS� xS�� xS7� yP?� yP=� yR]~ yQ��@� yL � yS� yS�� yS7� zP@� zP=� zR�~ zQ:�@� zL � zS� zS�� zS7� {PA� {P=� {R�~ {Q���@� {L � {S� {S�� {S7� |PB� |P6� |R�~ |Q��@� |L � |S� |S�� |SC� }PD� }P6� }Rf~ }Q�@� }L � }S� }S�� }SC� ~PE� ~P6� ~R]~ ~Q�@� ~L � ~S� ~S�� ~SC� PF� P6� R�~ Q��@� L � S� S�� SC�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �PG� �P6� �R�~ �Q���@� �L � �S� �S�� �SC� �PH� �P6� �R�~ �Q��@� �L � �S� �S�� �SI� �PJ� �P6� �Rf~ �Q�@� �L � �S� �S�� �SI� �PK� �P6� �R]~ �Q�@� �L � �S� �S�� �SI� �PL� �P6� �R�~ �Q9�@� �L � �S� �S�� �SI� �PM� �P6� �R�~ �Q�i�@� �L � �S� �S�� �SI� �PN� �P=� �R�~ �QD�@� �L � �S� �S�� �SI� �PO� �P=� �Rf~ �Q�@� �L � �S� �S�� �SI� �PP� �P=� �R]~ �Q��@� �L � �S� �S�� �SI� �PQ� �P=� �R�~ �Q� �@� �L � �S� �S�� �SI� �PR� �P=� �R�~ �Q@��@� �L � �S� �S�� �SI� �PS� �PT� �R�~ �Q��@� �L � �S� �S�� �PU� �PV� �PT� �R�~ �Q�@� �L � �S� �S�� �PU� �PW� �PT� �R]~ �Q�@� �L � �S� �S�� �PU� �PX� �PT� �R�~ �Q��@� �L � �S� �S�� �PU� �PY� �PT� �R�~ �Q�i�@� �L � �S� �S�� �PU� �PZ� �P[� �R�~ �QD�@� �L � �S� �S�� �S\� �P]� �P[� �R�~ �Q�@� �L � �S� �S�� �S\� �P^� �P[� �R]~ �Q��@� �L � �S� �S�� �S\� �P_� �P[� �R�~ �Q� �@� �L � �S� �S�� �PU� �P`� �P[� �R�~ �Q@��@� �L � �S� �S�� �S\� �Pa� �PT� �R�~ �Q��@� �L � �S� �S�� �Sb� �Pc� �PT� �R�~ �Q�@� �L � �S� �S�� �Sb� �Pd� �PT� �R]~ �Q��@� �L � �S� �S�� �Sb� �Pe� �PT� �R�~ �Q��@� �L � �S� �S�� �Sb� �Pf� �PT� �R�~ �Q�i�@� �L � �S� �S�� �Sb� �Pg� �P[� �R�~ �QD�@� �L � �S� �S�� �Sh� �Pi� �P[� �R�~ �Q�@� �L � �S� �S�� �Sh� �Pj� �P[� �R]~ �Q���@� �L � �S� �S�� �Sh� �Pk� �P[� �R�~ �Q�/�@� �L � �S� �S�� �Sh� �Pl� �P[� �R�~ �QC�@� �L � �S� �S�� �Sh� �Pm� �Pn� �R�~ �Q��@� �L � �S� �S�� �So�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �Pp� �Pn� �Rf~ �Q�@� �L � �S� �S�� �So� �Pq� �Pn� �R]~ �Q�@� �L � �S� �S�� �So� �Pr� �Pn� �R�~ �Q��@� �L � �S� �S�� �So� �Ps� �Pn� �R�~ �Q��@� �L � �S� �S�� �So� �Pt� �Pu� �R�~ �QD�@� �L � �S� �S�� �Sv� �Pw� �Pu� �Rf~ �Q�@� �L � �S� �S�� �Sv� �Px� �Pu� �R]~ �Q��@� �L � �S� �S�� �Sv� �Py� �Pu� �R�~ �Q���@� �L � �S� �S�� �So� �Pz� �Pu� �R�~ �Q�o�@� �L � �S� �S�� �Sv� �P{� �Pn� �R�~ �Q��@� �L � �S� �S�� �S|� �P}� �Pn� �Rf~ �Q�@� �L � �S� �S�� �S|� �P~� �Pn� �R]~ �Q�@� �L � �S� �S�� �S|� �P� �Pn� �R�~ �Q��@� �L � �S� �S�� �S|� �P�� �Pn� �R�~ �Q��@� �L � �S� �S�� �S|� �P�� �Pu� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �Pu� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �Pu� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �Pu� �R�~ �Q���@� �L � �S� �S�� �S�� �P�� �Pu� �R�~ �Q� �@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q���@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QC�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �W�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �W�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �W�� �P�� �P�� �R�~ �Q� �@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q@��@� �L � �S� �S�� �W�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�/�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q@��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�%�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q� �@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q@��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S��D�lppppppppppppppppppppppppppppppp;@;@;@;@;@;@;@;@;@ ;@ ;@ ;@ ;@ ;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@� P�� P�� R]~ QB�@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R]~ QB�@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ QD�@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R]~ Q��@� L � S� S�� S�� P�� P�� R�~ Q�%�@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R]~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P� P�� R�~ QD�@� L � S� S�� S�� P� P�� R�~ Q�@� L � S� S�� S�� P� P�� R]~ Q<�@� L � S� S�� S�� P� P�� R�~ Q�%�@� L � S� S�� S�� P� P�� R�~ Q��@� L � S� S�� S�� P� P� R�~ Q��@� L � S� S�� S� P� P� R�~ Q�@� L � S� S�� S� P � P� R]~ QB�@� L � S� S�� S� P � P� R�~ Q��@� L � S� S�� S� P � P� R�~ Q��@� L � S� S�� S� P � P� R�~ Q��@� L � S� S�� S � P� P� R�~ Q�@� L � S� S�� S � P� P� R]~ QB�@� L � S� S�� S � P� P� R�~ Q��@� L � S� S�� S �D�lppppppppppppppppppppppppppppppp ;@!;@";@#;@$;@%;@&;@';@(;@);@*;@+;@,;@-;@.;@/;@0;@1;@2;@3;@4;@5;@6;@7;@8;@9;@:;@;;@<;@=;@>;@?;@� P� P� R�~ Q��@� L � S� S�� S � !P� !P� !R�~ !QD�@� !L � !S� !S�� !S� "P� "P� "R�~ "Q�@� "L � "S� "S�� "S� #P� #P� #R]~ #Q��@� #L � #S� #S�� #S� $P� $P� $R�~ $Q�%�@� $L � $S� $S�� $S� %P� %P� %R�~ %Q��@� %L � %S� %S�� %S� &P� &P� &R�~ &Q��@� &L � &S� &S�� &S� 'P� 'P� 'R�~ 'Q�@� 'L � 'S� 'S�� 'S� (P� (P� (R]~ (Q@U�@� (L � (S� (S�� (S� )P� )P� )R�~ )Q���@� )L � )S� )S�� )S� *P� *P� *R�~ *Q@��@� *L � *S� *S�� *S� +P � +P!� +R�~ +Q��@� +L � +S� +S�� +S"� ,P#� ,P!� ,R�~ ,Q�@� ,L � ,S� ,S�� ,S"� -P$� -P!� -R]~ -QB�@� -L � -S� -S�� -S"� .P%� .P!� .R�~ .Q��@� .L � .S� .S�� .S"� /P&� /P!� /R�~ /Q��@� /L � /S� /S�� /S"� 0P'� 0P!� 0R�~ 0Q��@� 0L � 0S� 0S�� 0S(� 1P)� 1P!� 1R�~ 1Q�@� 1L � 1S� 1S�� 1S(� 2P*� 2P!� 2R]~ 2QB�@� 2L � 2S� 2S�� 2S(� 3P+� 3P!� 3R�~ 3Q��@� 3L � 3S� 3S�� 3S(� 4P,� 4P!� 4R�~ 4Q��@� 4L � 4S� 4S�� 4S(� 5P-� 5P.� 5R�~ 5Q��@� 5L � 5S� 5S�� 5S/� 6P0� 6P.� 6R�~ 6Q�@� 6L � 6S� 6S�� 6S/� 7P1� 7P.� 7R]~ 7Q�@� 7L � 7S� 7S�� 7S/� 8P2� 8P.� 8R�~ 8Q���@� 8L � 8S� 8S�� 8S/� 9P3� 9P.� 9R�~ 9Q��@� 9L � 9S� 9S�� 9S/� :P4� :P.� :R�~ :Q��@� :L � :S� :S�� :S5� ;P6� ;P.� ;R�~ ;Q�@� ;L � ;S� ;S�� ;S5� <P7� <P.� <R]~ <Q�@� <L � <S� <S�� <S5� =P8� =P.� =R�~ =Q���@� =L � =S� =S�� =S5� >P9� >P.� >R�~ >Q��@� >L � >S� >S�� >S5� ?P:� ?P;� ?R�~ ?QD�@� ?L � ?S� ?S�� ?S5�D�lppppppppppppppppppppppppppppppp@;@A;@B;@C;@D;@E;@F;@G;@H;@I;@J;@K;@L;@M;@N;@O;@P;@Q;@R;@S;@T;@U;@V;@W;@X;@Y;@Z;@[;@\;@];@^;@_;@� @P<� @P;� @R�~ @Q�@� @L � @S� @S�� @S5� AP=� AP;� AR]~ AQ��@� AL � AS� AS�� AS5� BP>� BP;� BR�~ BQ��@� BL � BS� BS�� BS5� CP?� CP;� CR�~ CQ�o�@� CL � CS� CS�� CS5� DP@� DPA� DR�~ DQ��@� DL � DS� DS�� DSB� EPC� EPA� ER�~ EQ�@� EL � ES� ES�� ESB� FPD� FPA� FR]~ FQB�@� FL � FS� FS�� FSB� GPE� GPA� GR�~ GQ��@� GL � GS� GS�� GSB� HPF� HPA� HR�~ HQ��@� HL � HS� HS�� HSB� IPG� IPA� IR�~ IQ��@� IL � IS� IS�� ISH� JPI� JPA� JR�~ JQ�@� JL � JS� JS�� JSH� KPJ� KPA� KR]~ KQC�@� KL � KS� KS�� KSH� LPK� LPA� LR�~ LQ���@� LL � LS� LS�� LSH� MPL� MPA� MR�~ MQ��@� ML � MS� MS�� MSH� NPM� NPN� NR�~ NQ��@� NL � NS� NS�� NSO� OPP� OPN� OR�~ OQ�@� OL � OS� OS�� OSO� PPQ� PPN� PR]~ PQ�@� PL � PS� PS�� PSO� QPR� QPN� QR�~ QQ��@� QL � QS� QS�� QSO� RPS� RPN� RR�~ RQ�i�@� RL � RS� RS�� RSO� SPT� SPN� SR�~ SQ��@� SL � SS� SS�� SSU� TPV� TPN� TR�~ TQ�@� TL � TS� TS�� TSU� UPW� UPN� UR]~ UQ�@� UL � US� US�� USU� VPX� VPN� VR�~ VQ��@� VL � VS� VS�� VSU� WPY� WPN� WR�~ WQ�i�@� WL � WS� WS�� WSU� XPZ� XPN� XR�~ XQ��@� XL � XS� XS�� XS[� YP\� YPN� YR�~ YQ�@� YL � YS� YS�� YS[� ZP]� ZPN� ZR]~ ZQC�@� ZL � ZS� ZS�� ZS[� [P^� [PN� [R�~ [Q@��@� [L � [S� [S�� [S[� \P_� \PN� \R�~ \Q��@� \L � \S� \S�� \S[� ]P`� ]Pa� ]R�~ ]Q��@� ]L � ]S� ]S�� ]Sb� ^Pc� ^Pa� ^R�~ ^Q�@� ^L � ^S� ^S�� ^Sb� _Pd� _Pa� _R]~ _QB�@� _L � _S� _S�� _Sb�D�lppppppppppppppppppppppppppppppp`;@a;@b;@c;@d;@e;@f;@g;@h;@i;@j;@k;@l;@m;@n;@o;@p;@q;@r;@s;@t;@u;@v;@w;@x;@y;@z;@{;@|;@};@~;@;@� `Pe� `Pa� `R�~ `Q��@� `L � `S� `S�� `Sb� aPf� aPa� aR�~ aQ��@� aL � aS� aS�� aSb� bPg� bPa� bR�~ bQ��@� bL � bS� bS�� bSh� cPi� cPa� cR�~ cQ�@� cL � cS� cS�� cSh� dPj� dPa� dR]~ dQB�@� dL � dS� dS�� dSh� ePk� ePa� eR�~ eQ��@� eL � eS� eS�� eSh� fPl� fPa� fR�~ fQ��@� fL � fS� fS�� fSh� gPm� gPa� gR�~ gQ��@� gL � gS� gS�� gSn� hPo� hPa� hR�~ hQ�@� hL � hS� hS�� hSn� iPp� iPa� iR]~ iQB�@� iL � iS� iS�� iSn� jPq� jPa� jR�~ jQ��@� jL � jS� jS�� jSn� kPr� kPa� kR�~ kQ��@� kL � kS� kS�� kSn� lPs� lPt� lR�~ lQ��@� lL � lS� lS�� lSu� mPv� mPt� mR�~ mQ�@� mL � mS� mS�� mSu� nPw� nPt� nR]~ nQ�@� nL � nS� nS�� nSu� oPx� oPt� oR�~ oQ��@� oL � oS� oS�� oSu� pPy� pPt� pR�~ pQ�i�@� pL � pS� pS�� pSu� qPz� qPt� qR�~ qQ��@� qL � qS� qS�� qS{� rP|� rPt� rR�~ rQ�@� rL � rS� rS�� rS{� sP}� sPt� sR]~ sQ�@� sL � sS� sS�� sS{� tP~� tPt� tR�~ tQ��@� tL � tS� tS�� tS{� uP� uPt� uR�~ uQ�i�@� uL � uS� uS�� uS{� vP�� vP�� vR�~ vQD�@� vL � vS� vS�� vS{� wP�� wP�� wR�~ wQ�@� wL � wS� wS�� wS{� xP�� xP�� xR]~ xQ��@� xL � xS� xS�� xS{� yP�� yP�� yR�~ yQ��@� yL � yS� yS�� yS{� zP�� zP�� zR�~ zQ@��@� zL � zS� zS�� zS{� {P�� {Pt� {R�~ {Q��@� {L � {S� {S�� {S�� |P�� |Pt� |R�~ |Q�@� |L � |S� |S�� |S�� }P�� }Pt� }R]~ }Q�@� }L � }S� }S�� }S�� ~P�� ~Pt� ~R�~ ~Q���@� ~L � ~S� ~S�� ~S�� P�� Pt� R�~ Q��@� L � S� S�� S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q@��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�%�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�%�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�%�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�%�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�%�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �QB�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q�@� �L � �S� �S�� �S� �P� �P� �R]~ �QB�@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �QD�@� �L � �S� �S�� �S�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P � �P� �R�~ �Q�@� �L � �S� �S�� �S� �P � �P� �R]~ �Q��@� �L � �S� �S�� �S� �P � �P� �R�~ �Q�%�@� �L � �S� �S�� �S� �P � �P� �R�~ �Q��@� �L � �S� �S�� �S� �P � �P� �R�~ �Q��@� �L � �S� �S�� �P� �P� �P� �Rf~ �Q�@� �L � �S� �S�� �P� �P� �P� �R]~ �Q�@� �L � �S� �S�� �P� �P� �P� �R�~ �Q��@� �L � �S� �S�� �P� �P� �P� �R�~ �Q�i�@� �L � �S� �S�� �P� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q�@� �L � �S� �S�� �S� �P� �P� �R]~ �QB�@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q�@� �L � �S� �S�� �S� �P� �P� �R]~ �QB�@� �L � �S� �S�� �S� �P � �P� �R�~ �Q��@� �L � �S� �S�� �S� �P!� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P"� �P#� �R�~ �Q��@� �L � �S� �S�� �S$� �P%� �P#� �R�~ �Q�@� �L � �S� �S�� �S$� �P&� �P#� �R]~ �QB�@� �L � �S� �S�� �S$� �P'� �P#� �R�~ �Q��@� �L � �S� �S�� �S$� �P(� �P#� �R�~ �Q��@� �L � �S� �S�� �S$� �P)� �P#� �R�~ �Q��@� �L � �S� �S�� �S*� �P+� �P#� �R�~ �Q�@� �L � �S� �S�� �S*� �P,� �P#� �R]~ �QB�@� �L � �S� �S�� �S*� �P-� �P#� �R�~ �Q��@� �L � �S� �S�� �S*� �P.� �P#� �R�~ �Q��@� �L � �S� �S�� �S*� �P/� �P0� �R�~ �QD�@� �L � �S� �S�� �S1� �P2� �P0� �R�~ �Q�@� �L � �S� �S�� �S1� �P3� �P0� �R]~ �Q��@� �L � �S� �S�� �S1�D�lppppppppppppppppppppppppppppppp;@;@;@;@;@;@;@;@;@ ;@ ;@ ;@ ;@ ;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@� P4� P0� R�~ Q�%�@� L � S� S�� S1� P5� P0� R�~ Q��@� L � S� S�� S1� P6� P7� R�~ Q��@� L � S� S�� S1� P8� P7� R�~ Q�@� L � S� S�� S9� P:� P7� R]~ Q��@� L � S� S�� S9� P;� P<� R�~ Q��@� L � S� S�� S=� P>� P<� R�~ Q�@� L � S� S�� S=� P?� P<� R]~ Q�@� L � S� S�� S=� P@� P<� R�~ Q��@� L � S� S�� S=� PA� P<� R�~ Q�i�@� L � S� S�� S=� PB� P<� R�~ Q��@� L � S� S�� SC� PD� P<� R�~ Q�@� L � S� S�� SC� PE� P<� R]~ Q�@� L � S� S�� SC� PF� P<� R�~ Q��@� L � S� S�� SC� PG� P<� R�~ Q�i�@� L � S� S�� SC� PH� P<� R�~ Q��@� L � S� S�� SI� PJ� P<� R�~ Q�@� L � S� S�� SI� PK� P<� R]~ Q�@� L � S� S�� SI� PL� P<� R�~ Q��@� L � S� S�� SI� PM� P<� R�~ Q�i�@� L � S� S�� SI� PN� PO� R�~ Q��@� L � S� S�� SP� PQ� PO� Rf~ Q�@� L � S� S�� SP� PR� PO� R]~ Q�@� L � S� S�� SP� PS� PO� R�~ Q��@� L � S� S�� SP� PT� PO� R�~ Q�i�@� L � S� S�� SP� PU� PV� RW~ Q��@� L � S� S�� SX� PY� PV� R�~ Q�@� L � S� S�� SX� PZ� PV� R�~ Q8�@� L � S� S�� SX� P[� PV� R�~ Q;�@� L � S� S�� SX� P\� PV� RW~ Q��@� L � S� S�� S]� P^� PV� R�~ Q�@� L � S� S�� S]� P_� PV� R�~ Q�@� L � S� S�� S]�D�lppppppppppppppppppppppppppppppp ;@!;@";@#;@$;@%;@&;@';@(;@);@*;@+;@,;@-;@.;@/;@0;@1;@2;@3;@4;@5;@6;@7;@8;@9;@:;@;;@<;@=;@>;@?;@� P`� PV� R�~ Q��@� L � S� S�� S]� !Pa� !PV� !RW~ !Q��@� !L � !S� !S�� !Sb� "Pc� "PV� "R�~ "Q�@� "L � "S� "S�� "Sb� #Pd� #PV� #R�~ #Q9�@� #L � #S� #S�� #Sb� $Pe� $PV� $R�~ $Q�f�@� $L � $S� $S�� $Sb� %Pf� %Pg� %R�~ %Q�@� %L � %S� %S�� %Sh� &Pi� &Pg� &Rf~ &Q��@� &L � &S� &S�� &Sh� 'Pj� 'Pg� 'R]~ 'QC�@� 'L � 'S� 'S�� 'Sh� (Pk� (Pg� (R�~ (Q��@� (L � (S� (S�� (Sh� )Pl� )Pg� )R�~ )Q��@� )L � )S� )S�� )Sh� *Pm� *Pn� *R�~ *QD�@� *L � *S� *S�� *So� +Pp� +Pn� +R�~ +Q�@� +L � +S� +S�� +So� ,Pq� ,Pn� ,R]~ ,Q��@� ,L � ,S� ,S�� ,So� -Pr� -Pn� -R�~ -Q�d�@� -L � -S� -S�� -So� .Ps� .Pn� .R�~ .Q���@� .L � .S� .S�� .So� /Pt� /Pg� /R�~ /Q�@� /L � /S� /S�� /Su� 0Pv� 0Pg� 0Rf~ 0Q��@� 0L � 0S� 0S�� 0Su� 1Pw� 1Pg� 1R]~ 1QC�@� 1L � 1S� 1S�� 1Su� 2Px� 2Pg� 2R�~ 2Q��@� 2L � 2S� 2S�� 2Su� 3Py� 3Pg� 3R�~ 3Q��@� 3L � 3S� 3S�� 3Su� 4Pz� 4Pn� 4R�~ 4QD�@� 4L � 4S� 4S�� 4Su� 5P{� 5Pn� 5Rf~ 5Q�@� 5L � 5S� 5S�� 5Su� 6P|� 6Pn� 6R]~ 6Q9�@� 6L � 6S� 6S�� 6Su� 7P}� 7Pn� 7R�~ 7Q�d�@� 7L � 7S� 7S�� 7Su� 8P~� 8Pn� 8R�~ 8Q���@� 8L � 8S� 8S�� 8Su� 9P� 9P�� 9R�~ 9Q��@� 9L � 9S� 9S�� 9P�� :P�� :P�� :Rf~ :Q�@� :L � :S� :S�� :P�� ;P�� ;P�� ;R]~ ;Q�@� ;L � ;S� ;S�� ;P�� <P�� <P�� <R�~ <Q��@� <L � <S� <S�� <P�� =P�� =P�� =R�~ =Q�i�@� =L � =S� =S�� =P�� >P�� >P�� >R�~ >Q��@� >L � >S� >S�� >P�� ?P�� ?P�� ?R�~ ?Q�@� ?L � ?S� ?S�� ?P��D�lppppppppppppppppppppppppppppppp@;@A;@B;@C;@D;@E;@F;@G;@H;@I;@J;@K;@L;@M;@N;@O;@P;@Q;@R;@S;@T;@U;@V;@W;@X;@Y;@Z;@[;@\;@];@^;@_;@� @P�� @P�� @R]~ @Q�@� @L � @S� @S�� @P�� AP�� AP�� AR�~ AQ��@� AL � AS� AS�� AP�� BP�� BP�� BR�~ BQ�i�@� BL � BS� BS�� BP�� CP�� CP�� CR�~ CQ��@� CL � CS� CS�� CP�� DP�� DP�� DR�~ DQ�@� DL � DS� DS�� DP�� EP�� EP�� ER]~ EQ�@� EL � ES� ES�� EP�� FP�� FP�� FR�~ FQ��@� FL � FS� FS�� FP�� GP�� GP�� GR�~ GQ�i�@� GL � GS� GS�� GP�� HP�� HP�� HR�~ HQ��@� HL � HS� HS�� HS�� IP�� IP�� IR�~ IQ�@� IL � IS� IS�� IS�� JP�� JP�� JR]~ JQ�@� JL � JS� JS�� JS�� KP�� KP�� KR�~ KQ��@� KL � KS� KS�� KS�� LP�� LP�� LR�~ LQ�i�@� LL � LS� LS�� LS�� MP�� MP�� MR�~ MQ��@� ML � MS� MS�� MS�� NP�� NP�� NRf~ NQ�@� NL � NS� NS�� NS�� OP�� OP�� OR]~ OQ�@� OL � OS� OS�� OS�� PP�� PP�� PR�~ PQ��@� PL � PS� PS�� PS�� QP�� QP�� QR�~ QQ�i�@� QL � QS� QS�� QS�� RP�� RP�� RR�~ RQ��@� RL � RS� RS�� RS�� SP�� SP�� SR�~ SQ�@� SL � SS� SS�� SS�� TP�� TP�� TR]~ TQ�@� TL � TS� TS�� TS�� UP�� UP�� UR�~ UQ��@� UL � US� US�� US�� VP�� VP�� VR�~ VQ�i�@� VL � VS� VS�� VS�� WP�� WP�� WR�~ WQ��@� WL � WS� WS�� WS�� XP�� XP�� XR�~ XQ�@� XL � XS� XS�� XS�� YP�� YP�� YR]~ YQ�@� YL � YS� YS�� YS�� ZP�� ZP�� ZR�~ ZQ��@� ZL � ZS� ZS�� ZS�� [P�� [P�� [R�~ [Q�i�@� [L � [S� [S�� [S�� \]�� \]�� \^�~ \Q��@� \L � \S� \S�� \_�� ]]�� ]]�� ]^�~ ]Q�@� ]L � ]S� ]S�� ]_�� ^]�� ^]�� ^^]~ ^Q�@� ^L � ^S� ^S�� ^_�� _]�� _]�� _^�~ _Q��@� _L � _S� _S�� __��D�lppppppppppppppppppppppppppppppp`;@a;@b;@c;@d;@e;@f;@g;@h;@i;@j;@k;@l;@m;@n;@o;@p;@q;@r;@s;@t;@u;@v;@w;@x;@y;@z;@{;@|;@};@~;@;@� `]�� `]�� `^�~ `Q�i�@� `L � `S� `S�� `_�� aP�� aP�� aR�~ aQ��@� aL � aS� aS�� aS�� bP�� bP�� bRf~ bQ�@� bL � bS� bS�� bS�� cP�� cP�� cR]~ cQ�@� cL � cS� cS�� cS�� dP�� dP�� dR�~ dQ��@� dL � dS� dS�� dS�� eP�� eP�� eR�~ eQ�i�@� eL � eS� eS�� eS�� fP�� fP�� fR�~ fQ��@� fL � fS� fS�� fS�� gP�� gP�� gR�~ gQ�@� gL � gS� gS�� gS�� hP�� hP�� hR]~ hQ��@� hL � hS� hS�� hS�� iP�� iP�� iR�~ iQ���@� iL � iS� iS�� iS�� jP�� jP�� jR�~ jQ��@� jL � jS� jS�� jS�� kP�� kP�� kR�~ kQD�@� kL � kS� kS�� kS�� lP�� lP�� lR�~ lQ�@� lL � lS� lS�� lS�� mP�� mP�� mR]~ mQ���@� mL � mS� mS�� mS�� nP�� nP�� nR�~ nQ��@� nL � nS� nS�� nS�� oP�� oP�� oR�~ oQ��@� oL � oS� oS�� oS�� pP�� pP�� pR�~ pQ��@� pL � pS� pS�� pS�� qP�� qP�� qR�~ qQ�@� qL � qS� qS�� qS�� rP�� rP�� rR]~ rQ��@� rL � rS� rS�� rS�� sP�� sP�� sR�~ sQ���@� sL � sS� sS�� sS�� tP�� tP�� tR�~ tQ��@� tL � tS� tS�� tS�� uP�� uP�� uR�~ uQD�@� uL � uS� uS�� uS�� vP�� vP�� vR�~ vQ�@� vL � vS� vS�� vS�� wP�� wP�� wR]~ wQ���@� wL � wS� wS�� wS�� xP�� xP�� xR�~ xQ��@� xL � xS� xS�� xS�� yP�� yP�� yR�~ yQ��@� yL � yS� yS�� yS�� zP�� zP�� zR�~ zQ��@� zL � zS� zS�� zS�� {P�� {P�� {R�~ {Q�@� {L � {S� {S�� {S�� |P�� |P�� |R]~ |QB�@� |L � |S� |S�� |S�� }P�� }P�� }R�~ }Q��@� }L � }S� }S�� }S�� ~P�� ~P�� ~R�~ ~Q��@� ~L � ~S� ~S�� ~S�� P�� P�� R�~ QD�@� L � S� S�� S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�%�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �QD�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q� �@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q@��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �Rf~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R]~ �Q�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P�� �P�� �R�~ �Q�@� �L � �S� �S�� �S�� �P� �P�� �R]~ �Q�@� �L � �S� �S�� �S��D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P� �P�� �R�~ �Q��@� �L � �S� �S�� �S�� �P� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S�� �P� �P�� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P�� �Rf~ �Q�@� �L � �S� �S�� �S� �P� �P�� �R]~ �Q�@� �L � �S� �S�� �S� �P� �P�� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P�� �R�~ �Q�i�@� �L � �S� �S�� �S� �P � �P � �R�~ �Q��@� �L � �S� �S�� �S � �P � �P � �R�~ �Q�@� �L � �S� �S�� �S � �P � �P � �R]~ �Q�@� �L � �S� �S�� �S � �P� �P � �R�~ �Q��@� �L � �S� �S�� �S � �P� �P � �R�~ �Q�i�@� �L � �S� �S�� �S � �P� �P � �R�~ �Q��@� �L � �S� �S�� �S� �P� �P � �R�~ �Q�@� �L � �S� �S�� �S� �P� �P � �R]~ �Q�@� �L � �S� �S�� �S� �P� �P � �R�~ �Q��@� �L � �S� �S�� �S� �P� �P � �R�~ �Q�i�@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �Rf~ �Q�@� �L � �S� �S�� �S� �P� �P� �R]~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P� �P� �R�~ �Q�i�@� �L � �S� �S�� �S� �P� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P � �P� �Rf~ �Q�@� �L � �S� �S�� �S� �P!� �P� �R]~ �Q�@� �L � �S� �S�� �S� �P"� �P� �R�~ �Q��@� �L � �S� �S�� �S� �P#� �P� �R�~ �Q�i�@� �L � �S� �S�� �S� �P$� �P� �R�~ �Q��@� �L � �S� �S�� �S%� �P&� �P� �Rf~ �Q�@� �L � �S� �S�� �S%� �P'� �P� �R]~ �Q�@� �L � �S� �S�� �S%� �P(� �P� �R�~ �Q��@� �L � �S� �S�� �S%� �P)� �P� �R�~ �Q�i�@� �L � �S� �S�� �S%�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P*� �P+� �R�~ �Q��@� �L � �S� �S�� �S,� �P-� �P+� �Rf~ �Q�@� �L � �S� �S�� �S,� �P.� �P+� �R]~ �Q�@� �L � �S� �S�� �S,� �P/� �P+� �R�~ �Q��@� �L � �S� �S�� �S,� �P0� �P+� �R�~ �Q�i�@� �L � �S� �S�� �S,� �P1� �P+� �R�~ �Q��@� �L � �S� �S�� �S2� �P3� �P+� �Rf~ �Q�@� �L � �S� �S�� �S2� �P4� �P+� �R]~ �Q�@� �L � �S� �S�� �S2� �P5� �P+� �R�~ �Q��@� �L � �S� �S�� �S2� �P6� �P+� �R�~ �Q�i�@� �L � �S� �S�� �S2� �P7� �P8� �R�~ �Q��@� �L � �S� �S�� �S9� �P:� �P8� �R�~ �Q�@� �L � �S� �S�� �S9� �P;� �P8� �R]~ �Q�@� �L � �S� �S�� �S9� �P<� �P8� �R�~ �Q��@� �L � �S� �S�� �S9� �P=� �P8� �R�~ �Q�i�@� �L � �S� �S�� �S9� �P>� �P?� �R�~ �Q��@� �L � �S� �S�� �S@� �PA� �P?� �R�~ �Q�@� �L � �S� �S�� �S@� �PB� �P?� �R]~ �QB�@� �L � �S� �S�� �S@� �PC� �P?� �R�~ �Q��@� �L � �S� �S�� �S@� �PD� �P?� �R�~ �Q��@� �L � �S� �S�� �S@� �PE� �PF� �R�~ �Q��@� �L � �S� �S�� �SG� �PH� �PF� �R�~ �Q�@� �L � �S� �S�� �SG� �PI� �PF� �R]~ �QB�@� �L � �S� �S�� �SG� �PJ� �PF� �R�~ �Q��@� �L � �S� �S�� �SG� �PK� �PF� �R�~ �Q��@� �L � �S� �S�� �SG� �PL� �PM� �R�~ �Q��@� �L � �S� �S�� �SN� �PO� �PM� �Rf~ �Q�@� �L � �S� �S�� �SN� �PP� �PM� �R]~ �Q�@� �L � �S� �S�� �SN� �PQ� �PM� �R�~ �Q��@� �L � �S� �S�� �SN� �PR� �PM� �R�~ �Q�i�@� �L � �S� �S�� �SN� �PS� �PT� �R�~ �QD�@� �L � �S� �S�� �SN� �PU� �PT� �Rf~ �Q�@� �L � �S� �S�� �SN�D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �PV� �PT� �R]~ �Q��@� �L � �S� �S�� �SN� �PW� �PT� �R�~ �Q��@� �L � �S� �S�� �SN� �PX� �PT� �R�~ �Q@��@� �L � �S� �S�� �SN� �PY� �PM� �R�~ �Q��@� �L � �S� �S�� �SZ� �P[� �PM� �Rf~ �Q�@� �L � �S� �S�� �SZ� �P\� �PM� �R]~ �Q�@� �L � �S� �S�� �SZ� �P]� �PM� �R�~ �Q��@� �L � �S� �S�� �SZ� �P^� �PM� �R�~ �Q�i�@� �L � �S� �S�� �SZ� �P_� �P`� �R�~ �Q��@� �L � �S� �S�� �[a� �Pb� �P`� �R�~ �Q�@� �L � �S� �S�� �[a� �Pc� �P`� �R]~ �Q�@� �L � �S� �S�� �[a� �Pd� �P`� �R�~ �Q��@� �L � �S� �S�� �[a� �Pe� �P`� �R�~ �Q��@� �L � �S� �S�� �[a� �Pf� �Pg� �R�~ �Q��@� �L � �S� �S�� �Sh� �Pi� �Pg� �R�~ �Q�@� �L � �S� �S�� �Sh� �Pj� �Pg� �R]~ �QB�@� �L � �S� �S�� �Sh� �Pk� �Pg� �R�~ �Q��@� �L � �S� �S�� �Sh� �Pl� �Pg� �R�~ �Q��@� �L � �S� �S�� �Sh� �Pm� �Pg� �R�~ �Q��@� �L � �S� �S�� �Sn� �Po� �Pg� �R�~ �Q�@� �L � �S� �S�� �Sn� �Pp� �Pg� �R]~ �QB�@� �L � �S� �S�� �Sn� �Pq� �Pg� �R�~ �Q��@� �L � �S� �S�� �Sn� �Pr� �Pg� �R�~ �Q��@� �L � �S� �S�� �Sn� �]s� �]t� �^�~ �Q��@� �L � �S� �S�� �_u� �]v� �]t� �^�~ �Q�@� �L � �S� �S�� �_u� �]w� �]t� �^]~ �QB�@� �L � �S� �S�� �_u� �]x� �]t� �^�~ �Q��@� �L � �S� �S�� �_u� �]y� �]t� �^�~ �Q��@� �L � �S� �S�� �_u� �Pz� �P{� �R�~ �Q��@� �L � �S� �S�� �S|� �P}� �P{� �R�~ �Q�@� �L � �S� �S�� �S|� �P~� �P{� �R]~ �QB�@� �L � �S� �S�� �S|� �P� �P{� �R�~ �Q��@� �L � �S� �S�� �S|�D�lppppppppppppppppppppppppppppppp;@;@;@;@;@;@;@;@;@ ;@ ;@ ;@ ;@ ;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@� P�� P{� R�~ Q��@� L � S� S�� S|� P�� P�� R�~ QD�@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R]~ Q��@� L � S� S�� S�� P�� P�� R�~ Q�%�@� L � S� S�� S|� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� W�� P�� P�� R�~ Q�@� L � S� S�� W�� P�� P�� R]~ QB�@� L � S� S�� W�� P�� P�� R�~ Q��@� L � S� S�� W�� P�� P�� R�~ Q��@� L � S� S�� W�� P�� P�� R�~ QD�@� L � S� S�� W�� P�� P�� R�~ Q�@� L � S� S�� W�� P�� P�� R]~ Q��@� L � S� S�� W�� P�� P�� R�~ Q�%�@� L � S� S�� W�� P�� P�� R�~ Q@��@� L � S� S�� W�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R]~ Q9�@� L � S� S�� S�� P�� P�� R�~ Q���@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ QD�@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R]~ Q6�@� L � S� S�� S�� P�� P�� R�~ Q�i�@� L � S� S�� S�� P�� P�� R�~ Q@��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q�@� L � S� S�� S�� P�� P�� R]~ Q9�@� L � S� S�� S�� P�� P�� R�~ Q���@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S�� P�� P�� R�~ Q��@� L � S� S�� S��D�lppppppppppppppppppppppppppppppp ;@!;@";@#;@$;@%;@&;@';@(;@);@*;@+;@,;@-;@.;@/;@0;@1;@2;@3;@4;@5;@6;@7;@8;@9;@:;@;;@<;@=;@>;@?;@� P�� P�� R�~ Q�@� L � S� S�� S�� !P�� !P�� !R]~ !Q9�@� !L � !S� !S�� !S�� "P�� "P�� "R�~ "Q���@� "L � "S� "S�� "S�� #P�� #P�� #R�~ #Q��@� #L � #S� #S�� #S�� $P�� $P�� $R�~ $QD�@� $L � $S� $S�� $S�� %P�� %P�� %R�~ %Q�@� %L � %S� %S�� %S�� &P�� &P�� &R]~ &Q6�@� &L � &S� &S�� &S�� 'P�� 'P�� 'R�~ 'Q�i�@� 'L � 'S� 'S�� 'S�� (P�� (P�� (R�~ (Q@��@� (L � (S� (S�� (S�� )P�� )P�� )R�~ )Q��@� )L � )S� )S�� )S�� *P�� *P�� *R�~ *Q�@� *L � *S� *S�� *S�� +P�� +P�� +R]~ +Q9�@� +L � +S� +S�� +S�� ,P�� ,P�� ,R�~ ,Q���@� ,L � ,S� ,S�� ,S�� -P�� -P�� -R�~ -Q��@� -L � -S� -S�� -S�� .P�� .P�� .R�~ .QD�@� .L � .S� .S�� .S�� /P�� /P�� /R�~ /Q�@� /L � /S� /S�� /S�� 0P�� 0P�� 0R]~ 0Q6�@� 0L � 0S� 0S�� 0S�� 1P�� 1P�� 1R�~ 1Q�i�@� 1L � 1S� 1S�� 1S�� 2P�� 2P�� 2R�~ 2Q@��@� 2L � 2S� 2S�� 2S�� 3P�� 3P�� 3R�~ 3Q��@� 3L � 3S� 3S�� 3S�� 4P�� 4P�� 4R�~ 4Q�@� 4L � 4S� 4S�� 4S�� 5P�� 5P�� 5R]~ 5Q9�@� 5L � 5S� 5S�� 5S�� 6P�� 6P�� 6R�~ 6Q���@� 6L � 6S� 6S�� 6S�� 7P�� 7P�� 7R�~ 7Q��@� 7L � 7S� 7S�� 7S�� 8P�� 8P�� 8R�~ 8Q��@� 8L � 8S� 8S�� 8W�� 9P�� 9P�� 9Rf~ 9Q�@� 9L � 9S� 9S�� 9W�� :P�� :P�� :R]~ :Q�@� :L � :S� :S�� :W�� ;P�� ;P�� ;R�~ ;Q��@� ;L � ;S� ;S�� ;W�� <P�� <P�� <R�~ <Q�i�@� <L � <S� <S�� <W�� =P�� =P�� =R�~ =QD�@� =L � =S� =S�� =W�� >P�� >P�� >Rf~ >Q�@� >L � >S� >S�� >W�� ?P�� ?P�� ?R]~ ?Q��@� ?L � ?S� ?S�� ?W��D�lppppppppppppppppppppppppppppppp@;@A;@B;@C;@D;@E;@F;@G;@H;@I;@J;@K;@L;@M;@N;@O;@P;@Q;@R;@S;@T;@U;@V;@W;@X;@Y;@Z;@[;@\;@];@^;@_;@� @P�� @P�� @R�~ @Q� �@� @L � @S� @S�� @W�� AP�� AP�� AR�~ AQ@��@� AL � AS� AS�� AW�� BP�� BP�� BR�~ BQ��@� BL � BS� BS�� BS�� CP�� CP�� CRf~ CQ�@� CL � CS� CS�� CS�� DP�� DP�� DR]~ DQ�@� DL � DS� DS�� DS�� EP�� EP�� ER�~ EQ��@� EL � ES� ES�� ES�� FP�� FP�� FR�~ FQ�i�@� FL � FS� FS�� FS�� GP�� GP�� GR�~ GQD�@� GL � GS� GS�� GS�� HP�� HP�� HRf~ HQ�@� HL � HS� HS�� HS�� IP�� IP�� IR]~ IQ��@� IL � IS� IS�� IS�� JP�� JP�� JR�~ JQ� �@� JL � JS� JS�� JS�� KP�� KP�� KR�~ KQ@��@� KL � KS� KS�� KS�� LP�� LP�� LR�~ LQ��@� LL � LS� LS�� LS�� MP�� MP�� MR�~ MQ�@� ML � MS� MS�� MS�� NP�� NP�� NR]~ NQB�@� NL � NS� NS�� NS�� OP�� OP�� OR�~ OQ��@� OL � OS� OS�� OS�� PP�� PP�� PR�~ PQ��@� PL � PS� PS�� PS�� Q]�� Q]�� Q^�~ QQ��@� QL � QS� QS�� Q_�� R]�� R]�� R^�~ RQ�@� RL � RS� RS�� R_�� S]�� S]�� S^]~ SQ�@� SL � SS� SS�� S_�� T]�� T]�� T^�~ TQ��@� TL � TS� TS�� T_�� U]�� U]�� U^�~ UQ��@� UL � US� US�� U_�� V]�� V]�� V^�~ VQ��@� VL � VS� VS�� VW�� W]�� W]�� W^�~ WQ�@� WL � WS� WS�� WW�� X]�� X]�� X^]~ XQ�@� XL � XS� XS�� XW�� Y]�� Y]�� Y^�~ YQ��@� YL � YS� YS�� YW�� Z]�� Z]�� Z^�~ ZQ��@� ZL � ZS� ZS�� ZW�� []�� []�� [^�~ [QD�@� [L � [S� [S�� [W�� \]�� \]�� \^�~ \Q�@� \L � \S� \S�� \W�� ]]�� ]]�� ]^]~ ]Q��@� ]L � ]S� ]S�� ]W�� ^]�� ^]�� ^^�~ ^Q<�@� ^L � ^S� ^S�� ^W�� _]�� _]�� _^�~ _Q�i�@� _L � _S� _S�� _W��D�lppppppppppppppppppppppppppppppp`;@a;@b;@c;@d;@e;@f;@g;@h;@i;@j;@k;@l;@m;@n;@o;@p;@q;@r;@s;@t;@u;@v;@w;@x;@y;@z;@{;@|;@};@~;@;@� `P�� `P�� `R�~ `Q��@� `L � `S� `S�� `S�� aP�� aP�� aR�~ aQ�@� aL � aS� aS�� aS�� bP � bP�� bR]~ bQB�@� bL � bS� bS�� bS�� cP � cP�� cR�~ cQ��@� cL � cS� cS�� cS�� dP � dP�� dR�~ dQ��@� dL � dS� dS�� dS�� eP � eP � eR�~ eQD�@� eL � eS� eS�� eS�� fP � fP � fR�~ fQ�@� fL � fS� fS�� fS�� gP � gP � gR]~ gQ��@� gL � gS� gS�� gS�� hP � hP � hR�~ hQ�%�@� hL � hS� hS�� hS�� iP � iP � iR�~ iQ��@� iL � iS� iS�� iS�� jP � jP�� jR�~ jQ��@� jL � jS� jS�� jS � kP � kP�� kR�~ kQ�@� kL � kS� kS�� kS � lP � lP�� lR]~ lQB�@� lL � lS� lS�� lS � mP � mP�� mR�~ mQ��@� mL � mS� mS�� mS � nP � nP�� nR�~ nQ��@� nL � nS� nS�� nS � oP � oP � oR�~ oQD�@� oL � oS� oS�� oS � pP � pP � pR�~ pQ�@� pL � pS� pS�� pS � qP � qP � qR]~ qQ��@� qL � qS� qS�� qS � rP � rP � rR�~ rQ�%�@� rL � rS� rS�� rS � sP � sP � sR�~ sQ��@� sL � sS� sS�� sS � tP � tP � tR�~ tQ��@� tL � tS� tS�� tS � uP � uP � uRf~ uQ�@� uL � uS� uS�� uS � vP � vP � vR]~ vQ�@� vL � vS� vS�� vS � wP � wP � wR�~ wQ��@� wL � wS� wS�� wS � xP � xP � xR�~ xQ�i�@� xL � xS� xS�� xS � yP � yP � yR�~ yQ��@� yL � yS� yS�� yS � zP � zP � zRf~ zQ�@� zL � zS� zS�� zS � {P � {P � {R]~ {Q�@� {L � {S� {S�� {S � |P � |P � |R�~ |Q��@� |L � |S� |S�� |S � }P � }P � }R�~ }Q�i�@� }L � }S� }S�� }S � ~P! � ~P � ~R�~ ~Q��@� ~L � ~S� ~S�� ~S" � P# � P � Rf~ Q�@� L � S� S�� S" �D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P$ � �P � �R]~ �Q�@� �L � �S� �S�� �S" � �P% � �P � �R�~ �Q��@� �L � �S� �S�� �S" � �P& � �P � �R�~ �Q�i�@� �L � �S� �S�� �S" � �P' � �P( � �R�~ �Q��@� �L � �S� �S�� �S) � �P* � �P( � �R�~ �Q�@� �L � �S� �S�� �S) � �P+ � �P( � �R]~ �Q�@� �L � �S� �S�� �S) � �P, � �P( � �R�~ �Q��@� �L � �S� �S�� �S) � �P- � �P( � �R�~ �Q�i�@� �L � �S� �S�� �S) � �P. � �P/ � �R�~ �Q��@� �L � �S� �S�� �S0 � �P1 � �P/ � �R�~ �Q�@� �L � �S� �S�� �S0 � �P2 � �P/ � �R]~ �Q�@� �L � �S� �S�� �S0 � �P3 � �P/ � �R�~ �Q��@� �L � �S� �S�� �S0 � �P4 � �P/ � �R�~ �Q�i�@� �L � �S� �S�� �S0 � �P5 � �P6 � �R�~ �QD�@� �L � �S� �S�� �S0 � �P7 � �P6 � �R�~ �Q�@� �L � �S� �S�� �S0 � �P8 � �P6 � �R]~ �Q��@� �L � �S� �S�� �S0 � �P9 � �P6 � �R�~ �Q� �@� �L � �S� �S�� �S0 � �P: � �P6 � �R�~ �Q@��@� �L � �S� �S�� �S0 � �P; � �P/ � �R�~ �Q��@� �L � �S� �S�� �S< � �P= � �P/ � �R�~ �Q�@� �L � �S� �S�� �S< � �P> � �P/ � �R]~ �Q�@� �L � �S� �S�� �S< � �P? � �P/ � �R�~ �Q��@� �L � �S� �S�� �S< � �P@ � �P/ � �R�~ �Q�i�@� �L � �S� �S�� �S< � �PA � �PB � �R�~ �Q��@� �L � �S� �S�� �SC � �PD � �PB � �R�~ �Q�@� �L � �S� �S�� �SC � �PE � �PB � �R]~ �QB�@� �L � �S� �S�� �SC � �PF � �PB � �R�~ �Q��@� �L � �S� �S�� �SC � �PG � �PB � �R�~ �Q��@� �L � �S� �S�� �SC � �]H � �]B � �^�~ �Q��@� �L � �S� �S�� �_I � �]J � �]B � �^�~ �Q�@� �L � �S� �S�� �_I � �]K � �]B � �^~ �QB�@� �L � �S� �S�� �_I � �]L � �]B � �^M ~ �Q��@� �L � �S� �S�� �_I �D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �]N � �]B � �^�~ �Q��@� �L � �S� �S�� �_I � �PO � �PP � �R�~ �Q��@� �L � �S� �S�� �SQ � �PR � �PP � �R�~ �Q�@� �L � �S� �S�� �SQ � �PS � �PP � �R]~ �Q�@� �L � �S� �S�� �SQ � �PT � �PP � �R�~ �Q���@� �L � �S� �S�� �SQ � �PU � �PP � �R�~ �Q��@� �L � �S� �S�� �SQ � �PV � �PW � �R�~ �QD�@� �L � �S� �S�� �SX � �PY � �PW � �R�~ �Q�@� �L � �S� �S�� �SX � �PZ � �PW � �R]~ �Q��@� �L � �S� �S�� �SX � �P[ � �PW � �R�~ �Q>�@� �L � �S� �S�� �SQ � �P\ � �PW � �R�~ �Q���@� �L � �S� �S�� �SX � �P] � �PP � �R�~ �Q��@� �L � �S� �S�� �S^ � �P_ � �PP � �R�~ �Q�@� �L � �S� �S�� �S^ � �P` � �PP � �R]~ �Q�@� �L � �S� �S�� �S^ � �Pa � �PP � �R�~ �Q���@� �L � �S� �S�� �S^ � �Pb � �PP � �R�~ �Q�i�@� �L � �S� �S�� �S^ � �Pc � �PP � �R�~ �Q��@� �L � �S� �S�� �Sd � �Pe � �PP � �R�~ �Q�@� �L � �S� �S�� �Sd � �Pf � �PP � �R]~ �Q�@� �L � �S� �S�� �Sd � �Pg � �PP � �R�~ �Q��@� �L � �S� �S�� �Sd � �Ph � �PP � �R�~ �Q�i�@� �L � �S� �S�� �Sd � �Pi � �Pj � �R�~ �Q��@� �L � �S� �S�� �Sk � �Pl � �Pj � �R�~ �Q�@� �L � �S� �S�� �Sk � �Pm � �Pj � �R]~ �Q�@� �L � �S� �S�� �Sk � �Pn � �Pj � �R�~ �Q��@� �L � �S� �S�� �Sk � �Po � �Pj � �R�~ �Q�i�@� �L � �S� �S�� �Sk � �Pp � �Pj � �R�~ �Q��@� �L � �S� �S�� �Sq � �Pr � �Pj � �R�~ �Q�@� �L � �S� �S�� �Sq � �Ps � �Pj � �R]~ �Q�@� �L � �S� �S�� �Sq � �Pt � �Pj � �R�~ �Q��@� �L � �S� �S�� �Sq � �Pu � �Pj � �R�~ �Q�i�@� �L � �S� �S�� �Sq � �Pv � �Pw � �R�~ �Q��@� �L � �S� �S�� �Sx �D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �Py � �Pw � �R�~ �Q�@� �L � �S� �S�� �Sx � �Pz � �Pw � �R]~ �Q�@� �L � �S� �S�� �Sx � �P{ � �Pw � �R�~ �Q��@� �L � �S� �S�� �Sx � �P| � �Pw � �R�~ �Q�i�@� �L � �S� �S�� �Sx � �P} � �Pw � �R�~ �Q��@� �L � �S� �S�� �S~ � �P � �Pw � �R�~ �Q�@� �L � �S� �S�� �S~ � �P� � �Pw � �R]~ �Q�@� �L � �S� �S�� �S~ � �P� � �Pw � �R�~ �Q��@� �L � �S� �S�� �S~ � �P� � �Pw � �R�~ �Q�i�@� �L � �S� �S�� �S~ � �P� � �Pw � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �Pw � �R�~ �Q�@� �L � �S� �S�� �S� � �P� � �Pw � �R]~ �Q�@� �L � �S� �S�� �S� � �P� � �Pw � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �Pw � �R�~ �Q�i�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R]~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q���@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R]~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q���@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �Rf~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R]~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q�i�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �Rf~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R]~ �QE�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� �D�lppppppppppppppppppppppppppppppp�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@�;@� �P� � �P� � �R�~ �Q���@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� � �S�� �S� � �P� � �P� � �R]~ �Q�l�@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �QD�@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� � �S�� �S� � �P� � �P� � �R]~ �Q�j�@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q���@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q�z�@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� � �S�� �S� � �P� � �P� � �R]~ �Q�l�@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �QD�@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� � �S�� �S� � �P� � �P� � �R]~ �Q�j�@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q���@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q�z�@� �L � �S� � �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R]~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �QD�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q�@� �L � �S� �S�� �S� � �P� � �P� � �R]~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q<�@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� � �P� � �P� � �R�~ �Q��@� �L � �S� �S�� �S� �D�lppppppppppppppppppppppppppppppp;@;@;@;@;@;@;@;@;@ ;@ ;@ ;@ ;@ ;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@;@� P� � P� � Rf~ Q�@� L � S� S�� S� � P� � P� � R]~ Q�@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ Q�i�@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � Rf~ Q�@� L � S� S�� S� � P� � P� � R]~ Q�@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ Q�i�@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � Rf~ Q�@� L � S� S�� S� � P� � P� � R]~ Q�@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ Q�i�@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ Q�@� L � S� S�� S� � P� � P� � R]~ Q��@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ QD�@� L � S� S�� S� � P� � P� � R�~ Q�@� L � S� S�� S� � P� � P� � R]~ Q���@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ QC�@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ Q�@� L � S� S�� S� � P� � P� � R]~ Q��@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ Q��@� L � S� S�� S� � P� � P� � R�~ QD�@� L � S� S�� S� � P� � P� � R�~ Q�@� L � S� S�� S� � P� � P� � R]~ Q���@� L � S� S�� S� �D�lppppppppppppppppppppppppppppppp ;@!;@";@#;@$;@%;@&;@';@(;@);@*;@+;@,;@-;@.;@/;@0;@1;@2;@3;@4;@5;@6;@7;@8;@9;@:;@;;@<;@=;@>;@?;@� P� � P� � R�~ Q��@� L � S� S�� S� � !P� � !P� � !R�~ !QC�@� !L � !S� !S�� !S� � "P� � "P� � "R�~ "Q��@� "L � "S� "S�� "S� � #P� � #P� � #R�~ #Q�@� #L � #S� #S�� #S� � $P� � $P� � $R]~ $Q�@� $L � $S� $S�� $S� � %P� � %P� � %R�~ %Q��@� %L � %S� %S�� %S� � &P� � &P� � &R�~ &Q��@� &L � &S� &S�� &S� � 'P� � 'P� � 'R�~ 'Q��@� 'L � 'S� 'S�� 'S � (P � (P� � (R�~ (Q�@� (L � (S� (S�� (S � )P � )P� � )R]~ )QB�@� )L � )S� )S�� )S � *P � *P� � *R�~ *Q��@� *L � *S� *S�� *S � +P � +P� � +R�~ +Q��@� +L � +S� +S�� +S � ,P � ,P � ,R�~ ,Q��@� ,L � ,S� ,S�� ,S � -P � -P � -R�~ -Q�@� -L � -S� -S�� -S � .P � .P � .R]~ .Q�@� .L � .S� .S�� .S � /P � /P � /R�~ /Q���@� /L � /S� /S�� /S � 0P � 0P � 0R�~ 0Q��@� 0L � 0S� 0S�� 0S � 1P � 1P � 1R�~ 1Q��@� 1L � 1S� 1S�� 1S � 2P � 2P � 2R�~ 2Q�@� 2L � 2S� 2S�� 2S � 3P � 3P � 3R]~ 3Q�@� 3L � 3S� 3S�� 3S � 4P � 4P � 4R�~ 4Q���@� 4L � 4S� 4S�� 4S � 5P � 5P � 5R�~ 5Q��@� 5L � 5S� 5S�� 5S � 6P � 6P � 6R�~ 6QD�@� 6L � 6S� 6S�� 6S � 7P � 7P � 7R�~ 7Q�@� 7L � 7S� 7S�� 7S � 8P � 8P � 8R]~ 8Q��@� 8L � 8S� 8S�� 8S � 9P � 9P � 9R�~ 9Q��@� 9L � 9S� 9S�� 9S � :P � :P � :R�~ :Q�o�@� :L � :S� :S�� :S � ;P � ;P � ;R�~ ;Q��@� ;L � ;S� ;S�� ;S � <P � <P � <R�~ <Q�@� <L � <S� <S�� <S � =P � =P � =R]~ =Q�@� =L � =S� =S�� =S � >P � >P � >R�~ >Q���@� >L � >S� >S�� >S � ?P � ?P � ?R�~ ?Q��@� ?L � ?S� ?S�� ?S �D�lppppppppppppppppppppppppppppppp@;@A;@B;@C;@D;@E;@F;@G;@H;@I;@J;@K;@L;@M;@N;@O;@P;@Q;@R;@S;@T;@U;@V;@W;@� @P � @P! � @R�~ @QD�@� @L � @S� @S�� @S � AP" � AP! � AR�~ AQ�@� AL � AS� AS�� AS � BP# � BP! � BR]~ BQ��@� BL � BS� BS�� BS � CP$ � CP! � CR�~ CQ��@� CL � CS� CS�� CS � DP% � DP! � DR�~ DQ�o�@� DL � DS� DS�� DS � EP& � EP � ER�~ EQ��@� EL � ES� ES�� ES' � FP( � FP � FR�~ FQ�@� FL � FS� FS�� FS' � GP) � GP � GR]~ GQ�@� GL � GS� GS�� GS' � HP* � HP � HR�~ HQ���@� HL � HS� HS�� HS' � IP+ � IP � IR�~ IQ��@� IL � IS� IS�� IS' � JP, � JP � JR�~ JQ��@� JL � JS� JS�� JS- � KP. � KP � KR�~ KQ�@� KL � KS� KS�� KS- � LP/ � LP � LR]~ LQ�@� LL � LS� LS�� LS- � MP0 � MP � MR�~ MQ���@� ML � MS� MS�� MS- � NP1 � NP � NR�~ NQ��@� NL � NS� NS�� NS- � O]2 � O]3 � O`�~ OQ��@� OL � OS� OS�� O_4 � P]5 � P]3 � P`�~ PQ�@� PL � PS� PS�� P_4 � Q]6 � Q]3 � Q`~ QQ�@� QL � QS� QS�� Q_4 � R]7 � R]3 � R`M ~ RQ��@� RL � RS� RS�� R_4 � S]8 � S]3 � S`�~ SQ�i�@� SL � SS� SS�� S_4 � TP9 � TP: � TR�~ TQ��@� TL � TS� � TS�� TS; � UP< � UP: � UR�~ UQ�@� UL � US� � US�� US; � VP= � VP: � VR~ VQ9�@� VL � VS� � VS�� VS; � WSS�4� �ppppppppppppppppppppppp>�@d�$ gg����D  ������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������ ����/��a��������������������������������������������������������������������������������������������������������������������������������������������������������������`���`���`���`��`���`���`���`���`���`���`���`���`�`�`�`���`���`���`��`���`���`���`��`�����`���`���`���`����������������� �������Oh��+'��0��������� 4 @ LX`hp������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������Ines FerreiraInes Ferreira@2 ���@�Fdћ�Microsoft Excel����՜.��+,��D��՜.��+,��\������������� �  DocumentSummaryInformation8�������������������������������������������������� �(\�dlKSOProductBuildVer�2052-10.1.0.6206